EHF Invited Speakers
S1 KATP channels
Mohammad Al-Mahdi Al-Karagholi (mahdi.alkaragholi@gmail.com)
Danish Headache Center, Department of Neurology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark
S2 The secondary headaches: a cul de sac for the headache expert ?
Christian Lampl (Christian.Lampl@ordensklinikum.at)
Headache Medical Center, Seilerstätte, Ordensklinikum Linz Barmherzige Schwestern, Austria
S3 Hormonal contraceptives: how they impact on migraine course
Simona Sacco (simona.sacco@univaq.it)
Department of Applied Clinical Sciences and Biotechnology, Section of Neurology, University of L’Aquila, L’Aquila, Italy
S4 EHF Guidelines on the use of CGRP(r) MAbs in migraine
Simona Sacco (simona.sacco@univaq.it)
Department of Applied Clinical Sciences and Biotechnology, Section of Neurology, University of L’Aquila, L’Aquila, Italy
S5 Novel Insight into Post Traumatic Headache: Lessons learned from Blast Exposed Civilians
Gal Ifergane (gal.ifergane@gmail.com)
Department of Neurology, Division of Brain Medicine, Soroka University Medical Center, Ben-Gurion University of the Negev, Beer-Sheva, Israel
S6 Imaging inflammation in animal models of migraine
Aaron Schain, Agustin Melo-Carrillo, Andrew Strassman, Rami Burstein
Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Correspondence: Aaron Schain (aschain@bidmc.harvard.edu)
S7 What have we learned from cellular and circuit mechanisms of the primary brain dysfunctions that cause familial hemiplegic migraine?
Daniela Pietrobon1,2 (daniela.pietrobon@unipd.it)
1Department of Biomedical Sciences and Padova Neuroscience Center University of Padova, 35121 Padova, Italy; 2CNR Institute of Neuroscience, 35121 Padova, Italy
S8 What is the evidence for role of inflammation in migraine? Why do NSAIDs work so effectively in acute treatment
M. Ashina (ashina@dadlnet.dk)
Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, University of Copenhagen, Denmark
S9 Emerging targets for treatment – apart from CGRP – PAC1 receptor and PACAP
Luise Haulund Vollesen
Danish Headache Centre and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark
S10 Counting cost: disability and lost productivity
T. J. Steiner (t.steiner@imperial.ac.uk)
Norwegian University of Science and Technology, Trondheim, Norway
S11 The migraine brain is inheritably hyper-responsive
Magis Delphine (dmagis@chuliege.be)
Headache Research Unit, University Department of Neurology CHR, Liège, Belgium
S12 Seizure activates the trigeminovascular system differently than CSD: Implications to differences between post-ictal headache and migraine
Agustin Melo Carrillo (amelo1@bidmc.harvard.edu)
Department of Anesthesia, Critical Care and Pain Medicine. Beth Israel Deaconess Medical Center. Harvard Medical School, Boston, MA, USA
S13 Cortical Spreading Depression as a trigger for migraine headache
Rami Burstein
Department of Anesthesia and Critical Care, Beth Israel Deaconess Medical Center
S14 Migraine onset in childhood is a genetic disease
Andrew Hershey (Andrew.Hershey@cchmc.org)
Cincinnati Children’s Hospital Medical Center, 3333 Burnet Avenue, MLC 2015, Cincinnati, OH 45229,USA
S15 Providing care: Cost-effective and affordable
Michela Tinelli (m.tinelli@lse.ac.uk)
Personal Social Services Research Unit, London School of Economics (LSE), Houghton Street, London WC2A 2AE, UK
S16 Expression of CGRP family of neuropeptides in the trigeminal system
Lars Edvinsson1,2, Karin Warfvinge1,2
1Departments of Internal Medicine, Lund University Hospital, Lund, Sweden; 2Department of Clinical Experimental Research, Copenhagen University Hospital, Glostrup, Denmark.
Correspondence: Lars Edvinsson (lars.edvinsson@med.lu.se)
S17 Managing secondary headaches with a multimodal expertise
Henrik Winther Schytz (henrikschytz@hotmail.com)
Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Denmark
S18 Hormonal contraceptives in women with migraine: pros and cons
E. Anne MacGregor (anne@annemacgregor.com)
Barts Health NHS Trust, London UK
S19 Cortical spreading depression as mechanism of the migraine aura: new mechanisms
Martin Lauritzen (martin.johannes.lauritzen@regionh.dk)
Department of Clinical Neurophysiology, Rigshospitalet and Institute for Neuroscience, University of Copenhagen, Glostrup, DK-2600, Denmark
S20 Pain regulation by non-neuronal cells and inflammation
Ru-Rong Ji (ru-rong.ji@duke.edu)
Center for Translational Pain Medicine, Departments of Anesthesiology and Neurobiology, Duke University Medical Center, Durham, North Carolina, 27710, USA
S21 Occipital Migraine and the Cerebellum
Rodrigo Noseda, Rami Burstein
Department of Anesthesia, Critical Care & Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston MA, USA
Correspondence: Rodrigo Noseda (rnoseda@bidmc.harvard.edu)
S22 The migraine brain is not hyper-responsive
Trond Sand1,2 (trond.sand@ntnu.no)
1Department of Neuromedicine and Movement Science, Faculty of Medicine and Health Sciences, NTNU - Norwegian University of Science and Technology, Trondheim, Norway; 2Department of Neurology and Clinical Neurophysiology, St. Olavs hospital HF, Trondheim University Hospital, 7006, Trondheim, Norway
S23 MRI studies can predict progression of disease years before it occurs
Roberta Messina, Maria A. Rocca, Massimo Filippi
Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy
Correspondence: Roberta Messina (messina.roberta@hsr.it)
S24 Three dimensional approch for DDI evaluation in Precision Medicine
Leda Marina Pomes1, Giovanna Gentile2, Maurizio Simmaco2, Marina Borro2, Paolo Martelletti3,4,5,6
1Residency Program in Laboratory Medicine, Gabriele d’Annunzio University, Chieti, Italy; 2Department of Neurosciences, Mental Health and Sensory Organs, Sapienza University, Rome Italy; 2Department of Clinical and Molecular Medicine, Sapienza University, Rome Italy; 3Residency Program in Internal Medicine, Sapienza University, Rome, Italy; 4Master in Headache Medicine, Sapienza University, Rome, Italy; 5Internal Medicine and Emergency Medicine Unit, Sant’Andrea Hospital, Rome, Italy; 6Regional Referral Headache Center, Sant’Andrea Hospital, Rome, Italy
Correspondence: Paolo Martelletti (paolo.martelletti@uniroma1.it)
S25 The EMA-EHF Documento for migraine
Efstratia Vatzaki1*, Sabine Strauss2, Jean-Michel Dogne3, Juan Garcia Burgos1, Thomas Girard1 and Paolo Martelletti4
1European Medicine Agency, London, UK; 2Medicines Evaluation Board, The Netherlands; 3Head of the Department of Pharmacy, Namur Thrombosis and Hemostasis Centre - Narilis University of Namur, Belgium; 4European Headache Federation, Rome, Italy
Correspondence: Efstratia Vatzaki (Efstratia.Vatzaki@ema.europa.eu)
S26 Precision medicine general concept in clinical pratice
Marina Borro, Giovanna Gentile, Maurizio Simmaco
Department of Neurosciences, Mental Health and Sensory Organs, Faculty of Medicine and Psychology, Sapienza University of Roma and Sant'Andrea Hospital of Rome, Laboratory of Clinical Biochemistry
Correspondence: Maurizio Simmaco (maurizio.simmaco@uniroma1.it)
S27 Correlation of migraine attacks with neck pain and tension
E Anne MacGregor1, Stephen Donoghue2, Marina Vives-Mestres2
1Barts Health NHS Trust, London UK; 2Curelator Inc., Cambridge MA, USA
Correspondence: E Anne MacGregor (anne@annemacgregor.com)
Suspected? →
| Not suspected | Low (levels 1-3) | Medium (levels 4-6) | High (levels 7-10) | No answer |
TOTAL
n (%)
|
Association? ↓
| ||||||
Associated ‘trigger’ | 19 | 13 | 31 | 92 | 6 | 161 (20.8) |
Associated ‘protector’ | 0 | 0 | 0 | 0 | 0 | 0 (0) |
No association | 56 | 40 | 81 | 147 | 16 | 340 (43.9) |
Not analyzed | 72 | 37 | 47 | 99 | 18 | 273 (35.3) |
TOTAL
n (%)
| 147 (19) | 90 (11.6) | 159 (20.5) | 338 (43.7) | 40 (5.2) | 774 |
S28 Brainstem aura is not real
Anne Ducros (a-ducros@chu-montpellier.fr)
University of Montpellier, and Headache Centre, Neurology department, Montpellier University Hospital, France
S29 Migraine with brainstem aura does exist
Jes Olesen (jes.olesen@regionh.dk)
Rigshospitalet and university of Copenhagen, Denmark
S30 Manual Approach to Tension-Type Headache: Is this a Reliable Approach?
César Fernández-de-las-Peñas (cesar.fernandez@urjc.es)
Departamento de Fisioterapia, Terapia Ocupacional, Rehabilitación y Medicina Física. Universidad Rey Juan Carlos, Alcorcón, Madrid, Spain
S31 Differences and similarities observed in functional imaging of headache studies
Anders Hougaard (ahougaard@dadlnet.dk)
Danish Headache Center & Dept. of Neurology, Righospitalet Glostrup, University of Copenhagen, Denmark
S32 Migraine in childhood is an environmental disease - focus on the role of epigenetic
G. Natalucci1, N. Faedda2, G. Turturo1, V. Guidetti1
1Department of Human Neuroscience, “Sapienza” University of Rome, Rome, Italy; 2Behavioural Neuroscience, Department of Human Neuroscience, “Sapienza” University of Rome, Rome, Italy
Correspondence: V. Guidetti (vincenzo.guidetti@uniroma1.it)
S33 Sports and headache
Randolph W. Evans
Department of Neurology, Baylor College of Medicine, Houston, Texas
S34 Post-traumatic headache is a unique headache disorder
Mattias Linde (mattias.linde@ntnu.no)
Department of Neuromedicine and Movement Science, NTNU Norwegian University of Science and Technology, Trondheim, Norway
S35 Fifty years of Norwegian contributions to headache research
L. J. Stovner (lars.stovner@ntnu.no)
Norwegian Advisoy Unit on Headaches, Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology (NTNU), and St. Olavs Hospital, Trondheim, Norway
S36 Correlation of migraine attacks with neck pain and tension
E. Anne MacGregor1, Stephen Donoghue2, Marina Vives-Mestres2
1Barts Health NHS Trust, London UK, 2Curelator Inc., Cambridge MA, USA
Correspondence: E. Anne MacGregor
SISC Invited Speakers
S37 Comorbidities of Migraine - Sleep Disorders
Catello Vollono (lvol@libero.it)
Department of Neurology, Catholic University, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
S38 Nutraceuticals and headache
Lidia Savi (lsavi@cittadellasalute.to.it)
Headache Center LBS, Lugano, 6900, Switzerland
S39 Community pharmacies as epidemiological sentinels of headache
Paola Brusa1,2, Gianni Allais3,8, Cecilia Scarinzi4, Francesca Baratta1, Marco Parente1, Sara Rolando3, Roberto Gnavi4, Teresa Spadea4, Giuseppe Costa4, Chiara Benedetto3, Massimo Mana5,6, Mario Giaccone2,7, Andrea Mandelli7, Gian Camillo Manzoni8, Gennaro Bussone8
1Department of Science and Technology of Drugs, University of Turin, via Pietro Giuria 9, 10125, Turin, Italy; 2Order of Pharmacists of Turin, Via Sant'Anselmo, 14, 10125, Turin, Italy; 3Department of Surgical Sciences, Women’s Headache Center, University of Turin, Via Ventimiglia 3, 10126, Turin, Italy; 4Epidemiology Unit, ASL TO3, Via Sabaudia 164, 10095, Grugliasco (Turin), Italy; 5ATF Informatics, Via Cascina Colombaro 56, 12100, Cuneo, Italy; 6Federfarma Piemonte, Via Sant'Anselmo, 14, 10125, Turin, Italy; 7FOFI, Federation of the Orders of Italian Pharmacists, Via Palestro 75, 00185, Rome, Italy; 8FI.CEF Onlus, Italian Headache Foundation, via Celoria 11, 20133 Milan, Italy
Correspondence: Paola Brusa (paola.brusa@unito.it)
S40 Digital health and clinical decision support : the HealthSOAF project and the Calabria Headache Network
Rosario Iannacchero1, Carmela Mastrandrea1, Domenico Conforti2
1Regional Headache Centre , Neurology Division “ Pugliese-Ciaccio “ Hospital Catanzaro Italy; 2 Department of Mechanical Energy Management Engineering, University of Calabria Rende Italy
Correspondence: Rosario Iannacchero (centrocefaleeaopc@gmail.com)
S41 Headaches and cranio-cervico-mandibular disorders: EBP manual therapy
Riccardo Rosa1,2 (clinicadelmalditesta@gmail.com)
1La Sapienza University of Roma, Italy; 2Clinica del Mal di Testa, via campania 37, Roma, 00161, Italy
S42 Spontaneous intracranial hypotension headache
Enrico Ferrante (enricoferrante@libero.it)
Neurology Department San Carlo Hospital- Potenza
S43 The standard of care for chronic migraine in lombardia SISC centres: results of a collaborative study
Paola Merlo1*, Valentina Rebecchi2, Natascia Ghiotto3, Lucia Princiotta Cariddi2, Fabio Antonaci4,5, Andrea Giorgetti6, Franco Di Palma7, Edgard Matta8, Giorgio Dalla Volta9, Grazia Sances3 on behalf of SISC - Società Italiana per lo Studio delle Cefalee - Sezione Lombardia, Italy
1UO Neurologia - Centro Cefalee, Humanitas Gavazzeni, Bergamo; 2Centro Cefalee UOC Neurologia –Varese - ASST Settelaghi – Univ. Insubria; 3Headache Science Centre, National Neurologic Institute C. Mondino, Pavia; 4UC Neurologia Speciale d'Urgenza, Istituto Neurologico Nazionale, Pavia; 5Dipartimento di Scienze del Sistema Nervoso e del Comportamento Università di Pavia; 6Centro Cefalee, Dipartimento di Neuroscienze H di Legnano ASST Ovest milanese; 7Centro Cefalee UOC Neurologia della ASST Lariana - Ospedale S. Anna, Como; 8Centro Cefalee UOC Neurologia ASST Bergamo ovest; 9Centro Cefalee UO Neurologia - Istituto Clinico Città di Brescia, Brescia
Correspondence: Paola Merlo (paola.merlo@gavazzeni.it)
S44 Migraine pathophysiology
Gianluca Coppola (gianluca.coppola@gmail.com)
Sapienza University of Rome Polo Pontino, Department of Medico-Surgical Sciences and Biotechnologies, Latina, Italy
S45 The use of a phytotherapic compound containing Tanacetum Parthenium and Andrographis, in combination with CoQ10 and Riboflavin, for migraine prophylaxis: a randomized double blind versus placebo clinical trial
Cherubino Di Lorenzo (cherub@inwind.it)
IRCCS Fondazione Don Carlo Gnocchi, Milan, Italy
S46 Migraine and Metabolic Syndrome
Cherubino Di Lorenzo (cherub@inwind.it)
IRCCS Fondazione Don Carlo Gnocchi, Milan, Italy
S47 Migraine and Ketogenic Diet
Francesco Pierelli1, Gianluca Coppola2, Cherubino Di Lorenzo3
1INM Neuromed IRCCS, Pozzilli (IS), Italy; 2G. B. Bietti Foundation-IRCCS, Department of Neurophysiology of Vision and Neurophthalmology, Rome, Italy; 3IRCCS Fondazione Don Carlo Gnocchi, Milan, Italy
Correspondence: Francesco Pierelli; Cherubino Di Lorenzo (cherub@inwind.it)
S48 Headache attributed to disorder of homoeostasis
Federico Mainardi (fmainardi@iol.it)
Headache Centre, Neurological Division, SS Giovanni e Paolo Hospital, Venice, Italy
S49 Chronic primary headaches
Paolo Rossi (paolo.rossi9079@gmail.com)
INI Grottaferrata
S50 Nocturnal onset headache
Carlo Lisotto (carlo.lisotto@aas5.sanita.fvg.it)
Headache Centre, Department of Neurology, Azienda Sanitaria Friuli Occidentale, Pordenone, Italy
S51 Headache and Physiotherapy
César Fernández-de-las-Peñas (cesar.fernandez@urjc.es)
Departamento de Fisioterapia, Terapia Ocupacional, Rehabilitación y Medicina Física, Universidad Rey Juan Carlos, Alcorcón, Madrid, Spain
S52 Migraine and Psychiatric Comorbidity
Maria Pia Prudenzano
Headache Center, “L. Amaducci” Clinic, Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Italy
EHF Oral Presentation
O1 New pharmacology, expression profiles and probes of CGRP receptors
Debbie L. Hay1 (dl.hay@auckland.ac.nz)
School of Biological Sciences, The University of Auckland, Auckland, New Zealand
O2 Efficacy, Safety, and Tolerability of Orally Administered Atogepant for the Prevention of Episodic Migraine: Results from a Phase 2b/3 Study
Peter J. Goadsby1 David W. Dodick,2 Joel M. Trugman,3 Michelle Finnegan,3 Hassan Lakkis,3 Kaifeng Lu,3 Armin Szegedi3
1NIHR-Wellcome Trust King’s Clinical Research Facility, King’s College London, UK; 2Mayo Clinic, Phoenix, AZ, USA; 3Allergan plc, Madison, NJ, USA
Correpondence: Peter J. Goadsby (kuang_amy@allergan.com)
O3 Alterations in CGRP and PACAP38 levels in cluster headache
Agneta Snoer1&, Anne Luise Haulund Vollesen1&, Rasmus Paulin Beske1, Song Guo1, Jan Hoffmann2, Jan Fahrenkrug3, Niklas Rye Jørgesen4,5, Torben Martinussen6, Rigmor Højland Jensen1, Messoud Ashina1
1Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark; 2Department of Systems Neuroscience, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 3Department of Clinical Biochemistry, Bispebjerg Hospital, University of Copenhagen, Denmark; 4Department of Clinical Biochemistry, Rigshospitalet Glostrup, Denmark; 5OPEN, Odense Patient Data Explorative Network, Odense University Hospital/Institute of Clinical Research, University of Southern Denmark, Odense, Denmark; 6Section of Biostatistics, University of Copenhagen, Denmark
Correspondence: Messoud Ashina (ashina@dadlnet.dk)
O4 Medication overuse in a post-hoc analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine
Sheena K. Aurora, Paula A Morrow, Dustin D Ruff, Eric Pearlman
Eli Lilly and Company, Indianapolis, IN 46285, USA
Correspondence: Sheena K. Aurora (sheena.aurora@lilly.com)
O5 Study CGAL: a placebo-controlled study of galcanezumab in patients with episodic cluster headache: results from the 8-week double-blind treatment phase
James M. Martinez1, Peter J. Goadsby2,3, David Dodick4, Jennifer N. Bardos1, Tina M. Myers Oakes1, Brian A. Millen1, Chunmei Zhou1, Sherie A. Dowsett1, Sheena K. Aurora1, Jyun Yan Yang1, Robert R. Conley1,5
1Eli Lilly and Company, Indianapolis, IN, USA; 2University of California, San Francisco, CA, USA; 3NIHR-Wellcome Trust King’s Clinical Research Facility, King’s College London, London, UK; 4Mayo Clinic, Phoenix, AZ, USA; 5University of Maryland School of Medicine, Baltimore, MD, USA
Correpondence: Sherie A. Dowsett (dowsett_sherie_a@lilly.com)
O6 Migraine with prolonged aura: a rare and peculiar condition? Results form a prospective diary-aided study
Michele Viana1, Grazia Sances G1, Mattias Linde2, Giuseppe Nappi1, Peter Goadsby3 and Cristina Tassorelli1,4.
1Headache Science Center, C. Mondino National Neurological Institute, Pavia, Italy; 2Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway; 3Headache Group – NIHR-Wellcome Trust Clinical Research Facility, King’s College London, London, UK; 4Department of Brain and Behavioral Sciences, University of Pavia
Correspondence: Michele Viana (michele.viana@ymail.com)
Variable | PROLONGED AURAS (PA) | NON-PA | Sig. |
---|---|---|---|
Number
| 38 | 178 | |
Visual symptoms (VS) | 37 (97) | 175 (98) | 0.69 |
• DVP | 19 (50) | 77 (43) | 0.44 |
• Positive | 23 (60) | 119 (67) | 0.45 |
• Negative | 12 (31) | 70 (39) | 0.37 |
• Number of elementary visual disturbance^ per aura | 1.97 (1.05) | 1.94 (0.93) | 0.83 |
Sensory symptoms (SS) | 26 (68) | 49 (27) |
<0.0001
|
Dysphasic symptoms (DS) | 12 (31) | 10 (7) |
<0.0001
|
Number of symptoms (VS, SS, DS)/aura |
<0.0001
| ||
• 1 | 10 (26) | 127 (71) | |
• 2 | 19 (50) | 46 (26) | |
• 3 | 9 (23) | 5 (3) | |
Time relation between aura symptoms in one aura | 0.28 | ||
• B* starts simultaneously with A* | 11 (42) | 14 (27) | |
• B starts during A | 11 (42) | 18 (37) | |
• B starts when A ceased | 2 (8) | 5 (10) | |
• B starts after an interval of time after A has ceased | 2 (8) | 12 (24) | |
Headache | 38 (100) | 159 (83) | 0.10 |
• Started before/together with Aura (n=157) | 7 (22) | 27 (21) | 0.88 |
• Intensity (n=192) | 2.3 (0.8) | 2.2 (0.8) | 0.59 |
• Unilateral pain (n=192) | 27 (75) | 100 (64) | 0.21 |
• Throbbing pain (n=187) | 17 (47) | 71 (47) | 0.98 |
• Pain aggravated by physical activity (n=189) | 27 (73) | 98 (65) | 0.32 |
• Associated symptom: nausea (n=192) | 23 (62) | 101 (65) | 0.73 |
• Associated symptom: vomiting (n=189) | 8 (23) | 25 (16) | 0.35 |
• Associated symptom: photophobia (n=192) | 29 (78) | 126 (81) | 0.68 |
• Associated symptom: phonophobia (n=191) | 23 (62) | 99 (64) | 0.81 |
• Associated symptom: osmophobia (n=189) | 6 (43) | 53 (34) | 0.31 |
O7 Ten factors associated to migraine chronification: a cross-sectional study on 318 long-term migraine sufferers
Michele Viana1, Sara Bottiroli1, Grazia Sances1, Giuseppe Nappi1, Cristina Tassorelli1,2
1Headache Science Center, National Neurological Institute C. Mondino; 2Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy
Correspondence: Michele Viana (michele.viana@ymail.com)
Variable | Sign | OR 95% CI |
---|---|---|
SOCIO-DEMOGRAPHIC and LIFESTYLE VARIABLES | ||
Marital Status | ||
- Single | Ref | |
- Married |
0.002
| 3.65 (1.63-8.19) |
- Separated/divorced/Widowed |
0.031
| 4.19 (1.13-15.47) |
Physical Activity |
0.029
| 0.42 (0.19-0.91) |
MIGRAINE CHARACTERISTICS | ||
Age of onset |
0.016
| 0.94 (0.89-0.98) |
Use of at least one migraine preventive medication (whenever for EM, before chronification + MO onset for CM-MO) |
0.014
| 2.36 (1.18-4.71) |
OBSTETRICIAN AND GYNECOLOGICAL HISTORY | ||
Combined Oral Contraceptives (previous/current use vs absent use) |
0.031
| 3.38 (1.10-10.3) |
FAMILY HYSTORY | ||
Family history for headache | 0.082 | 2.63 (0.88-7.86) |
MEDICAL HYSTORY | ||
Depression |
0.012
| 2.91 (1.25-6.73) |
Traumatic head injuries |
0.002
| 3.54 (1.57-7.99) |
Insomnia | ||
- no | Ref | |
- only insomnia | 0.94 | 1.02 (0.47-2.20) |
- insomnia + use of hypnotic drugs |
0.006
| 5.59 (1.65-18.93) |
Snoring |
0.036
| 2.24 (1.05-4.79) |
PSYCHOLOGICAL VARIABLES | ||
Childhood Trauma Questionnaire (total score) |
0.012
| 1.48 (1.09-2.02) |
O8 Long-term effects of the non-paralytic botulinum toxin A molecule BiTox in migraine animal models
Ramla AbuukarAbdullahi1,2, Joseph O. Lloyd1, Martyn G Jones1, Giorgio Lambru2, Adnan Al-Kaisy3, Bazbek Davletov4, Anna P. Andreou1,2
1Headache Research, Wolfson CARD, King's College London; 2Headache Centre, Guy's and St Thomas' NHS Trust; 3Pain Management and Neuromodulation Centre, Guy's and St Thomas' NHS Trust; 4Department of Biomedical Science, University of Sheffield
Correspondence: Anna P. Andreou (anna.andreou@headache-research.com)
O9 White matter microstructure changes in migraine: a diffusional kurtosis imaging study
Sait Ashina1, Bettina Conti2, Benjamin Ades-Aron2, Yvonne Lui2, Mia Minen3, Dmitry Novikov2, Timothy Shepherd2, and Els Fieremans2
1Departements of Neurology, Anesthesia, Critical Care and Pain Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, USA; 2Department of Radiology, New York University School of Medicine, NYU Langone Medical Center, New York, NY, USA; 3Department of Neurology, New York University School of Medicine, NYU Langone Medical Center, New York, NY, USA
Correspondence: Sait Ashina (sashina@bidmc.harvard.edu)
O10 Meningeal contribution to migraine pain: a 3T magnetic resonance angiography study
Sabrina Khan1*, Faisal Mohammad Amin1, Casper Emil Christensen1, Hashmat Ghanizada1, Samaira Younis1, Anne Christine Rye Andersen1, Patrick J. H. de Koning2, Henrik B. W. Larsson3, Messoud Ashina1
1Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark; 2Division of Image Processing, Department of Radiology, Leiden University Medical Center, Leiden, Netherlands; 3Functional Imaging Unit, Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark
Correspondence: Sabrina Khan (sksabrinakhan@gmail.com)
O11 Migraine induction with calcitonin gene-related peptide in patients from erenumab trials
Casper Emil Christensen&; Samaira Younis&; Marie Deen; Sabrina Khan; Hashmat Ghanizada; Messoud Ashina
1Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Correspondence: Messoud Ashina (ashina@dadlnet.dk)
O12 Incidence, clinical characteristics and long-term course of headache in patients with stroke (DMKG multicenter study)
Thomas Dresler1,2, Sarah Dietrich3, Andrea Düring4, Daniel Rothkirch5, Filipp Filippopulos6, Ozan Eren6, Andreas Straube6, Stephan Zierz3, Gudrun Goßrau4, Torsten Kraya3
1Department of Psychiatry and Psychotherapy, University of Tuebingen, Tuebingen, Germany; 2LEAD Graduate School & Research Network, University of Tuebingen, Tübingen, Germany; 3Department of Neurology, Martin-Luther-University Halle-Wittenberg, Halle/ Saale, Germany; 4University Pain Center, University of Dresden (coop.: Elblandklinikum, Meißen), Germany; 5Department of Neurology, BG Clinic Bergmannstrost, Halle/ Saale, Germany; 6Department of Neurology, Ludwig-Maximilians-University Munich, Munich-Grosshadern, Germany
Correspondence: Thomas Dresler (thomas.dresler@med.uni-tuebingen.de)
O13 Headache in transient ischemic attacks
Elena R. Lebedeva1,2, Natalia M. Gurary3, Jes Olesen4
1Department of Neurology and Neurosurgery, the Ural State Medical University, 620000, Yekaterinburg, Russia; 2International Headache Center “Europe-Asia”, Yekaterinburg, 620144, Russia,cosomos@k66.ru; 3Medical Union “New Hospital”, Yekaterinburg, 620000, Russia; 4Danish Headache Center, Department of Neurology, Rigshospitalet-Glostrup, University of Copenhagen, Copenhagen, 2600, Denmark
Correspondence: Elena R. Lebedeva (elenalebedeva1971@gmail.com)
O14 OPTIMIZATION OF VAGUS NERVE STIMULATION EFFICACY ON CORTICAL SPREADING DEPRESSION
Andreia Lopes de Morais1,3, Tsubasa Takizawa1, Inge Mulder1, Tao Qin, BS1, Bruce Simon4, Rubem Carlos Araujo Guedes3, Cenk Ayata1,2
1Department of Radiology, Massachusetts General Hospital, Boston, MA, USA; 2Department of Neurology, Massachusetts General Hospital, Boston, MA, USA; 3Department of Nutrition, UFPE, Recife, Pernambuco, Brazil; 4Electrocore LLC, Basking Ridge, NJ, USA
Correnspondence: Cenk Ayata (cayata@mgh.harvard.edu)
O15 DNA methylation pattern of CALCA gene in patients with migraine
Elisa Rubino1, Silvia Boschi1,2, Alessandro Vacca1, Salvatore Gentile3, Lorenzo Pinessi3, Maria Teresa Giordana1,3, Innocenzo Rainero1,3
1Department of Neuroscience “Rita Levi Montalcini”, University of Torino, Italy; 2Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Italy; 3Department of Neuroscience and Mental Health, AOU Città della Salute e della Scienza di Torino, Italy
Correpondence: Elisa Rubino (elisa.rubino@unito.it)
O16 The impact of chronic headache on workdays, unemployment and disutility in the general population
Espen Saxhaug Kristoffersen1,2, Knut Stavem3,4,5, Christofer Lundqvist1,3,5,6, Michael Bjørn Russell1,3
1Head and Neck Research Group, Research Centre, Akershus University Hospital, Lørenskog; 2Department of General Practice, Institute of Health and Society, University of Oslo, Oslo 3Institute of Clinical Medicine, Campus Akershus University Hospital, University of Oslo, Nordbyhagen; 4Department of Pulmonary Medicine, Medical Division, Akershus University Hospital, Lørenskog 5HØKH, Research Centre, Akershus University Hospital, Lørenskog; 6Department of Neurology, Akershus University Hospital, Lørenskog, Norway
Correspondence: Espen Saxhaug Kristoffersen (e.s.kristoffersen@medisin.uio.no)
O17 Phase 3 studies (EVOLVE-1 & EVOLVE-2) of galcanezumab in episodic migraine: subgroup analyses of efficacy by low- versus high-frequency of migraine headaches
Stephen Silberstein1, Virginia L Stauffer2, Katie Day2, Qi Zhang2, Sarah Lipsius3, Maria-Carmen Wilson4
1Thomas Jefferson University, Philadelphia, Pennsylvania, 19102, USA; 2Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana, 46285, USA; 3Syneos Health, Raleigh, North Carolina, 27604, USA; 4Ochsner Health System, Covington, Louisiana, 70433, USA
Correspondence: Stephen Silberstein; Virginia L Stauffer (stauffer_virginia@lilly.com)
LFEM | HFEM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Treatment | Baseline meana (SD) | N | LSM change from baseline ± SE | LSM change difference ± SE | p-valueb | Baseline meana (SD) | N | LSM change from baseline ± SE | LSM change difference ± SE | p-valueb | p-valuec |
Placebo | 5.8 (1.1) | 295 | -0.9 ± 0.2 | 10.9 (2.0) | 580 | -3.4 ± 0.2 | |||||
Galca 120mg | 5.8 (1.1) | 150 | -2.8 ± 0.3 | -1.8 ± 0.3 | <.001 | 10.9 (2.0) | 286 | -5.4 ± 0.3 | -2.0 ± 0.3 | <.001 | .642 |
Galca 240mg | 5.8 (1.2) | 145 | -2.3 ± 0.3 | -1.4 ± 0.3 | <.001 | 10.7 (2.0) | 283 | -5.5 ± 0.3 | -2.1 ± 0.3 | <.001 | .101 |
LFEM | HFEM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Treatment | Baseline meana (SD) | N | LSM change from baseline ± SE | LSM change difference ± SE | p-valueb | Baseline meana (SD) | N | LSM change from baseline ± SE | LSM change difference ± SE | p-valueb | p-valuec |
Placebo | 4.8 (1.7) | 295 | -0.8 ± 0.2 | 8.9 (3.3) | 580 | -2.7 ± 0.2 | |||||
Galca 120mg | 4.8 (1.8) | 150 | -2.4 ± 0.2 | -1.7 ± 0.2 | <.001 | 8.8 (3.4) | 286 | -4.6 ± 0.2 | -1.9 ± 0.2 | <.001 | .493 |
Galca 240mg | 4.9 (1.7) | 145 | -2.1 ± 0.2 | -1.4 ± 0.2 | <.001 | 8.7 (3.1) | 283 | -4.6 ± 0.2 | -1.9 ± 0.2 | <.001 | .152 |
LFEM | HFEM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Treatment | Baseline meana (SD) | N | LSM change from baseline ± SE | LSM change difference ± SE | p-valueb | Baseline meana (SD) | N | LSM change from baseline ± SE | LSM change difference ± SE | p-valueb | p-valuec |
Placebo | 25.7 (22.6) | 241 | -9.8 ± 1.4 | 36.9 (31.5) | 483 | -15.1 ± 1.2 | |||||
Galca 120mg | 25.1 (21.8) | 126 | -18.6 ± 1.8 | -8.8 ± 1.9 | <.001 | 35.3 (30.2) | 254 | -22.3 ± 1.5 | -7.2 ± 1.5 | <.001 | .557 |
Galca 240mg | 28.7 (24.6) | 124 | -15.9 ± 1.8 | -6.2 ± 1.9 | .001 | 37.2 (29.7) | 241 | -22.1 ± 1.5 | -7.0 ± 1.6 | <.001 | .737 |
O18 Persistence of effect of galcanezumab in patients with episodic or chronic migraine: phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2 and REGAIN studies
Sheena K. Aurora, Qi Zhang1*, Virginia L. Stauffer1
Eli Lilly and Company, Indianapolis, IN, USA
Correspondence: Qi Zhang (zhang_qi_x1@lilly.com)
O19 Efficacy of galcanezumab in patients who failed prior preventive treatments for migraine: results from EVOLVE-1, EVOLVE-2 and REGAIN studies
Grazia Dell’Agnello1, Antje Tockhorn-Heidenreich2, Qi Zhang3, Dustin D. Ruff3, Eric M. Pearlman3, Sheena K. Aurora3, Janet H. Ford3
1Eli Lilly SpA, Sesto Fiorentino, Italy; 2Eli Lilly and Company Limited, Erl Wood Manor, Windlesham, Surrey, UK; 3Eli Lilly and Company, Indianapolis, IN, USA
O20 Cephalic and extracephalic neurophysiological effects of botulinum toxin type A treatment in chronic migraine
Gianluca Coppola1*, Francesca Cortese1, Davide Di Lenola1, Cherubino Di Lorenzo2, Vincenzo Parisi3, Francesco Pierelli1,4.
1Sapienza University of Rome Polo Pontino, Department of Medico-Surgical Sciences and Biotechnologies, Latina, Italy; 2Don Carlo Gnocchi Onlus Foundation, Milan, Italy; 3G.B. Bietti Foundation IRCCS, Research Unit of Neurophysiology of Vision and Neurophthalmology, Rome, Italy; 4IRCCS-Neuromed, Pozzilli (IS), Italy
Correspondence: Gianluca Coppola (gianluca.coppola@gmail.com)
O21 Idiopathic Intracranial Hypertension: Consensus Guidelines on Management
S. P. Mollan1,2, B. Davis3, N. C. Silver4, S. Shaw5, C. Malucci6,7, B. R. Wakerley8,9, A. Krishnan4, S. V. Chavda10, S. Ramalingam10, J. Edwards11,12, K. Hemmings13, M. Williamson13, M. A. Burdon2, G. Hassan-smith1,13, K. Digre14, G. T. Liu15, R. H. Jensen16, A. J. Sinclair1,2,13,17
1Neurometabolism, Institute of Metabolism and Systems Research, University of Birmingham, Edgbaston, B15 2TT, UK; 2Birmingham Neuro-Ophthalmology, Queen Elizabeth Hospital, Birmingham, B15 2WB, UK; 3Department of Neurology, University Hospital North Midlands NHS Trust, Stoke-on-Trent, ST4 6QG; 4Department of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, L9 7LJ, UK; 5Department of Neurosurgery, University Hospital North Midlands NHS Trust, Royal Stoke University Hospital, Newcastle Road, Stoke-on-Trent, ST4 6QG, UK; 6Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, L9 7LJ, UK; 7Department of Paediatric Neurosurgery, Alder Hey Children's NHS Foundation Trust, Liverpool L12 2AP, UK; 8Department of Neurology, Gloucestershire Hospitals NHS Foundation Trust, GL53 7AG, UK; 9Nuffield Department of Clinical Neurosciences, Oxford OX3 9DU, UK; 10Department of Neuroradiology, University Hospitals Birmingham, Queen Elizabeth Hospital, Birmingham, B15 2WB, UK; 11Department of Neurology, Sandwell and West Birmingham NHS Trust, City Hospital, Dudley Road, Birmingham, UK; 12Department of Neurology, University Hospitals Birmingham, Queen Elizabeth Hospital, Birmingham, B15 2WB, UK; 13IIH-UK, Tyne & Wear, NE38 7JX, UK; 14Departments of Ophthalmology and Neurology, Moran Eye Center, University of Utah, Salt Lake City, Utah, USA; 15Neuro-ophthalmology Services, Children's Hospital of Philadelphia and Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA; 16Danish Headache Center, Department of Neurology, Rigshospitalet-Glostrup, University of Copenhagen, Denmark; 17Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, B15 2TH, UK
Correspondence: S. P. Mollan (soozmollan@doctors.org.uk)
O22 Long-term outcomes after reversible cerebral vasoconstriction syndrome: recurrence, cardiovascular events and mortality in a prospective follow-up study
Rosalie Boitet1, Solène De Gaalon2, Grégory Marin3, Claire Duflos3, Caroline Roos2, Jérôme Mawet2, Cécilia Burcin2, Ursula Fiedler2, Marie-Germaine Bousser4 et Anne Ducros1
1Neurology Department & 3Statistics, Montpellier University Hospital, Montpellier; 2Emergency Headache Centre & 4Neurology Department, Lariboisière Hospital, APHP, Paris, France
Correspondence: Rosalie Boitet (rosalie.boitet@gmail.com)
O23 Complete detoxification is the most effective in reducing disability in patients with medication-overuse headache: A randomized controlled open-label trial
Mia Nielsen, Louise N. Carlsen, Rigmor H. Jensen, Signe B. Munksgaard, Ida M. S. Engelstoft, Lars Bendtsen
Danish Headache Center, Neurological Clinic, Rigshospitalet, Glostrup, Denmark
Correspondence: Louise N. Carlsen (louise.ninett.carlsen@regionh.dk)
O24 The economic and humanistic burden of episodic and chronic migraine in Europe
Hicham Benhaddi1; Timothy Fitzgerald2; Sophie McCabe3; Ruth Zeidman3
1Teva Pharmaceuticals, Wilrijk, Belgium; 2Teva Pharmaceuticals, Frazer, Pennsylvania, USA; 3Covance Market Access, London, UK
Correspondence: Hicham Benhaddi (mhowell@hcg-int.com)
O25 Headache outcome measures in medically refractory chronic migraine patients treated with OnabotulinumtoxinA
Lagrata Susie1, Ahmed Maha1, Miller Sarah1,2, Matharu Manjit1,2
1Headache Group, National Hospital for Neurology and Neurosurgery, Queen Square, London; 2Institute of Neurology, University College London, National Hospital for Neurology and Neurosurgery, Queen Square, London
Correspondence: Matharu Manjit (m.matharu@uclmail.net)
Variables | Univariable Analysis r2 | Multivariable Analysis β, Standard error | p=value |
---|---|---|---|
Change in headache days | 0.292 | 1.126, 0.120 | 0.294 |
Change in pain intensity | 0.488 | 0.539, 0.090 | <0.001 |
Change in pain duration | 0.303 | 0.194, 0.083 | 0.022 |
HIT-6 points | 0.130 | 0.216, 0.217 | 0.321 |
O26 Searching for a neural signature of hallodynia in migraine: a volumetric MRI study
Francesca Pistoia1, Claudia Marsecano2, Antonio Carolei1, Riccardo Cornia1, Luana Evangelista1, Alessandra Splendiani2, Simona Sacco1
1Neurological Institute, Department of Applied Clinical Science and Biotechnology, University of L’Aquila, L’Aquila, Italy; 2Radiology section, Department of Applied Clinical Science and Biotechnology, University of L’Aquila, L’Aquila, Italy
Correspondence: Francesca Pistoia (francesca.pistoia@univaq.it)
O27 Dopaminergic symptoms in migraine: a case series on 1148 patients
P. Barbanti1, P. Ferroni2,3, G. Egeo1, L. Fofi1, C. Aurilia1
1Headache and Pain Unit IRCCS San Raffaele Pisana, Rome, Italy; 2Department of Human Sciences and Quality of Life Promotion, San Raffaele Roma Open University, Rome, Italy; 3Interinstitutional Multidisciplinary Biobank (BioBIM), IRCCS San Raffaele Pisana, Rome, Italy
Correpondence: P. Barbanti (piero.barbanti@sanraffaele.it)
O28 Non-invasive vagus nerve stimulation (nVNS) for the acute treatment of episodic migraine: additional findings from the randomised, sham-controlled, double-blind PRESTO trial
Paolo Martelletti1, Licia Grazzi2, Giulia Pierangeli3, Innocenzo Rainero4, Pierangelo Geppetti5, Anna Ambrosini6, Paola Sarchielli7, Piero Barbanti8, Cristina Tassorelli9,10, Eric Liebler11, Marina de Tommaso12
1Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy; 2Headache Center, Carlo Besta Neurological Institute and Foundation, Milano, Italy; 3Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy; 4Department of Neuroscience, University of Turin, Turin, Italy; 5Headache Centre, University Hospital of Careggi, Florence, Italy; 6IRCCS Neuromed, Pozzilli (IS), Italy; 7Neurologic Clinic, Santa Maria della Misericordia Hospital, Perugia, Italy; 8Headache and Pain Unit, IRCCS San Raffaele Pisana, Rome, Italy; 9Headache Science Centre, IRCCS C. Mondino Foundation, Pavia, Italy; 10University of Pavia, Pavia, Italy; 11electroCore, LLC, Basking Ridge, New Jersey, USA; 12Neurophysiology and Pain Unit, University of Bari Aldo Moro, Bari, Italy
Correspondence: Paolo Martelletti (paolo.martelletti@uniroma1.it)
O29 Tocilizumab in patients with giant cell arteritis: results from a Phase 3 randomized controlled trial
Susan P. Mollan1*, Katie Tuckwell2, Sophie Dimonaco2, Micki Klearman3, Neil Collinson2, John H. Stone4
1Birmingham Neuro-Ophthalmology Unit, Department of Ophthalmology, University Hospitals Birmingham NHS Trust, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom; 2Roche Products Ltd., Welwyn Garden City, United Kingdom; 3Genentech, South San Francisco, California; 4Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, Massachusetts, United States
Correspondence: Susan P. Mollan (susan.mollan@uhb.nhs.uk)
O30 Response to lasmiditan for acute treatment of migraine based on prior response to triptan therapy
Kerry Knievel1, Louise Lombard2, Andrew Buchanan2, Simin Baygani2, Joel Raskin2, Joshua Tobin3
1Barrow Neurological Institute, Phoenix, AZ 85013, USA; 2Eli Lilly and Company, Indianapolis, IN 46285, USA; 321st Century Neurology, Xenoscience, Phoenix, AZ 85013, USA
Correspondence: Kerry Knievel; Joshua Tobin (josh.bytheway@rxcomms.com)
O31 Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine
Kathleen A. Day1, Michael Ament2, Virginia L. Stauffer1, Vladimir Skljarevski1, Qi Zhang1, Eric M. Pearlman1, Sheena K Aurora1
1Eli Lilly and Company, Indianapolis, IN 46285 USA; 2Ament Headache Center, Denver, CO, 80206, USA
Correspondence: Virginia L. Stauffer (stauffer_virginia@lilly.com)
Δ from BL in: | EVOLVE-1 Galcanezumab | EVOLVE-2 Galcanezumab | REGAIN Galcanezumab | ||||
---|---|---|---|---|---|---|---|
120 mg (N=210) | 240 mg (N=208) | 120 mg (N=226) | 240 mg (N=220) | 120 mg (N=273) | 240 mg (N=274) | ||
Moderate to severe monthly HDs | Δ (SE) vs. BL (PBO) | -2.89 (0.21) | -2.31 (0.18) | -2.92 (0.33) | |||
Δ (SE) vs. BL | -4.24 (0.25) | -4.15 (0.25) | -3.90 (0.22) | -3.78 (0.22) | -4.90 (0.40) | -4.64 (0.39) | |
Δ (SE) vs. PBO | -1.35 (0.23) | -1.26 (0.24) | -1.59 (0.23) | -1.47 (0.24) | -1.98 (0.38) | -1.72 (0.38) | |
95% CI vs. PBO | (-1.81, -0.89) | (-1.72, -0.80) | (-2.05, -1.13) | (-1.93, -1.01) | (-2.73, -1.23) | (-2.47, -0.97) | |
p-value vs. PBO | <.001 | <.001 | <.001 | <.001 | <.001 | <.001 | |
Mean severity of remaining MHDs | Δ (SE) vs. BL (PBO) | -0.17 (0.02) | -0.15 (0.02) | -0.12 (0.02) | |||
Δ (SE) vs. BL | -0.19 (0.03) | -0.22 (0.03) | -0.20 (0.03) | -0.22 (0.03) | -0.19 (0.02) | -0.19 (0.02) | |
Δ (SE) vs. PBO | -0.02 (0.03) | -0.05 (0.03) | -0.06 (0.03) | -0.08 (0.03) | -0.07 (0.02) | -0.07 (0.02) | |
95% CI vs. PBO | (-0.07, 0.03) | (-0.10, 0.01) | (-0.11, -0.01) | (-0.13, -0.03) | (-0.11, -0.03) | (-0.11, -0.03) | |
p-value vs. PBO | .447 | .086 | .031 | .004 | <.001 | <.001 | |
Monthly MHDs with nausea and/or vomiting | Δ (SE) vs. BL (PBO) | -1.17 (0.16) | -0.87 (0.13) | -1.92 (0.27) | |||
Δ (SE) vs. BL | -1.91 (0.19) | -2.05 (0.19) | -2.02 (0.17) | -1.77 (0.17) | -3.13 (0.33) | -3.20 (0.33) | |
Δ (SE) vs. PBO | -0.74 (0.18) | -0.88 (0.18) | -1.14 (0.18) | -0.90 (0.18) | -1.21 (0.32) | -1.28 (0.31) | |
95% CL for Δ | (-1.10, -0.39) | (-1.23, -0.52) | -0.90 (0.18)) | (-1.25, -0.55) | (-1.82, -0.59) | (-1.90, -0.66) | |
p-value vs. PBO | <.001 | <.001 | <.001 | <.001 | <.001 | <.001 | |
Monthly MHDs with photophobia and phonophobia | Δ (SE) vs. BL (PBO) | -2.10 (0.23) | -1.47 (0.19) | -2.25 (0.36) | |||
Δ (SE) vs. BL | -3.50 (0.27) | -3.54 (0.27) | -3.22 (0.24) | -3.00 (0.24) | -3.81 (0.43) | -3.58 (0.43) | |
Δ (SE) vs. PBO | -1.39 (0.26) | -1.43 (0.26) | -1.76 (0.25) | -1.53 (0.25) | -1.56 (0.41) | -1.33 (0.41) | |
95% CI vs. PBO | (-1.90, -0.89) | (-1.94, -0.93) | (-2.25, -1.27) | (-2.02, -1.04) | (-2.37, -0.75) | (-2.14, -0.52) | |
p-value vs. PBO | <.001 | <.001 | <.001 | <.001 | <.001 | .001 | |
Monthly MHDs with aura | Δ (SE) vs. BL (PBO) | -0.96 (0.12) | -0.97 (0.12) | -1.42 (0.24) | |||
Δ (SE) vs. BL | -1.39 (0.14) | -1.38 (0.15) | -1.45 (0.15) | -1.44 (0.16) | -1.40 (0.29) | -1.89 (0.29) | |
Δ (SE) vs. PBO | -0.43 (0.14) | -0.42 (0.14) | -0.48 (0.17) | -0.48 (0.17) | 0.03 (0.28) | -0.47 (0.28) | |
95% CI vs. PBO | (-0.70, -0.16) | (-0.70, -0.15) | (-0.81, -0.16) | (-0.80, -0.15) | (-0.53, 0.58) | (-1.02, 0.09) | |
p-value vs. PBO | .002 | .002 | .004 | .004 | .922 | .098 | |
Monthly MHDs with prodromal symptoms other than aura | Δ (SE) vs. BL (PBO) | -1.23 (0.14) | -1.01 (0.14) | -1.15 (0.28) | |||
Δ (SE) vs. BL | -1.83 (0.17) | -1.69 (0.17) | -1.84 (0.17) | -1.74 (0.17) | -1.81 (0.34) | -2.18 (0.33) | |
Δ (SE) vs. PBO | -0.61 (0.17) | -0.46 (0.17) | -0.83 (0.18) | -0.72 (0.18) | -0.66 (0.32) | -1.03 (0.32) | |
95% CI vs. PBO | (-0.93, -0.28) | (-0.79, -0.14) | (-1.18, -0.47) | (-1.08, -0.36) | (-1.29, -0.02) | (-1.67, -0.40) | |
p-value vs. PBO | <.001 | . 006 | <.001 | <.001 | .042 | .001 |
O32 Factors associated with significant reduction in migraine headache days: a post hoc analysis of phase 3 placebo-controlled trials of patients with episodic and chronic migraine treated with galcanezumab
Sheena K. Aurora, Dustin D. Ruff, Qi Zhang, Eric M. Pearlman
Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, USA
Correspondence: Qi Zhang (zhang_qi_x1@lilly.com)
O33 Effect of galcanezumab on possible menstrual-related migraine: exploratory analyses results from EVOLVE-1, EVOLVE-2 and REGAIN
Maria S. Fernandes,1 Holland C. Detke,1 Qi Zhang,1 Jelena M. Pavlovic,2 Sheena K. Aurora1
1Eli Lilly and Company, Indianapolis, IN 46285 USA; 2Albert Einstein College of Medicine, Montefiore Headache Center, Bronx, NY 10461USA
Correspondence: Sheena K. Aurora (sheena.aurora@lilly.com)
Period | Treatment | N | Estimated Number of MRMHDs per 30 day Period (SE) | 95% CI | Rate Ratio per 30 day period | 95% CI | P-value |
---|---|---|---|---|---|---|---|
ITT patients with baseline number of MRMHDs >0 for Episodic Migraine | |||||||
Average of Month 1 to 6 | PBO | 321 | 1.58 (0.13) | 1.34, 1.86 | |||
120mg | 170 | 1.16 (0.12) | 0.96, 1.41 | 0.74 | 0.64, 0.85 | <0.001 | |
240mg | 159 | 1.12 (0.12) | 0.90, 1.38 | 0.71 | 0.60, 0.83 | <0.001 | |
ITT patients with baseline number of MRMHDs >0 for Chronic Migraine | |||||||
Average of Month 1 to 3 | PBO | 198 | 3.52 (0.18) | 3.18, 3.90 | |||
120mg | 112 | 2.58 (0.21) | 2.58, 3.40 | 0.84 | 0.73, 0.97 | 0.015 | |
240mg | 97 | 3.01 (0.20) | 2.64, 3.42 | 0.85 | 0.75, 0.98 | 0.021 |
O34 Primary angiitis of the central nervous system and reversible cerebral vasoconstriction syndrome: a comparative study of two cohorts
Hubert de Boysson1, Jean-Jacques Parienti2, Jérôme Mawet3, Caroline Arquizan4, Grégoire Boulouis5, Cécilia Burcin3, Olivier Naggara6, Mathieu Zuber7, Emmanuel Touzé8, Achille Aouba1, Marie-Germaine Bousser9, Christian Pagnoux10, Anne Ducros5
1Internal Medicine, Caen University Hospital, Caen, France; 2Biostatistics, Caen University Hospital, France; 3Emergency Headache Centre, Lariboisière Hospital, APHP, Paris, France; 5Neurology, Montpellier University Hospital, Montpellier, France; 6Neuroradiology, Centre Hospitalier Sainte-Anne, Paris-Descartes University, Paris, France; 7Vascular Neurology - Saint Joseph Hospital, Paris, France; 8Neurology, Caen University Hospital, France; 9Neurology, Lariboisière Hospital, APHP, Paris, France; 10Rheumatology, Mount Sinai Hospital, Toronto, Canada
Correspondence: Anne Ducros (a-ducros@chu-montpellier.fr)
O35 VALIDATION OF THE ITALIAN VERSION OF THE “IDENTIFY CHRONIC MIGRAINE” SCREENING TOOL: THE IT-EC-ID
Simona Sacco1, Silvia Benemei2, Sabina Cevoli3,4, Gianluca Coppola5, Pietro Cortelli3,4, Francesco De Cesaris2, Roberto De Icco6, Cristiano De Marco7, Cherubino Di Lorenzo5, Luana Evangelista1, Pierangelo Geppetti2, Alessia Manni8, Andrea Negro7, Giulia Pierangeli3,4, Francesco Pierelli9, Lanfranco Pellesi10, Luigi Alberto Pini10, Francesca Pistoia1, Maria Pia Prudenzano8, Antonio Russo11, Grazia Sances6, Valentina Taranta1, Cristina Tassorelli6,12, Gioacchino Tedeschi11, Maria Trojano8, Paolo Martelletti7
1Department of Applied Clinical Sciences and Biotechnology, Section of Neurology, University of L’Aquila, L’Aquila, Italy; 2Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy; 3IRCCS Institute of Neurological Science of Bologna, Bologna, Italy; 4Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy; 5Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University Polo Pontino, Latina, Italy; 6Headache Science Center, IRCCS C. Mondino Foundation, Pavia, Italy; 7Department of Clinical and Molecular Medicine, Regional Referral Headache Centre, Sant'Andrea Hospital, Sapienza University, Rome, Italy; 8Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Italy; 9IRCCS NEUROMED, Pozzilli (IS), Italy; 10Headache and Drug Abuse Research Centre, Policlinico Hospital, University of Modena e Reggio Emilia, Modena, Italy; 11Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, Second University of Naples, Napoli, Italy; 12Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy
Correspondence: Simona Sacco (simona.sacco@univaq.it)
O36 Migraine progression in natural subgroups of migraine based on comorbidities and concomitant conditions: results of the Chronic Migraine Epidemiology and Outcomes (CaMEO) study
Richard B. Lipton1, Vincent T. Martin2, Michael L. Reed3, Kristina M. Fanning,3 Aubrey Manack Adams,4 Dawn C. Buse,1
1Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, 10461, USA; 2University of Cincinnati Headache and Facial Pain Center, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA; 3Vedanta Research, Chapel Hill, NC, 27517, USA; 4Allergan plc, Irvine, CA, 92612, USA
Correspondence: Richard B. Lipton (Richard.Lipton@einstein.yu.edu)
Hazard Ratio (95% CI)* | ||||||
---|---|---|---|---|---|---|
LCA Class | Step 3 (Comorbid Class) | Step 4 (Allodynia) | Step 5 (Income ≥50k) | Step 6 (Age) | Step 7 (Gender) | Step 8 (MSSS) |
Most Comorbidities | 2.80 (2.06, 3.80) | 2.59 (1.91, 3.53) | 2.49 (1.83, 3.39) | 3.02 (2.17, 4.20) | 3.07 (2.21, 4.27) | 3.01† (2.17, 4.18) |
Resp/Psych | 1.86 (1.39, 2.47) | 1.75 (1.31, 2.33) | 1.75 (1.32, 2.34) | 1.87 (1.40, 2.49) | 1.93 (1.44, 2.58) | 1.87† (1.40, 2.50) |
Resp/Pain | 2.25 (1.68, 3.02) | 2.13 (1.59, 2.86) | 2.21 (1.64, 2.96) | 2.61 (1.91, 3.57) | 2.63 (1.92, 3.60) | 2.57† (1.88, 3.51) |
Respiratory | 1.40 (1.07, 1.82) | 1.33 (1.01, 1.74) | 1.35 (1.03, 1.76) | 1.40 (1.07, 1.83) | 1.42 (1.09, 1.87) | 1.41‡ (1.07, 1.84) |
Psych | 2.22 (1.63, 3.03) | 2.15 (1.58, 2.94) | 2.10 (1.54, 2.87) | 2.09 (1.53, 2.85) | 2.12 (1.55, 2.89) | 2.07† (1.52, 2.83) |
Cardiovascular | 1.21 (0.84, 1.74) | 1.21 (0.84, 1.74) | 1.25 (0.87, 1.80) | 1.46 (1.00, 2.13) | 1.40 (0.96, 2.04) | 1.41 (0.96, 2.05) |
Pain | 1.35 (0.93, 1.97) | 1.30 (0.89, 1.90) | 1.32 (0.91, 1.93) | 1.48 (1.01, 2.17) | 1.42 (0.96, 2.09) | 1.41 (0.96, 2.07) |
O37 Complete detoxification is the most feasible treatment for medication-overuse headache: A randomized controlled open-label trial
Ida M. S. Engelstoft, Louise N. Carlsen, Signe B. Munksgaard, Mia Nielsen, Rigmor H. Jensen, Lars Bendtsen
Danish Headache Center, Neurological Clinic, Rigshospitalet, Glostrup, Denmark
Correspondence: Louise N. Carlsen (louise.ninett.carlsen@regionh.dk)
O38 Impact of fremanezumab on response rates, acute medication use, and disability in patients with episodic migraine who have failed at least one prior migraine preventive medication
Paul K. Winner1; Rashmi B. Halker Singh2; Joshua M. Cohen3; Ronghua Yang3; Paul P. Yeung3; Verena Ramirez Campos4
1Premiere Research Institute, West Palm Beach, Florida, USA; 2Mayo Clinic, Phoenix, Arizona, USA; 3Teva Pharmaceuticals, Frazer, Pennsylvania, USA; 4Teva Pharmaceuticals, Buenos Aires, Argentina
Correspondence: Paul K. Winner (khokenson@hcg-int.com)
O39 Impact of fremanezumab on response rates, migraine days, and acute medication use in patients with chronic migraine who have failed at least one prior migraine preventive medication
Stephen D. Silberstein1, Jessica Ailani2, Joshua M. Cohen3, Ronghua Yang3, Paul P. Yeung3, Verena Ramirez Campos4
1Jefferson Headache Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA; 2Medstar Georgetown University Hospital, Washington, District of Columbia, USA; 3Teva Pharmaceuticals, Frazer, Pennsylvania, USA; 4Teva Pharmaceuticals, Buenos Aires, Argentina
O40 Efficacy of fremanezumab in migraine patients who have failed at least one prior migraine preventive medication
Peter McAllister1, David W. Dodick2, Joshua M. Cohen3, Ronghua Yang3, Paul P. Yeung3, Verena Ramirez Campos4
1New England Institute for Neurology and Headache, Stamford, Connecticut, USA; 2Department of Neurology, Mayo Clinic, Phoenix, Arizona, USA; 3Teva Pharmaceuticals, Frazer, Pennsylvania, USA; 4Teva Pharmaceuticals, Buenos Aires, Argentina
Correspondence: Peter McAllister (jpotuzak@hcg-int.com)
O41 Cluster headache is not associated with sleep apnea or specific sleep stages
Nunu Lund1; Mads Barloese2; Agneta Snoer1; Anja Petersen1; Poul Jørgen Jennum3; Rigmor H. Jensen1
1Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, University of Copenhagen, Denmark; 2Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet Glostrup, University of Copenhagen, Denmark; 3Danish Center for Sleep Medicine, Dept. of Neurophysiology, Rigshospitalet – Glostrup, University of Copenhagen, Denmark
Correspondence: Nunu Lund (nunu.lund@regionh.dk)
O42 Real-world preventative drug management of Chronic Migraine among Spanish Neurologists
D. García-Azorin1, S. Santos Lasaosa2, A. B. Gago-Veiga3, J. Viguera Romero4, A. L. Guerrero-Peral1, P. Pozo-Rosich5,6.
1Headache Unit, Neurology Department. Hospital Universitario Clínico de Valladolid. Valladolid, Spain; 2Headache monographic consult, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; 3Headache consult, Neurology Department. Hospital Universitario de la Princesa, Madrid, Spain; 4Headache consult. Neuroscience unit. Hospital Universitario Virgen Macarena, Seville, Spain; 1Headache Unit, Neurology Department. Hospital Universitario Clínico de Valladolid. Valladolid, Spain; 5Headache Unit. Neurology Department. Hospital Universitari Vall d’Hebron, Barcelona, Spain; 6Headache Research Group. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain
Correspondence: D. García-Azorin (davilink@hotmail.com)
O43 Effect of the H1-antihistamine clemastine on PACAP38 induced migraine
O44 CSF pressure fluctuations as a marker of isolated CSF hypertension in headache sufferers
L. Rapisarda1,2, G. Demonte1, F. Tosto1, M. Curcio1, B. Vescio5, C. Bombardieri 3, D. Mangialavori4, U. Aguglia2, A. Gambardella2, F. Bono1,2
1Headache Center, and Institutes of Neurology2, Neuroradiology3, Ophthalmology4, Department of Medical and Surgical Sciences, Magna Græcia University of Catanzaro, Italy;5Neuroimaging Research Unit, Institute of Bioimaging and Molecular Physiology, National Research Council, Catanzaro, Italy
Correspondence: G. Demonte (g.dem.1990@gmail.com)
O45 The practical and clinical utility of non-invasive vagus nerve stimulation (nVNS) as an acute treatment for episodic migraine: a post hoc analysis of the randomised sham-controlled PRESTO trial
Licia Grazzi1; Cristina Tassorelli2,3; Marina de Tommaso4; Giulia Pierangeli5; Paolo Martelletti6; Innocenzo Rainero7; Pierangelo Geppetti8; Anna Ambrosini9; Paola Sarchielli10; Eric Liebler11; Piero Barbanti12
1Headache Center, Carlo Besta Neurological Institute and Foundation, Milano, Italy; 2Headache Science Centre, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) C. Mondino Foundation, Pavia, Italy; 3University of Pavia, Pavia, Italy; 4Neurophysiology and Pain Unit, University of Bari Aldo Moro, Bari, Italy; 5IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy; 6Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy; 7Department of Neuroscience, University of Turin, Turin, Italy; 8Headache Centre, University Hospital of Careggi, Florence, Italy; 9IRCCS Neuromed, Pozzilli (IS), Italy; 10Neurologic Clinic, Santa Maria della Misericordia Hospital, Perugia, Italy; 11electroCore, LLC, Basking Ridge, New Jersey, USA; 12Headache and Pain Unit, IRCCS San Raffaele Pisana, Rome, Italy
Correspondence: Licia Grazzi (licia.grazzi@istituto-besta.it)
SISC Oral Presentation
O46 Headache as presenting symptom of neurosarcoidosis
C. Lisotto1, L. Toma2, E. Mampreso3, G. Zanchin4
1Headache Centre, Department of Neurology, Pordenone, Italy, 2Department of Neurology, Ferrara, Italy, 3Headache Centre, Department of Neurology, Piove di Sacco, Italy 4Headache Centre, Department of Neurosciences, Padua, Italy
Correspondence: C. Lisotto (carlo.lisotto@aas5.sanita.fvg.it)
O47 Association of Tanacethum Parthenium, 5 - hydroxy tryptophan and magnesium ( Aurastop) versus Mg tablet impact on aura phenomena and its evolution : an observational study
Lidia Savi (lsavi@cittadellasalute.to.it)
Headache Center LBS, Lugano, Switzerland
O48 Hemicrania continua-like headache revealed a subacute internal carotid artery dissection in patient with unrecognized connective tissue disorder
Silvia Ricci, Gaetano Salomone, Francesca Rossi, Alberto Polo
Neurology department- Mater Salutis Hospital- ULSS Scaligera, Verona, Italy
Correspondence: Silvia Ricci (silv.ricci@yahoo.it)
O49 Neurophysiological correlates of clinical improvement after Greater Occipital Nerve (GON) Block in Chronic Migraine: relevance for chronic migraine pathophysiology
Alessandro Viganò1,2, Maria Claudia Torrieri3, Massimiliano Toscano1,4, Francesca Puledda5, Barbara Petolicchio1, Tullia Sasso D’Elia2, Angela Verzina6, Sonia Ruggiero1, Marta Altieri1, Edoardo Vicenzini1, Jean Schoenen7, Vittorio Di Piero1,8
1Headache Centre & Neurocritical Care Unit. Department of Human Neurosciences, Sapienza – University of Rome, Rome, Italy; 2Molecular and Cellular Networks Lab. Department of Anatomy, Histology, Forensic medicine and Orthopaedics, Sapienza – University of Rome, Rome, Italy; 3Rita Levi Montalcini Department of Neuroscience, Città della Salute e della Scienza, Turin, Italy; 4Department of Neurology – Fatebenefratelli Hospital – Rome, Italy; 5Headache Group, Department of Basic and Clinical Neuroscience, King's College London, and NIHR-Wellcome Trust King's Clinical Research Facility, Wellcome Foundation Building, King's College Hospital, London, SE5 9PJ, UK; 6Department of Neurology, University of Perugia, Perugia, Italy; 7Headache Research Unit. Department of Neurology, University of Liège, Citadelle Hospital, Liège, Belgium; 8University Consortium for Adaptive Disorders and Head pain – UCADH, Pavia, Italy
Correspondence: Alessandro Viganò (alessandro.vigano@uniroma1.it)
O50 Short-Term Psychodynamic Psychotherapy versus OnabotulinumtoxinA as preventive therapy in Chronic Migraine: a real world study
M. Alessiani1, B. Petolicchio1,2, A. Viganò1, R. Di Giambattista3, M. Altieri1, E. Gilliéron3,V. Di Piero1,2
1Department of Human Neuroscience, Sapienza University of Rome, 00185 - Rome, Italy; 2 “Enzo Borzomati” Pain Medicine Unit – University Hospital Policlinico Umberto I, 00161-Rome, Italy; 3 Istituto Europeo di Psicoterapia Psicoanalitica (IREP), 00187 - Rome, Italy
Correspondence: B. Petolicchio (barbara.petolicchio@uniroma1.it)
O51 Resting-state between-networks functional connectivity is abnormal in chronic migraine patients
Gianluca Coppola1*, Barbara Petolicchio2, Antonio Di Renzo1, Emanuele Tinelli2, Cherubino Di Lorenzo3, Vincenzo Parisi1, Mariano Serrao4, Valentina Calistri2, Stefano Tardioli2, Gaia Cartocci2, Francesca Caramia2, Vittorio Di Piero2, and Francesco Pierelli4,5
1G.B. Bietti Foundation IRCCS, Research Unit of Neurophysiology of Vision and Neurophthalmology, Rome, Italy; 2Sapienza University of Rome, Department of Neurology and Psychiatry, Rome, Italy; 3Don Carlo Gnocchi Onlus Foundation, Milan, Italy; 4Sapienza University of Rome Polo Pontino, Department of Medico-Surgical Sciences and Biotechnologies, Latina, Italy; 5IRCCS-Neuromed, Pozzilli (IS), Italy
Correspondence: Gianluca Coppola (gianluca.coppola@gmail.com)
O52 New daily persistent headache in a pediatric cohort
Laura Papetti, Barbara Battan, Romina Moavero, Giorgia Sforza, Samuela Tarantino, Massimiliano Valeriani
Headache Center Bambino Gesù Children Hospital, Rome Italy
Correspondence: Laura Papetti (laura.papetti@opbg.net)
O53 Clinical report of nineteen Italian patients with nummular headache
Lanfranco Pellesi1, Silvia Benemei2, Sabina Cevoli3, Valentina Favoni3, Chiara Lupi2, Edoardo Mampreso4, Antonio Russo5, Simona Guerzoni1
1Medical Toxicology, Headache and Drug Abuse Centre, University of Modena e Reggio Emilia, Modena, Italy; 2Headache Centre, Careggi University Hospital, Department of Health Sciences, University of Florence, Florence, Italy; 3IRCCS Institute of Neurological Sciences of Bologna, Bologna, Italy; 4Headache Centre, Headache Centre, Neurology - Euganea, Padova Health Unit, Padua, Italy; 5Headache Centre, Department of Medical, Surgical, Neurological, Metabolic and Ageing Sciences, University of Campania “Luigi Vanvitelli”, Naples, Italy
Correspondence: Lanfranco Pellesi (lanfranco.pellesi@gmail.com)
Patient | Sex | Age (years) | Age of onset (years) | Duration (years) | Episodic | Chronic | Location | Accompanying symptoms | Quality of Pain | NRS |
---|---|---|---|---|---|---|---|---|---|---|
1 | M | 42 | 36 | 6 | X | Right, P | Conjunctival lacrimation | Stabbing | 3 | |
2 | M | 63 | 20 | 43 | X | Right, O | Confusion | Persistent | 5 | |
3 | F | 65 | 63 | 2 | X | Left, V | Tinnitus and dizziness | Stabbing | 8 | |
4 | M | 52 | 52 | 0.01 | X | V | Not present | Stinging and stabbing | 4 | |
5 | F | 33 | 33 | 0.25 | X | Right, P | Photophobia and nausea | Throbbing | 8 | |
6 | F | 40 | 40 | 0.01 | X | Left, O | Dizziness | Stabbing | 8 | |
7 | M | 39 | 39 | 0.01 | X | O | Dizziness | Stabbing | 9 | |
8 | M | 55 | 52 | 3 | X | Left, O | Not present | Stabbing | 8 | |
9 | F | 54 | 53 | 1 | X | Left, T | Not present | Throbbing | 5 | |
10 | F | 58 | 57 | 1 | X | V | Not present | Pressing and tightening | 2 | |
11 | F | 35 | 33 | 2 | X | Right, T | Not present | Pressing and tightening | 3 | |
12 | M | 44 | 18 | 26 | X | Left, P | Not present | Stinging | 5 | |
13 | M | 36 | 36 | 0.33 | X | Right, O | Not present | Throbbing | 7 | |
14 | M | 30 | 18 | 12 | X | Left, T | Conjunctival injection and ptosis | Pressing and tightening | 5 | |
15 | F | 40 | 40 | 0.17 | X | Left, T | Not present | Throbbing | 7 | |
16 | M | 67 | 20 | 47 | X | Right, V | Not present | Pressing and tightening | 5 | |
17 | F | 63 | 63 | 3 | X | Left, T | Not present | Pressing and tightening | 6 | |
18 | F | 25 | 25 | 6 | X | Right, T | Not present | Pressing and tightening | 5 | |
19 | M | 43 | 43 | 1 | X | Right, T | Facial redness | Stinging | 10 |
EHF Poster Presentation
P1 The cost of migraine in Greece: a half billion euros disease
Panagiotis Stafylas1, Marianthi Karaiskou2, Eirini Tsiamaki3, Maria Kalogeropoulou4, Dimos-Dimitrios Mitsikostas5
1HTA Consultant, HealThink, Thessaloniki, Greece; 2HTA Consultant, HealThink, Thessaloniki, Greece; 3Medical Advisor, Therapeutic Area Neuroscience, Novartis Hellas SACI, Athens, Greece; 4Health Economics Manager, Novartis Hellas SACI, Athens, Greece; 5Associate Professor of Neurology, National and Kapodistrian University of Athens, Athens, Greece
Correspondence: Maria Kalogeropoulou (maria.kalogeropoulou@novartis.com)
P2 Single-pulse transcranial magnetic stimulation (sTMS) for the treatment of migraine: a prospective real world experience
Lambru Giorgio1, Hill Bethany1, Lloyd Joseph2, Al-Kaisy Adnan3, Andreou Anna P1,2
1The Headache Centre, Guy’s and St Thomas’ NHS Foundation Trust, London, UK; 2Wolfson CARD, King’s College London, London, UK; 3Pain and Neuromodulation Academic Research Centre, Guy’s and St Thomas’ NHS Foundation Trust, London, UK
Correspondence: Lambru Giorgio (giorgiolambru@gmail.com)
P3 The impact of fremanezumab on symptoms associated with migraine in patients with episodic migraine
Jan L. Brandes1; Paul P. Yeung2; Ernesto Aycardi2; Ronghua Yang2; Yuju Ma2; Joshua M. Cohen2
1Nashville Neuroscience Group, Vanderbilt University, Department of Neurology, Nashville, Tennessee, USA; 2Teva Pharmaceuticals, Frazer, Pennsylvania, USA
Correspondence: Jan L. Brandes (jtuck@hcg-int.com)
P4 The impact of fremanezumab on symptoms associated with migraine in patients with chronic migraine
Peter McAllister1, Paul P. Yeung2, Ernesto Aycardi2, Ronghua Yang2, Yuju Ma2, Joshua M. Cohen2
1New England Institute for Neurology and Headache, Stamford, Connecticut, USA; 2Teva Pharmaceuticals, Frazer, Pennsylvania, USA
Correspondence: Peter McAllister (pwong@hcg-int.com)
P5 Long-term impact of fremanezumab on response rates, acute headache medication use, and disability in patients with episodic migraine: interim results of a 1-year study
Jan L. Brandes1*; Paul P. Yeung2; Joshua M. Cohen2; Sanjay K. Gandhi2; Timothy Fitzgerald2 ; Ronghua Yang,2; Yuju Ma2; Ernesto Aycardi2
1Nashville Neuroscience Group, Nashville, Tennessee; 2Teva Pharmaceuticals, Frazer, Pennsylvania, USA
Correspondence: Jan L. Brandes (MCoakley@hcg-int.com)
P6 Overview of fremanezumab pooled safety data from placebo-controlled phase 2 and 3 studies
Stephen D. Silberstein1, Nicola Faulhaber2, Xiaoping Ning3, Paul P. Yeung3, Jimmy Schiemann3, Ronghua Yang3, Yuju Ma3, Ernesto Aycardi3
1Thomas Jefferson University, Philadelphia, Pennsylvania, USA; 2Teva Pharmaceuticals, Ulm, Germany; 3Teva Pharmaceuticals, Frazer, Pennsylvania, USA
Correspondence: Stephen D. Silberstein (abormes@hcg-int.com)
P7 Reversion of patients with chronic migraine to an episodic migraine classification with fremanezumab treatment
Joshua M. Cohen1; Kristen Bibeau1; Maja Galic2; Michael J. Seminerio1; Verena Ramirez Campos3; Rashmi B. Halker Singh4; Jessica Ailani5
1Teva Pharmaceuticals, Frazer, Pennsylvania, USA; 2Teva Pharmaceuticals, Amsterdam, The Netherlands; 3Teva Pharmaceuticals, Buenos Aires, Argentina; 4Mayo Clinic, Phoenix, Arizona, USA; 5Medstar Georgetown University Hospital, Washington, District of Columbia, USA
Correspondence: Joshua M. Cohen (jbanigan@hcg-int.com)
P8 Efficacy of fremanezumab in patients with chronic migraine with or without concomitant use of preventive medication
Peter J. Goadsby1*, David W. Dodick2, Stephen D. Silberstein3, Paul P. Yeung4, Tricia Blankenbiller4, Xiaoping Ning4, Ronghua Yang4, Yuju Ma4, Ernesto Aycardi4, Marcelo E. Bigal4
1NIHR-Wellcome Trust King’s Clinical Research Facility, King’s College, London, UK; 2Mayo Clinic, Phoenix, Arizona, USA; 3Jefferson Headache Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA; 4Teva Pharmaceuticals, Frazer, Pennsylvania, USA
Correspondence: Peter J. Goadsby (srieger@hcg-int.com)
P9 The Effect of Cognitive Behavioural Therapy on Self-Efficacy and Headache Frequency, in Chronic Migraine
Ayhan Bingöl, Derya Uludüz, Özlem Mercan, Yasemin Akıncı, Duygu Deringöl, Sabahattin Saip, Aksel Siva
Department of Neurology, Istanbul University Cerrahpasa Faculty of Medicine, Istanbul, Turkey, 34096
Correspondence: Özlem Mercan (ozlemmercan3@gmail.com)
P10 Efficacy of fremanezumab in patients with chronic migraine and comorbid moderate to moderately severe depression
Joshua M. Cohen1, Paul P. Yeung1, Ernesto Aycardi1, Marcelo E. Bigal1, Ronghua Yang1, Kristen Bibeau1, Maja Galic2, Michael J. Seminerio1, Richard B. Lipton3, Dawn C. Buse3
1Teva Pharmaceuticals, Frazer, Pennsylvania, USA; 2Teva Pharmaceuticals, Amsterdam, The Netherlands; 3Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA
Correspondence: Joshua M. Cohen (mmathew@hcg-int.com)
P11 Achievement of response over time with fremanezumab in the treatment of chronic and episodic migraine
Stephen D. Silberstein1, Richard B. Lipton2, Merle L. Diamond3, Joshua M. Cohen4, Ronghua Yang4, Bo Jiang4
1Jefferson Headache Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA; 2Albert Einstein College of Medicine, Bronx, New York, USA; 3Diamond Headache Clinic, Chicago, Illinois, USA; 4Teva Pharmaceuticals, Frazer, Pennsylvania, USA
Correspondence: Stephen D. Silberstein (jtuck@hcg-int.com)
P12 The impact of fremanezumab on medication overuse in patients with chronic migraine
Stephen D. Silberstein1, Sait Ashina2, Zaza Katsarava3, Kristen Bibeau4, Michael J. Seminerio4, Danielle E. Harlow4, Joshua M. Cohen4
1Jefferson Headache Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA; 2Beth Israel Deaconess Medical Center Comprehensive Headache Center, Harvard Medical School, Boston, Massachusetts, USA; 3University of Essen, Unna, Germany; 4Teva Pharmaceuticals, Frazer, Pennsylvania, USA
Correspondence: Stephen D. Silberstein (khokenson@hcg-int.com)
P13 Work productivity amongst those with migraine: results from the My Migraine Voice survey
Todd J. Schwedt1, Rebeca Quintana2, Veruska Carboni3, Paolo Martelletti4, 5, Michel Lanteri-Minet6, Hans-Christoph Diener7, Annik K.-Laflamme8, Elena Ruiz de la Torre9, Audrey Craven10, Annette Vangaa Rasmussen11, Donna Walsh12, Simon Evans13, Paula Dumas14, Rachel Fink8, Angela Fiorin8, Stephanie Ribbe8, Pamela Vo8
1Neurology Arizona, Mayo Clinic, Phoenix, United States; 2GFK, Madrid, Spain; 3GfK Health, Basel, Switzerland; 4Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy; 5EHF; 6Département d’Evaluation et Traitement de la Douleur, Centre Hospitalo-Universitaire de Nice, -, France; 7Department of Neurology and Headache Center, University Duisburg-Essen, -, Germany; 8ovartis Pharma AG, Basel, Switzerland; 9European Headache Alliance, Brussels, Belgium; 10Migraine Association Ireland, Dublin, Ireland 11Rigshospitalet Glostrup, Copenhagen, Denmark; 12European Federation of Neurological Associations, Brussels, Belgium; 13Migraine Action, Leicester, United Kingdom; 14Migraine Again, United States
Correspondence: Todd J. Schwedt (Schwedt.Todd@mayo.edu)
P14 Headache following mild traumatic brain injury (MTBI) in a population-based, controlled, longitudinal study
Lena H. Nordhaug1, Mattias Linde1, Turid Follestad2 Toril Skandsen1, Anne Vik1
1Department of Neuromedicine and Movement Science, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Postbox 8905, 7491 Trondheim, Norway; 2Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway
Correspondence: Lena H. Nordhaug (lena.h.nordhaug@ntnu.no)
P15 A randomised, double-blind, placebo-controlled study of erenumab safety in patients with stable angina
Christophe Depre1, Lubomir Antalik2, Amaal Starling3, Michael Koren4, Osaro Eisele1, Daniel D. Mikol1
1Amgen Inc., Thousand Oaks, CA, USA; 2Regional Hospital, Cardiological Department, Slovakia; 3Mayo Clinic, Scottsdale, AZ, USA; 4Jacksonville Center for Clinical Research, Jacksonville, FL, USA
Correspondence: Lubomir Antalik (antalik@nspbr.sk)
Parameter | Erenumab 140 mg | Placebo |
---|---|---|
ETT | ||
Peak SBP | 172.1 (22.9) | 172.2 (22.4) |
Peak DBP | 90.1 (15.1) | 90.3 (15.4) |
Peak heart rate | 122.2 (19.7) | 122.6 (22.0) |
Post-ETT | ||
SBP | 134.5 (15.2) | 135.0 (18.5) |
DBP | 76.2 (9.3) | 79.2 (11.6) |
Heart rate | 73.3 (8.7) | 78.8 (13.7) |
P16 Burden and patient-reported outcomes of migraine patients with prior prophylactic treatment failure: Study design of the multinational BECOME study
Paolo Martelletti1, Christian Lucas2, Patricia Pozo-Rosich3, David Watson4, Charly Gaul5, Shannon Ritter6, Josefin Snellman6
1Department of Clinical and Molecular Medicine, Sapienza University of Rome, Sant'Andrea Hospital, Via di Grottarossa, Rome, Italy; 2Hopital Salengro, CHRU de Lille, Service de Neurochirurgie, Lille Cedex, France; 3Headache Unit, Neurology Department, Vall d'Hebron University Hospital, Barcelona, and Headache Research Group, Vall d’Hebron Institute of Research (VHIR), Universitat Autonoma of Barcelona, Spain; 4Hamilton Medical Group, Aberdeen, Scotland; 5Migraine and Headache Clinic Königstein, Königstein im Taunus, Germany; 6Novartis Pharma AG, Basel, Switzerland
Correspondence: Paolo Martelletti (paolo.martelletti@uniroma1.it)
P17 My Migraine Voice: a worldwide survey of 11,266 migraine patients
Elena Ruiz de la Torre1, Rebeca Quintana2, Veruska Carboni3, Paolo Martelletti4,5, Todd J. Schwedt6, Michel Lanteri-Minet7, Hans-Christoph Diener8, Annik K.-Laflamme9, Annette Vangaa Rasmussen10, Donna Walsh11, Audrey Craven12, Simon Evans13, Paula Dumas14, Rachel Fink9, Angela Fiorin9, Stephanie Ribbe9, Pamela Vo9
1European Headache Alliance, Brussels, Belgium; 2GFK, Madrid, Spain; 3GfK Health, Basel, Switzerland; 4Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy; 5EHF; 6Neurology Arizona, Mayo Clinic, Phoenix, United States; 7Département d’Evaluation et Traitement de la Douleur, Centre Hospitalo-Universitaire de Nice, France,; 8Department of Neurology and Headache Center, University Duisburg-Essen, -, Germany; 9Novartis Pharma AG, Basel, Switzerland; 10Rigshospitalet Glostrup, Copenhagen, Denmark; 11European Federation of Neurological Associations, Brussels, Belgium; 12Migraine Association Ireland, Dublin, Ireland; 13Migraine Action, Leicester, United Kingdom; 14Migraine Again, United States
Correspondence: Elena Ruiz de la Torre (elena@europeanheadachealliance.org)
P18 Economic burden of migraine: healthcare resource utilization in the My Migraine Voice survey
Paolo Martelletti1,2, Rebeca Quintana3, Veruska Carboni4, Todd J. Schwedt5, Michel Lanteri-Minet6, Hans- Christoph Diener7, Annik K.-Laflamme8, Elena Ruiz de la Torre9, Audrey Craven10, Simon Evans11, Donna Walsh12, Annette Vangaa Rasmussen13, Paula Dumas14, Rachel Fink8, Angela Fiorin8, Stephanie Ribbe8, Pamela Vo8
1Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy; 2EHF; 3GFK, Madrid, Spain; 4GfK Health, Basel, Switzerland; 5Neurology Arizona, Mayo Clinic, Phoenix, United States; 6Département d’Evaluation et Traitement de la Douleur, Centre Hospitalo-Universitaire de Nice, France; 7Department of Neurology and Headache Center, University Duisburg-Essen, Germany; 8Novartis Pharma AG, Basel, Switzerland 9European Headache Alliance, Brussels, Belgium; 10Migraine Association Ireland, Dublin, Ireland; 11Migraine Action, Leicester, United Kingdom; 12European Federation of Neurological Associations, Brussels, Belgium; 13Rigshospitalet Glostrup, Copenhagen, Denmark; 14Migraine Again, United States
Correspondence: Paolo Martelletti (paolo.martelletti@uniroma1.it)
Overall (N=11266) | No prior prophylactic treatment | No prophylactic TF | 1 prophylactic TF | 2 or more prophylactic TFs | |
---|---|---|---|---|---|
Brain scan | |||||
Proportion of patients (%) | 58% | 29% | 46% | 56% | 68% |
Average number of scans | 2.1 | 1.7 | 1.8 | 1.7 | 2.3 |
ER visits | |||||
Proportion of patients (%) | 38% | 17% | 28% | 28% | 46% |
Average number of visits | 3.3 | 2.9 | 2.5 | 2.7 | 3.5 |
Overnight hospital stay in past 12 months | |||||
Proportion of patients (%) | 23% | 8% | 14% | 15% | 29% |
Average nights of stay | 3.2 | 2.6 | 2.6 | 2.3 | 3.4 |
P19 Effect of galcanezumab following double-blind treatment in patients with migraine: results from EVOLVE-1 and EVOLVE-2
Qi Zhang, Paula A. Morrow, Virginia L. Stauffer, Vladimir Skljarevski, Eric M. Pearlman, Sheena K Aurora
Eli Lilly and Company, Indianapolis, IN 46285 USA
P20 Sustained efficacy over 1 year of treatment with erenumab: results from the extension phase of the STRIVE study in episodic migraine
Peter J. Goadsby1, Uwe Reuter2, Yngve Hallström3, Gregor Broessner4, Jo H Bonner5, Feng Zhang6, Sandhya Sapra6, Denise E Chou6, Jan Klatt7, Hernan Picard6, Robert A Lenz6, Daniel D Mikol6
1NIHR-Wellcome Trust King’s Clinical Research Facility, King’s College Hospital, London, UK; 2Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany; 3Neuro Center, St Görans Hospital, Stockholm, Sweden; 4Department of Neurology, Headache Outpatient Clinic, Medical University of Innsbruck, Innsbruck, Austria; 5Mercy Research, Saint Louis, MO, USA; 6Amgen Inc., Thousand Oaks, CA, USA; 7Novartis Pharma AG., Basel, Switzerland
Correspondence: Peter J. Goadsby (peter.goadsby@kcl.ac.uk)
Outcome measures | Erenumab 140 mg (ATP)(N=424) | Erenumab 70 mg (ATP)(N=421) |
---|---|---|
MMD | ||
Baseline MMD, mean (SD) | 8.23 (2.43) | 8.34 (2.48) |
Change from baseline to Week 52 | −4.64 (0.19) | −4.22 (0.22) |
Change from Week 24 to Week 52 (ATP) | −1.78 (0.19) | −1.10 (0.21) |
Proportion of patients achieving >=50% reduction from baseline in MMD at Week 52, n/N1 (%) | 239/368 (64.9) | 225/369 (61.0) |
MSMD | ||
Baseline MSMD, mean (SD) | 3.49 (3.49) | 3.60 (3.41) |
Change from baseline to Week 52 | −2.00 (0.15) | −1.75 (0.14) |
Change from Week 24 to Week 52 (ATP) | −0.98 (0.13) | −0.72 (0.14) |
P21 Efficacy outcomes in responder and nonresponder patients with episodic migraine treated preventively with erenumab in the STRIVE study
Gregor Brössner1, Uwe Reuter2, Jo H Bonner3, David W Dodick4, Hernan Picard5, Shihua Wen6, Shannon Ritter6, Jan Klatt7, Daniel D Mikol5
1Headache Outpatient Clinic, Medizinische Universität Innsbruck, Innsbruck, Austria; 2Charité Universitätsmedizin Berlin, Berlin, Germany; 3Mercy Clinic Neurology and Headache Center, Saint Louis, MO, USA; 4Mayo Clinic, Scottsdale, AZ, USA; 5Amgen Inc., Thousand Oaks, CA, USA; 6Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 7Novartis Pharma AG, Basel, Switzerland
Correspondence: Uwe Reuter (Uwe.Reuter@charite.de)
Erenumab 70 mg
|
Responders (n=135),
baseline
|
Responders,
change
|
Non responders (n=161), baseline
|
Non responders change
|
Overall
(n=312),
baseline
|
Overall,
change (mean±SE)
|
MMD
| 8.3 ±2.5 | −6.1 ±2.1 | 8.3 ±2.4 | −1.1 ±2.8 | 8.3 ±2.5 | −3.4 ±0.2 |
MSMD | 2.9 ±3.3 | −2.0 ±2.4 | 3.8 ±3.5 | −0.4 ±2.0 | 3.2 ±3.4 | −1.1 ±0.1 |
MPFID-EA | 13.5 ±8.5 | −9.9 ±6.8 | 14.1 ±8.9 | −2.4 ±7.0 | 14.0 ±8.9 | −5.8 ±0.5 |
MPFID-PI | 11.8 ±9.3 | −8.4 ±7.00 | 12.7 ±9.6 | −1.1 ±7.7 | 12.6 ±9.7 | −4.4 ±0.5 |
Erenumab 140 mg
|
Responders (n=159),
baseline
|
Responders,
change
|
Non responders (n=143), baseline
|
Non responders change
|
Overall
(n=318),
baseline
|
Overall,
Change (mean±SE)
|
MMD
| 8.2 ±2.4 | −6.0 ±2.1 | 8.5 ±2.5 | −1.4 ±2.3 | 8.3 ±2.5 | −3.8 ±0.2 |
MSMD | 3.2 ±3.4 | −2.3 ±2.6 | 3.6 ±3.5 | −0.9 ±1.7 | 3.4 ±3.5 | −1.6 ±0.1 |
MPFID-EA | 12.6 ±7.9 | −8.9 ±6.8 | 13.6 ±8.6 | −2.5 ±7.0 | 13.0 ±8.2 | −5.8 ±0.4 |
MPFID-PI | 11.5 ±8.3 | −7.6 ±7.0 | 12.8 ±9.7 | −1.8 ±8.00 | 12.0 ±9.0 | −4.8 ±0.5 |
P22 Efficacy of erenumab in patients with chronic migraine achieving ≥50% response: Subgroup analysis of a double-blind, randomised study
David Dolezil1, Jan Klatt2, Sunfa Cheng3, Feng Zhang3, Shihua Wen4, Shannon Ritter4, Daniel D Mikol3
1Prague Headache Center, DADO MEDICAL s.r.o., Prague, Czech Republic; 2Novartis Pharma AG, Basel, Switzerland; 3Amgen Inc., Thousand Oaks, CA, USA; 4Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
Correspondence: Jan Klatt (jan.klatt@novartis.com)
Outcome measures | Erenumab 70 mg | Erenumab 140 mg | ||||
---|---|---|---|---|---|---|
≥50% Responders (N=75) | Non-responders (N=113) | Overall population (N=188) | ≥50% Responders (N = 77) | Non-responders (N =110) | Overall population (N=187) | |
Change from baseline to Week 12 | ||||||
MMD | −12.2 (2.9) | −2.6 (4.3) | −6.6 (6.1) | −12.5 (4.6) | −2.2 (4.4) | −6.5 (6.8) |
MSMD | −5.2 (5.2) | −1.8 (4.1) | −3.3 (4.9) | −6.9 (5.6) | −2.4 (3.9) | −4.3 (5.2) |
HIT-6 | −10.0 (7.6) | −2.8 (5.1) | −5.7 (7.2) | −10.7 (8.0) | −1.7 (5.1) | −5.5 (7.9) |
MIDAS total score | −29.1 (45.4) | −12.6 (41.5) | −19.5 (43.8) | −35.0 (45.2) | −5.8 (38.4) | −18.1 (43.7) |
MSQ-RFP | 23.0 (19.4) | 6.0 (19.8) | 13.0 (21.3) | 25.7 (23.2) | 4.8 (16.2) | 13.7 (22.1) |
MSQ-RFR | 29.7 (18.6) | 9.4 (19.8) | 17.7 (21.7) | 32.7 (23.7) | 8.2 (18.5) | 18.7 (24.1) |
MSQ-EF | 30.5 (25.4) | 11.1 (26.7) | 19.1 (27.8) | 33.3 (27.2) | 6.3 (19.9) | 17.8 (26.8) |
P23 Long-term safety and tolerability of erenumab: Three-plus year results from an ongoing open-label extension study in episodic migraine
Messoud Ashina1*, Peter J. Goadsby2, Uwe Reuter3, Stephen Silberstein4, David Dodick5, Gregory A. Rippon6, Jan Klatt7, Feng Zhang6, Sunfa Cheng6, Daniel D. Mikol6
1Department of Neurology, Danish Headache Center, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; 2NIHR-Wellcome Trust King’s Clinical Research Facility, King’s College London, UK; 3Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany; 4Jefferson Headache Center, Thomas Jefferson University, Philadelphia, PA, USA; 5Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA; 6Amgen Inc., Thousand Oaks, CA, USA; 7Novartis Pharma AG, Basel, Switzerland
Correspondence: Messoud Ashina (ashina@dadlnet.dk)
P24 Assessment of the long-term safety and efficacy of erenumab during open-label treatment of subjects with chronic migraine
Stewart Tepper1, Messoud Ashina2, Uwe Reuter3, Jan L Brandes4, David Doležil5, Stephen Silberstein6, Paul Winner7, Feng Zhang8, Sunfa Cheng9, Daniel Mikol9
1Geisel School of Medicine at Dartmouth, Hanover, NH, USA; 2Department of Neurology, Danish Headache Center, Rigshospitalet Glostrup, University of Copenhagen, Copenhagen, Denmark; 3Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany; 4Nashville Neuroscience Group and Vanderbilt University Department of Neurology, Nashville, TN, USA; 5DADO MEDICAL sro, Prague Headache Center, Prague, Czech Republic; 6Jefferson Headache Center, Thomas Jefferson University, Philadelphia, PA, USA; 7Premiere Research Institute, Nova Southeastern University, West Palm Beach, FL, USA; 8Global Bio statistical Science, Amgen Inc, Thousand Oaks, CA, USA; 9Global Development, Amgen Inc, Thousand Oaks, CA, USA
Correspondence: Uwe Reuter (Uwe.Reuter@charite.de)
Adverse event | Erenumab 70 mg/140 mg (N=609), n (%) / e [r] |
---|---|
Viral upper respiratory tract infection | 96 (15.8) / 586.0 [16.4] |
Upper respiratory tract infection | 45 (7.4) / 624.5 [7.2] |
Sinusitis | 44 (7.2) / 620.4 [7.1] |
Arthralgia | 27 (4.4) / 636.7 [4.2] |
Migraine | 26 (4.3) / 638.5 [4.1] |
Outcome | Time-point | Erenumab 70-mg (OLE last dose received) (N=266) | Erenumab 140-mg (OLE last dose received) (N=203) |
---|---|---|---|
Change from baseline in MMD, mean (95% CI) | Baseline | 17.92 (17.38, 18.45) | 17.79 (17.16, 18.43) |
Week 40 | -7.81 (-8.64, -6.97 ) (n=228) | -9.96 (-10.91, -9.00 ) (n=187) | |
Week 52 | -8.49 (-9.35, -7.63) (n=214) | -10.48 (-11.52, -9.43) (n=165) | |
Change from baseline in MSMD, mean (95% CI) | Baseline | 10.22 (9.39, 11.06) | 8.32 (7.28, 9.35) |
Week 40 | -4.68 (-5.33, -4.04) (n=228) | -4.59 (-5.32, -3.85) (n=187) | |
Week 52 | -5.05 (-5.76, -4.34) (n=214) | -4.97 (-5.81, -4.13) (n=165) | |
Change from baseline in MSMD in subjects taking MSM, mean (95% CI) | Baseline | 12.40 (11.67, 13.13) | 11.35 (10.30, 12.40) |
Week 40 | -5.63 (-6.33, -4.93) | -6.15 (-7.00, -5.30) | |
Week 52 | -6.16 (-6.93, -5.40) | -6.71 (-7.67, -5.75) | |
≥50% responder rate, N1(%) | Week 40 | 108 (47.4) (n=228) | 126 (67.4) (n=187) |
Week 52 | 114 (53.3) (n=214) | 111 (67.3) (n=165) |
P25 Immunogenicity findings from Phase 3 galcanezumab trials in patients with episodic or chronic migraine
James M. Martinez, Sandra Garce, Greg Anglin, Michael Hodsdon, William Kielbasa, Brian A Moser, Eric Pearlman
Eli Lilly and Company, Indianapolis, IN, USA
Correspondence: James M. Martinez (martinez_james_michael@lilly.com)
P26 Lack of visual paired associative short-term plasticity in migraine patients between attacks
Gianluca Coppola1, Chiara Abagnale1, Federico Ranieri2, Clarissa Elizabeth Centurioni1, Gabriella Musumeci2, Fioravante Capone2, Giovanni Di Pino2, Vincenzo Parisi3, Vincenzo Di Lazzaro2, Francesco Pierelli1,4
1Sapienza University of Rome Polo Pontino, Department of medico-surgical sciences and biotechnologies, Latina, Italy; 2Research Unit of Neurology, Neurophysiology, Neurobiology, Department of Medicine, Università Campus Bio-Medico, Rome, Italy; 3G.B. Bietti Foundation IRCCS, Research Unit of Neurophysiology of Vision and Neurophthalmology, Rome, Italy; 4IRCCS Neuromed, Pozzilli (IS), Italy
Correspondence: Gianluca Coppola (gianluca.coppola@gmail.com)
P27 Effect of OnabotulinumtoxinA on the Frequency and Impact of Headaches in Patients with Chronic Migraine with or without a History of Acute Pain Medication Overuse: Results of the COMPEL Study
Stewart J. Tepper1* Maria-Carmen Wilson2 John F. Rothrock3 Amelia Orejudos4 Aubrey Manack Adams4 Andrew M. Blumenfeld5
1Neurology Department, Headache Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH, 03748, USA; 2Ochsner Health System, Covington, LA, 70433, USA; 3Department of Neurology, George Washington School of Medicine, Washington, DC 20037, USA; 4Allergan plc, Irvine, CA, 92612, USA; 5Headache Center of Southern California, The Neurology Center, Carlsbad, CA, 92024, USA
Correspondence: Stewart J. Tepper (Stewart.J.Tepper@Dartmouth.edu)
Variable | Medication Overuse (n=456) | No Medication Overuse (n=259) |
---|---|---|
Headache day frequency, d, mean (SD) | ||
Week 60 | –10.1 (6.8) | –10.3 (7.6) |
Week 108 | –11.4 (7.2) | –12.5 (7.5) |
Moderate/severe headache days, d, mean (SD) | ||
Week 60 | –8.8 (6.1) | –8.7 (6.2) |
Week 108 | –10.1 (7.0) | –10.0 (7.2) |
P28 Body Mass Index and its relationship with disability, severity, duration and frequency of headaches in female migraine patients
Mansouerh Togha, Faraidoon Haghdoost, Faezeh Khorsha, Soodeh Razeghi Jahromi, Zeinab Ghorbani
Headache Department, Iranian Center of neurological Research, Tehran University of Medical Sciences, Tehran, Iran
Correspondence: Faraidoon Haghdoost (faraidoon haghdoost)
P29 Effect of propranolol in a non-invasive human model of trigeminovascular activation
Eloísa Rubio-Beltran, Rianne M. Schoon, Jeffrey vd Berg, Jorie Versmissen, A.H. Jan Danser, Anton H. van den Meiracker, Antoinette MaassenVanDenBrink
Division of Pharmacology, Dept. of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands
Correspondence: Eloísa Rubio-Beltran (a.rubiobeltran@erasmusmc.nl)
P30 Effects of subthreshold single pulse Transcranial Magnetic Stimulation (sTMS) on activity of hypothalamic A11 region
J. Lloyd1, M Jones2,3, S McMahon2, R Abuukar Abdullahi1,4, AP Andreou1,4
1Headache Research-Wolfson CARD, King’s College London, London, UK; 2Neurorestoration Department, Wolfson Centre for Age-Related Diseases, King’s College London, London, UK; 3Zenith Neuroteck Ltd, London, UK; 4Headache Centre, Guy’s and St Thomas’s NHS Trust, King’s Health Partners, London, UK
Correspondence: J. Lloyd (k1633995@kcl.ac.uk)
P31 Intracranial pressure: a comparison of the non-invasive HeadSense monitor vs. lumbar pressure measurement
Jeppe Hvedstrup1, Aleksandra Radojicic2,3, Walid Moudrou4, Martin W Herklots5, Anton Wert6, Manfred Holzgraefe6, Mark Obermann6,7, Guus G Schoonman5, Rigmor H Jensen2, Henrik W Schytz1
1Headache Diagnostic Laboratory, Danish Headache Center and Department of Neurology, Rigshospitalet-Glostrup, faculty of health and sciences, university of Copenhagen, Denmark; 2Danish Headache Center and Department of Neurology, Rigshospitalet-Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark; 3Neurology Clinic, Clinical Center of Serbia, Belgrade, Serbia; 4Department of Neurology, Maastad Hospital, Rotterdam, The Netherlands 5Department of Neurology, Elsabeth-Tweesteden Hospital, Tilburg, The Netherlands 6Center of Neurology, Asklepios Hospitals Schildautal, Seesen, Germany; 7Department of Neurology, university Hospital Essen, University of Duisburg-Essen, Germany
Correspondence: Jeppe Hvedstrup (jeppe.hvedstrup.mann@regionh.dk)
P32 Triptans use in post-dural puncture headache
Federico Mainardi1, Giorgio Zanchin2, Carlo Lisotto3, Ferdinando Maggioni2
1Headache Centre, Neurological Division, SS Giovanni e Paolo Hospital, Venice, Italy; 2Headache Centre, Department of Neurosciences, Padua University, Padua, Italy; 3Headache Centre, San Vito al Tagliamento hospital, San Vito al Tagliamento, Italy
Correspondence: Federico Mainardi (fmainardi@iol.it)
P33 A case of autoimmune encephalitis preceded by posterior reversible encephalopathy syndrome and reversible cerebral vasoconstriction syndrome
Jaeho Kim, Mi Ji Lee
Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
Correspondence: Mi Ji Lee (mirony.lee@gmail.com)
P34 New insights in post-traumatic cluster headache through a cohort study
Lou Grangeon1,2, Emer O’Connor1, Layan Akijian1, Thanh Mai Pham Ngoc3, Manjit Matharu1
1Headache Group, Institute of Neurology and The National Hospital for Neurology and Neurosurgery, Queen Square, London; 2Department of Neurology, Rouen University Hospital, 76031, Rouen, France; 3Mathematics Institute of Orsay, Paris Sud University, CNRS, 91405 Orsay, France
Correspondence: Manjit Matharu (m.matharu@uclmail.net)
Predictive factor | OR | 95% CI | p value |
---|---|---|---|
Family History of CH | 2.32 | 1.41 - 3.86 | 0.001 |
Chronic CH | 1.53 | 1.04 - 2.26 | 0.032 |
Parietal location | 3.96 | 2.57 - 6.17 | <0.001 |
Presence of eye oedema | 1.53 | 1.03 - 2.27 | 0.035 |
Associated Chronic Migraine | 5.59 | 3.08 - 10.40 | < 0.001 |
Associated Episodic Migraine | 3.71 | 2.30 - 6.05 | < 0.001 |
Intractable to Acute Treatment | 2.16 | 1.03 - 4.61 | 0.043 |
Intractable to Preventive Treatment | 4.97 | 3.03 - 8.28 | < 0.001 |
P35 The relevance of associated symptoms of migraine according to migraine subtypes: A Clinical study
Aynur Özge1, Osman Özgür Yalın2, Derya Uludüz3, Özlem Mercan3, Mehmet Ali Sungur4, Aksel Siva3
1Mersin University School of Medicine, Professor, Neurology Department, Mersin, Turkey; 2University of Health Sciences, Istanbul Training and Research Hospital, MD, Neurology Department, İstanbul, Turkey; 3Istanbul University Cerrahpasa School of Medicine, Associate Professor, Neurology Department,İstanbul, Turkey; 4Düzce University School of Medicine, Professor, Biostatistics Department, Düzce, Turkey
Correspondence: Osman Özgür Yalın (osmanozguryalin@yahoo.com)
P36 Descriptive analysis of a population with chronic migraine in a tertiary Headache Center
Ana-Inês Martins, Joana Ramos-Lopes, Pedro Lopes, Bruno Silva, Sónia Batista, Lívia Sousa, Isabel Luzeiro
Neurology Department, Coimbra University and Hospital Centre, Coimbra, Portugal
Correspondence: Ana-Inês Martins (ana.inesm@hotmail.com)
P37 WHITE MATTER LESIONS IN CHRONIC MIGRAINE ARE RELATED WITH MOLECULAR MARKERS OF INFLAMMATION AND BLOOD BRAIN BARRIER DISRUPTION
C. Dominguez1, M. Saavedra1, X. Rodríguez-Osorio1, T. Sobrino2, F Campos2, J. Castillo2, R. Leira1,2
1Servicio de Neurología, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, 15706, Spain; 2Laboratorio de Investigación de Neurociencias Clínicas, Instituto de Investigación Sanitaria (IDIS). Santiago de Compostela, 15706, Spain
Correspondence: C. Dominguez (claravivero@hotmail.com)
P38 IRON DEPOSITS IN PERIAQUEDUCTAL GRAY MATTER ARE RELATED WITH POOR RESPONSE TO ONABOTULINUMTOXIN A IN CHRONIC MIGRAINE
C. Dominguez1, M. Saavedra1, X. Rodríguez-Osorio1, C. Villalba2, P. Ramos-Cabrer3, T. Sobrino4, F Campos4, J. Castillo4, R. Leira1,4
1Servicio de Neurología, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, 15706, Spain; 2Servicio de Radiología, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, 15706, Spain; 3Molecular Imaging Unit. CIC biomaGUNE. Donostia. Ikerbasque, Basque Foundation for Science. Bilbao , Spain; 4Laboratorio de Investigación de Neurociencias Clínicas, Instituto de Investigación Sanitaria (IDIS). Santiago de Compostela, 15706, Spain
Correspondence: C. Dominguez (claravivero@hotmail.com)
P39 Economic impact of migraine in the EU5: a matched analysis of the NHWS 2017 data on work productivity and healthcare resource use
Michael J. Doane1, Pamela Vo2, Aikaterini Bilitou3, Juanzhi Fang4, Annik K-Laflamme2, Shaloo Gupta5
1Kantar Health, Horsham, Pennsylvania, USA, 19044; 2Novartis Pharma AG, Kohlenstrasse, Basel, Switzerland, 4056;3Novartis Global Services Centre, Dublin, Ireland, D04A9N6; 4Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA, 07936; 5Kantar Health, Madison Ave, New York, USA, 10010
Correspondence: Pamela Vo (pamela.vo@novartis.com)
Non-migraine (N=1,569) | 4-7 HDs (N=783) | 8-14 HDs (N=429) | >=15 HDs (N=357) | |
---|---|---|---|---|
HRU in the past 6 months | % proportion of patients with at least 1 visit (N) | |||
Visited any HCP | 85.1%a (1336) | 96.0%b (752) | 95.6%b (410) | 94.1%b (336) |
Visited ER | 11.9%a (187) | 23.0%b,c (180) | 21.7%b (93) | 27.7%c (99) |
Visited Neurologist | 4.2%a (66) | 12.4%b (97) | 14.5%b (62) | 24.4%c (87) |
Hospitalized | 7.8%a (123) | 11.9%b (93) | 14.9%b (64) | 15.4%b (55) |
WPAI outcome in the past 7 days | Average % work impairment* (N) | |||
Absenteeism | 8.47%a (870) | 11.28%b (447) | 13.34%b,c (264) | 19.13%c (166) |
Presenteeism | 20.54%a (849) | 32.11%b (431) | 33.74%b (254) | 43.51%c (154) |
Overall Work Impairment | 22.62%a (841) | 34.77%b (427) | 36.95%b (251) | 47.20%c (154) |
P40 Humanistic burden of migraine in the EU5: a matched analysis of the NHWS 2017
Michael J. Doane1, Pamela Vo2, Aikaterini Bilitou3, Juanzhi Fang4, Annik K-Laflamme2, Shaloo Gupta5
1Kantar Health, Horsham, Pennsylvania, USA, 19044; 2Novartis Pharma AG, Kohlenstrasse, Basel, Switzerland, 4056; 3Novartis Global Services Centre, Dublin, Ireland, D04A9N6; 4Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA, 07936; 5Kantar Health, Madison Ave, New York, USA, 10010
Correspondence: Pamela Vo (pamela.vo@novartis.com)
Non-migraine controls (N=1,569) | 4-7 HDs (N=783) | 8-14 HDs (N=429) | ≥15 HDs (N=357) | |
---|---|---|---|---|
Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | |
Mental Component Summary Score | 45.17a | 41.02b | 40.03b | 36.52c |
Physical Component Summary Score | 50.87a | 48.11b | 47.15b | 42.69c |
SF-6D Utility Score | 0.70 | 0.64 | 0.63 | 0.58 |
EQ-5D Index | 0.83 | 0.75 | 0.73 | 0.58c |
Health Status, EQ VAS | 74.22a | 67.13b | 64.24c | 52.26d |
P41 Phase 3 studies (SAMURAI, SPARTAN) of lasmiditan compared to placebo for acute treatment of migraine
Linda A. Wietecha1, Bernice Kuca2, Josephine Asafu-Adjei1, Sheena K. Aurora1
1Eli Lilly and Company, Indianapolis, IN; 2CoLucid Pharmaceuticals, Inc., a wholly owned subsidiary of Eli Lilly and Company
Correspondence: Linda A. Wietecha (wietecha_linda_a@lilly.com)
P42 Conversion from chronic to episodic migraine with erenumab, a specific inhibitor of the calcitonin gene-related peptide receptor
Richard B. Lipton1, Stewart J. Tepper2, Stephen Silberstein3, David Kudrow4, Messoud Ashina5, Uwe Reuter6, David Dodick7, Feng Zhang8, Gregory A. Rippon8, Daniel D. Mikol8
1Department of Neurology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA; 2Geisel School of Medicine at Dartmouth, Hanover, NH, USA; 3Thomas Jefferson University, Philadelphia, PA, USA; 4California Medical Clinic for Headache, Santa Monica, CA, USA; 5Department of Neurology, Danish Headache Center, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; 6Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany; 7Mayo Clinic, Phoenix, AZ, USA; 8Amgen Inc., Thousand Oaks, CA, USA
Correspondence: Richard B. Lipton (richard.lipton@einstein.yu.edu)
P43 Erenumab impact on patient-reported outcomes in chronic migraine in the presence of acute medication overuse
Stewart J Tepper1, Messoud Ashina2, Jan Klatt3, Pooja Desai4, Feng Zhang4, Sunfa Cheng4, Daniel D Mikol4
1Geisel School of Medicine at Dartmouth, Hanover, NH, USA; 2Department of Neurology, Danish Headache Center, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; 3Novartis Pharma AG, Basel, Switzerland; 4Amgen Inc., Thousand Oaks, CA, USA
Correspondence: Messoud Ashina (ashina@dadlnet.dk)
Medication overuse | Without medication overuse | |||||
---|---|---|---|---|---|---|
Placebo (N=113) | Erenumab 70 mg (N=77) | Erenumab 140 mg (N=78) | Placebo (N=168) | Erenumab 70 mg (N=111) | Erenumab 140 mg (N=109) | |
HIT-6 total score (range: 36–78) | ||||||
Baseline score, mean (SD) | 63.8 (5.0) | 63.9 (4.4) | 63.3 (4.8) | 63.0 (5.3) | 63.0 (5.4) | 62.2 (6.2) |
Change from baseline | −2.9 (−4.1, −1.7) | −5.2 (−6.7, −3.7) | −5.4 (−6.9, −3.9) | −3.4 (−4.4, −2.3) | −6.0 (−7.2, −4.6) | −5.8 (−7.1, −4.6) |
Difference from placebo | −2.3 (−4.2, −0.3) | −2.5 (−4.4, −0.6) | −2.6 (−4.2, −1.0) | −2.5 (−4.1, −0.8) | ||
MIDAS total score | ||||||
Baseline score, mean (SD) | 71.6 (52.7) | 69.3 (43.4) | 66.6 (55.7) | 65.5 (58.2) | 63.3 (47.5) | 56.8 (49.4) |
Change from baseline | −3.6 (−12.0, 4.8) | −22.0 (−32.0, −12.1) | −16.1 (−26.1, −6.1) | −11.2 (−17.0, −5.5) | −18.40 (−25.2, 11.6) | −23.5 (−30.3, −16.6) |
Difference from placebo | −18.5 (−31.4, −5.5) | −12.5 (−25.4, 0.4) | −7.2 (−16.1, 1.7) | −12.2 (−21.1, −3.3) | ||
MSQ-RFR (range: 0–100) | ||||||
Baseline score, mean (SD) | 41.3 (17.4) | 42.9 (16.5) | 43.7 (17.3) | 43.8 (17.7) | 46.0 (19.4) | 46.8 (20.3) |
Change from baseline | 11.7 (8.0, 15.4) | 17.1 (12.6, 21.5) | 17.4 (13.0, 21.9) | 12.0 (9.0, 15.1) | 18.4 (14.7, 22.1) | 20.6 (16.8, 24.3) |
Difference from placebo | 5.4 (−0.4, 11.2) | 5.7 (0.0, 11.51) | 6.4 (1.6, 11.2) | 8.5 (3.7, 13.3) | ||
MSQ-RFP (range: 0–100) | ||||||
Baseline score, mean (SD) | 60.8 (19.5) | 63.8 (21.6) | 61.1 (20.0) | 59.9 (20.4) | 60.6 (21.6) | 64.2 (21.8) |
Change from baseline | 7.7 (4.4, 11.1) | 11.6 (7.6, 15.6) | 10.5 (6.5, 14.4) | 10.0 (7.3, 12.7) | 14.2 (11.0, 17.5) | 16.7 (13.4, 20.0) |
Difference from placebo | 3.9 (−1.3, 9.0) | 2.7 (−2.4, 7.9) | 4.3 (0.0, 8.5) | 6.8 (2.5, 11.0) | ||
MSQ-EF (range: 0–100) | ||||||
Baseline score, mean (SD) | 53.8 (24.3) | 50.8 (23.9) | 55.4 (24.8) | 52.4 (26.7) | 55.6 (26.1) | 57.7 (27.9) |
Change from baseline | 8.2 (4.2, 12.2) | 17.1 (12.3, 21.9) | 15.9 (11.1, 20.7) | 11.3 (7.9, 14.8) | 19.4 (15.3, 23.5) | 21.2 (17.1, 25.4) |
Difference from placebo | 8.9 (2.7, 15.1) | 7.7 (1.5, 13.9) | 8.1 (2.7, 13.4) | 9.9 (4.5, 15.3) |
P44 Long-term efficacy of erenumab in patients with chronic migraine who failed prior prophylactic treatment
Messoud Ashina1, Stewart J Tepper2, Jan L Brandes3, Uwe Reuter4, Guy Boudreau5, David Doležil6, Jan Klatt7, Feng Zhang8, Sunfa Cheng8, Daniel D Mikol8
1Department of Neurology, Danish Headache Center, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; 2Geisel School of Medicine at Dartmouth, Hanover, NH, USA; 3Nashville Neuroscience Group, Nashville, TN, USA; 4Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany; 5Centre de Traitement Neurologique, Montreal, QC, Canada; 6Prague Headache Center, DADO MEDICAL s.r.o., Prague, Czech Republic; 7Novartis Pharma AG, Basel, Switzerland; 8Amgen Inc., Thousand Oaks, CA, USA
Correspondence: Messoud Ashina (ashina@dadlnet.dk)
Treatment failure subgroup | 52-week OLE completers by last dose received | ||||||
---|---|---|---|---|---|---|---|
Erenumab 70 mg/140 mgN=416 | Erenumab 70 mgN=189a | Erenumab 140 mgN=137a | |||||
OLE visit weeks | Week 12n=395 | Week 40n=300 | Week 52n=261 | Week 40n=166 | Week 52n=150 | Week 40n=124 | Week 52n=109 |
Change from BLb in MMD, mean (SE) | −6.84 (0.32) | −7.75 (0.38) | −8.58 (0.41) | −7.16 (0.48) | −7.86 (0.52) | −8.58 (0.62) | −9.66 (0.65) |
Change from BLb in MSMD, mean (SE) | −4.17 (0.26) | −4.78 (0.29) | −5.56 (0.34) | −4.75 (0.38) | −5.47 (0.43) | −4.93 (0.47) | −5.75 (0.54) |
Percentage of patients with ≥50% responsec(95% CI) | 40 (35, 44) | 50 (44, 56) | 55 (49, 61) | 43 (36, 51) | 49 (41, 57) | 60 (51, 68) | 63 (54, 72) |
P45 Changes in patient functioning and disability: results from two phase 3 double-blind placebo-controlled clinical trials evaluating galcanezumab for episodic migraine prevention (EVOLVE-1 and EVOLVE-2)
Janet H. Ford; David W. Ayer; Qi Zhang; Jeffrey N. Carter; Vladimir Skljarevski; Sheena K. Aurora
Eli Lilly and Company, Indianapolis, IN, USA
Correspondence: Jeffrey N. Carter (carter_jeffrey_n@lilly.com)
P46 100% response rate to galcanezumab in patients with episodic migraine: randomized, double-blind, placebo-controlled studies
Abraham Jim Nagy1, Eric Pearlman2, Dustin Ruff2, Kathleen Day2, Noah Rosen3
1Nevada Headache Institute, Las Vegas, NV, 89113, USA; 2Eli Lilly and Company, and/or one of its subsidiaries, Indianapolis, IN, 46285, USA; 3Hofstra Northwell School of Medicine at Hofstra University, Department of Neurology, Hempstead, NY, 11549, USA
Correspondence: Eric Pearlman (eric.pearlman@lilly.com)
P47 Diagnostic screeners for migraine: a methodological caveat
C. Ertsey1, É. Csépány2, M. Magyar1,2, T. Gyüre2, Bozsik Gy2, M. Tóth3
1Department of Neurology, Semmelweis University, Budapest, Hungary; 2János Szentágothai Doctoral School of Neurosciences, Semmelweis University, Budapest, Hungary; 3Department of Neurology, Vaszary Kolos Hospital, Esztergom, Hungary
Correspondence: C. Ertsey (konfreg1@bcdtravel.hu)
P48 Comparison of personality traits and dependence behavior between MOH patients and illicit drug users
Baraldi Carlo, Pellesi Lanfranco, Guerzoni Simona, Cainazzo Maria Michela, Lo Castro Flavia, Pini Luigi Alberto
Medical Toxicology-Headache and Drug Abuse Centre, Department of Diagnostic Medicine, Clinical and Public Health, University of Modena and Reggio Emilia, Via del Pozzo 71, 41124, Modena, Italy.
Correspondence: Baraldi Carlo (infocarlo.baraldi@gmail.com)
P49 VALIDITY AND RELIABILITY TURKISH HEADACHE IMPACT TEST (HIT-6) IN PATIENTS WITH EPISODIC AND CHRONIC MIGRAINE
P. Yalınay Dikmen1, M. Bozdag2, M. Gunes3, S. Kosak1, B. Tasdelen4, D. Uludüz3, A. Ozge2
1Acıbadem University, School of Medicine, Department of Neurology, Istanbul, Turkey; 2Mersin University, Faculty of Medicine, Department of Neurology, Mersin, Turkey; 3Istanbul University, Cerrahpasa Faculty of Medicine, Department of Neurology, Istanbul, Turkey; 4Mersin University, Faculty of Medicine, Department of Biostatistics and Medical Informatics, Mersin, Turkey
Correspondence: P. Yalınay Dikmen (pinar.yalinay@acibadem.com)
P50 Retrospective analysis of peripheral nerve block for the treatment of headaches and cranial neuralgias in the neurology section of a general hospital
Vanesa Adell1, Jessica García-Alhama2, Sonia Jaraba2, Joan Prat3, Mariano Huerta2
1Neurology department, IDIBELL, Hospital de Viladecans, Barcelona, Spain; 2Neurology department, Hospital de Viladecans, Barcelona, Spain; 3Neurology department, Hospital Universitari de Bellvitge, Barcelona, Spain.
Correspondence: Vanesa Adell (vanesa.adell@bellvitgehospital.cat)
P51 RELATIONSHIP BETWEEN SEVERITY OF MIGRAINE AND VITAMIN D DEFICIENCY: A CASE CONTROL STUDY
L. Rapisarda1, A.D. Montisano1, A. Sarica2, G. Demonte1, F. Tosto1, A. Gambardella1,2, F. Bono1,2
1Headache Center, Institute of Neurology, Department of Medical and Surgical Sciences, Magna Graecia University of Catanzaro, Italy; 2Neuroscience Research Center, Department of Medical and Surgical Sciences, Magna Graecia University of Catanzaro, Italy
Correspondence: L. Rapisarda (laura_rapisarda90@yahoo.it)
P52 A case-control study of visual-vestibular mismatch in childhood with primary headaches
Daniele Monzani1, Pellesi Lanfranco2, Guerzoni Simona2, Cainazzo Maria Michela2, Lo Castro Flavia2, Baraldi Carlo2, Pini L Alberto2
1Otolaryngology Unit, Department of Diagnostic Medicine, Clinical and Public Health, University of Modena and Reggio Emilia, Via del Pozzo 71, 41124, Modena, Italy; 2 Medical Toxicology-Headache and Drug Abuse Centre, Department of Diagnostic Medicine, Clinical and Public Health, University of Modena and Reggio Emilia, Via del Pozzo 71, 41124, Modena, Italy
Correspondence: Baraldi Carlo (Carloinfocarlo.baraldi@gmail.com)
Stabilometric findings
| ||||
Eyes Open
| ||||
Parameter
|
C
|
TTH
|
M
|
p*
|
Ellipse Surface | 20.134±13.203 | 339.181±223.8 | 339.745±195.423 | <0.0001 |
Ellipse Lenght | 22.596±10.623 | 530.733±195.997 | 548.924±164.403 | <0.0001 |
Mean Sway Velocity | 22.76±13.617 | 12.391±3.64 | 11.127±3.0396 | 0.0004 |
FFTx | 24.269±11.488 | 0.071±0.084 | 0.047±0.04 | <0.0001 |
FFTy | 20.726±10.452 | 0.0455±0.038 | 0.0526±0.045 | <0.0001 |
Eyes Closed
| ||||
Parameter
|
C
|
TTH
|
M
|
P
|
Ellipse Surface | 22.927±10.991 | 407.681±211.192 | 410.367±208.812 | <0.0001 |
Ellipse Lenght | 36.3±78.973 | 793.875±600.239 | 728.162±257.888 | <0.0001 |
Mean Sway Velocity | 26.292±11.498 | 17.793±10.976 | 14.171±5.635 | 0.01 |
FFTx | 22.132±12.584 | 0.045±0.039 | 0.045±0.046 | <0.0001 |
FFTy | 20.884±8.691 | 0.049±0.054 | 0.038±0.031 | <0.0001 |
Romberg Index | 2.157±2.137 | 1.478±0.634 | 1.292±0.489 | 0.155 |
Destabilisation Index | 5.295±4.964 | 4.119±3.071 | 2.641±1.067 | 0.0735 |
Stabilometric findings OKN Right and Left
| ||||
OKN Right
| ||||
Parameter
|
C
|
TTH
|
M
|
p*
|
Ellipse Surface | 21.986±12.159 | 509.318±303.792 | 456.057±391.45 | <0.0001 |
Ellipse Lenght | 18.531±15.928 | 683.604±265.269 | 690.163±151.569 | <0.0001 |
Mean Sway Velocity | 22.409±11.745 | 15.643±4.279 | 14.046±2.87 | 0.0053 |
FFTx | 23.562±9.849 | 0.065±0.092 | 0.033±0.021 | <0.0001 |
FFTy | 19.2102 11.78949 | .0681818 .0972438 | .0444298 .0327543 | <0.0001 |
OKN Left
| ||||
Parameter
|
C
|
TTH
|
M
|
P*
|
Ellipse Surface | 29.778±13.215 | 527.543±291.058 | 436.288±340.867 | <0.001 |
Ellipse Lenght | 1252.205±5381.505 | 725.216±270.133 | 708.717±224.549 | 0.8630 |
Mean Sway Velocity | 22.409±11.745 | 15.643±4.279 | 14.046±2.87 | 0.4209 |
FFTx | 21.458±12.251 | 0.035±0.013 | 0.065±0.071 | <0.0001 |
FFTy | 24.837±13.58 | 0.068±0.072 | 0.042±0.031 | <0.0001 |
P53 Primary headaches associated with physical exertion
Füsun Mayda Domaç, Sergül Zengin, Mehmet Fatih Demir
Health Sciences University, Erenköy Mental and Neurological Diseases Training and Research Hospital, Neurology Department, Istanbul, Turkey
Correspondence: Füsun Mayda Domaç (fusundomac@yahoo.com.tr)
P54 Headache burden in the Emergency Room
A.Quka1,O. Cibuku1,2, I.Zekja1, I. Xhura1,2, J. Kruja1,2
1Neurology Department, UHC MotherTeresa, Tirana, 1000, Albania; 2Neurology, Faculty of Medicine, University of Medicine, Tirana, 1000, Albania
Correspondence: A.Quka (aidaquka@gmail.com)
P55 Prevalence and risk factors of tension-type headache among adolescents in Kharkiv city (Ukraine)
Stepanchenko Kostiantyn (kosty0516@gmail.com)
Department of neurology and child neurology, Kharkiv Medical Academy of Postgraduate Education, Kharkiv, 61176, Ukraine
P56 Pediatric migraine: A new pediatric migraine-spesific comorbidity index on prognosis
Didem Derici Yıldırım1, Bahar Taşdelen1, Derya Uludüz2, Aynur Özge3, Osman Özgür Yalın4, Saim Yoloğlu4
1Department of Biostatistics and Medical Informatics, Mersin University Faculty of Medicine, Mersin, Turkey; 2Istanbul University, Cerrahpasa School of Medicine, Neurology Department, İstanbul, Turkey; 3Mersin University, School of Medicine, Neurology Department, Mersin, Turkey; 4Health Sciences University, Istanbul Training and Research Hospital, İstanbul, Turkey
Correspondence: Osman Özgür Yalın (osmanozguryalin@yahoo.com)
P57 Characteristics of Isolated Headache patients in Cerebral Venous Sinus Thrombosis (CVST): The Results of VENOST - national survey
Derya Uludüz1, Osman Özgür Yalın2, Taşkın Duman3, Füsun Mayda Domaç4, Şerefnur Öztürk5, Vildan Yayla6, Ali Yavuz Karahan7, Nazire Afşar8, Mehmet Ali Sungur9, VENOST Study Group
1Istanbul University Cerrahpasa School of Medicine, Professor, Neurology Department,İstanbul, Turkey; 2University of Health Sciences, Istanbul Training and Research Hospital, Associate Professor, Neurology Department, İstanbul, Turkey; 3Hatay Mustafa Kemal University School of Medicine, Professor, Neurology Department, Hatay, Turkey; 4University of Health Sciences, Erenköy Training and Research Hospital, Associate Professor, Neurology Department, İstanbul, Turkey; 5Selçuk University School of Medicine, Professor, Neurology Department, Konya, Turkey; 6University of Health Sciences, İstanbul Sadi Konuk Training and Research Hospital, Professor, Neurology Department, İstanbul, Turkey; 7Uşak University School of Medicine, Professor, Neurology Department, Uşak, Turkey; 8Acıbadem University School of Medicine, Professor, Neurology Department, İstanbul, Turkey; 9 University of Health Sciences, Bakırköy Training and Research Hospital, MD, Neurology Department, İstanbul, Turkey; 10Düzce University School of Medicine, Professor, Biostatistics Department, Düzce, Turkey
Correspondence: Osman Özgür Yalın (osmanozguryalin@yahoo.com)
P58 One-year incidence of Chronic Migraine in Tertiary Headache Outpatient Clinics: A multi-center study
Aynur Özge1, Derya Uludüz2, Osman Özgür Yalın3, Seden Demirci4, Macit Selekler5, Ali Akyol6, Şebnem Bıçakçı7, Vesile Öztürk8, Musa Öztürk9, Betül Baykan10, Mehmet Ali Sungur11, Aksel Siva2
1Mersin University School of Medicine, Professor, Neurology Department, Mersin, Turkey; 2Istanbul University Cerrahpasa School of Medicine, Associate Professor, Neurology Department,İstanbul, Turkey; 3University of Health Sciences, Istanbul Training and Research Hospital, MD, Neurology Department, İstanbul, Turkey; 4Isparta Süleyman Demirel University School of Medicine, Assistant Professor, Neurology Department, Isparta, Turkey; 5Kocaeli University School of Medicine, Professor, Neurology Department, Kocaeli, Turkey; 6Aydın University School of Medicine, Professor, Neurology Department, Aydın, Turkey; 7Çukurova University School of Medicine, Professor, Neurology Department, Adana, Turkey; 8Dokuz Eylül University School of Medicine, Professor, Neurology Department, İzmir, Turkey; 9University of Health Sciences, Bakırköy Training and Research Hospital, MD, Neurology Department, İstanbul, Turkey; 10İstanbul University School of Medicine, Professor, Neurology Department, İstanbul, Turkey; 11Düzce University School of Medicine, Professor, Biostatistics Department, Düzce, Turkey
Correspondence: Osman Özgür Yalın (osmanozguryalin@yahoo.com)
P59 Vestibular Migraine presenting as an acute peripheral vestibulopathy: clinical and vestibular function test profiles
Zeljka Calic1,2,3, Rachael L Taylor4, Allison Young4, Leigh M McGarvie4, Cecilia Cappelen-Smith1,2,3, Denis Cordato1,2,3, Miriam S Welgampola4,5
1Department of Neurophysiology, Liverpool Hospital, 2170, Australia; 2South Western Sydney Clinical School, University of New South Wales, Sydney, 2170, Australia; 3Ingham Institute for Applied Medical Research, Liverpool, 2170, Australia; 4Institute of Clinical Neurosciences, Royal Prince Alfred Hospital, Camperdown, 2006, Australia; 5Central Clinical School, Sydney Medical School, University of Sydney, Camperdown, 2006, Australia
Correspondence: Zeljka Calic (zcalic@hotmail.com)
P60 Headache in the Pediatric Emergency Department: proposal of diagnostic and therapeutic algorithm of management
Roberta Rossi1, Antonia Versace1, Barbara Lauria1, Giulia Grasso1, Emanuele Castagno1, Fulvio Ricceri2,3, Rosaura Pagliero1, Antonio Francesco Urbino1
1A.O.U. Città della Salute e della Scienza di Torino, Regina Margherita Children’s Hospital, Department of Pediatric Emergency, Pediatric Headache Centre, Turin, Italy; 2Unit of Cancer Epidemiology, Department of Medical Sciences, University of Turin, Turin, Italy; 3Unit of Epidemiology, Regional Health Service, ASL TO3, Grugliasco (TO), Italy.
Correspondence: Roberta Rossi (roberta.rossi15@gmail.com)
P61 Correlation between pediatric primary headache and specific learning disabilities: a case-control study
Ausilia Enea1, Antonia Versace1*, Barbara Lauria1, Giulia Grasso1, Roberta Rossi1, Emanuele Castagno1, Stefania Benetti1, Veronica Sciannameo2,3, Antonio Francesco Urbino1
1A.O.U. Città della Salute e della Scienza di Torino, Regina Margherita Children’s Hospital, Department of Pediatric Emergency, Pediatric Headache Centre, Turin, Italy; 2Unit of Cancer Epidemiology, Department of Medical Sciences, University of Turin, Turin, Italy; 3Unit of Epidemiology, Regional Health Service, ASL TO3, Grugliasco (TO), Italy
Correspondence: Antonia Versace (aversace@cittadellasalute.to.it)
P62 Astrocytes contribute to the trigeminal central sensitization and cephalic cutaneous hypersensitivity in rat model of chronic migraine
M. Megemont, A. Descheemaeker, R. Dallel, L. Monconduit and P. Luccarini*
Université Clermont Auvergne, Inserm, Neuro-Dol, F-63000 Clermont-Ferrand, France
Correspondence: M. Megemont (philippe.luccarini@uca.fr)
P63 Withdrawn
P64 Сortical excitability in chronic migraine patients after OnabotulinumtoxinA preventive treatment
Vladlena Shevchenko1, Ada Artemenkoˡ, Mikhail Bzhiljanski2, Fedor Bushkov2, Nikolay Yahnoˡ, Alexey Kurenkov3
1Research Department of Neurology, Scientific-technological Park of biomedicine, I.M. Sechenov First Moscow State Medical University, Moscow, 119991, Russia; 2Rehabilitation centre «Preodolenie», Moscow, Russia, 127083; 3Scientific Centre of Children’s Health of the Ministry of Health of the Russian Federation, Moscow, 119991, Russian Federation
Correspondence: Vladlena Shevchenkoˡ (vladashevchenko@list.ru)
P65 Beyond the headache phase of a migraine attack: closer look at the burden of migraine phases - results from the worldwide My Migraine Voice survey
Michel Lanteri-Minet1, Rebeca Quintana2, Veruska Carboni3, Paolo Martelletti4, 5, Todd J. Schwedt6, Hans- Christoph Diener7, Annik K.-Laflamme8, Elena Ruiz de la Torre9, Audrey Craven10, Simon Evans11, Donna Walsh12, Annette Vangaa Rasmussen13, Paula Dumas14, Rachel Fink8, Angela Fiorin8, Stephanie Ribbe8, Pamela Vo8
1Département d’Evaluation et Traitement de la Douleur, Centre Hospitalo-Universitaire de Nice, Nice, France; 2GFK, Madrid, Spain; 3GfK Health, Basel, Switzerland; 4Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy; 5EHF; 6Neurology Arizona, Mayo Clinic, Phoenix, United States; 7Department of Neurology and Headache Center, University Duisburg-Essen, Germany; 8Novartis Pharma AG, Basel, Switzerland; 9European Headache Alliance, Brussels, Belgium; 10Migraine Association Ireland, Dublin, Ireland; 11Migraine Action, Leicester, United Kingdom; 12European Federation of Neurological Associations, Brussels, Belgium; 13Rigshospitalet Glostrup, Copenhagen, Denmark; 14Migraine Again, United States
Correspondence: Michel Lanteri-Minet (lanteri-minet.m@chu-nice.fr)
Proportion of respondents (%) | Premonitory phase | Headache phase | Postdromal phase |
---|---|---|---|
Duration of phase | |||
< 4 hours | 51% | 20% | 30% |
4-24 hours | 30% | 45% | 40% |
>24 hours | 14% | 34% | 27% |
Not experiencing this phase | 6% | 1% | 3% |
Duration of the phase >24 hours in migraine patients with: | |||
- no failure to migraine preventive treatment | 11% | 27% | 20% |
- 1 failure to migraine preventive treatment | 11% | 29% | 23% |
- ≥2 failures to migraine preventive treatment | 17% | 38% | 30% |
Feeling very to extremely limited during the phase | 29% | 71% | 30% |
P66 Withdrawn
P67 Carbon monoxide inhalation induces headache but no migraine in patients with migraine without aura
Hashmat Ghanizada1, Nanna Arngrim1, Henrik Winther Schytz1, Jes Olesen1, Messoud Ashina1
1Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Valdemar Hansens vej 5, DK-2600 Glostrup, Denmark
Correspondence: Messoud Ashina (ashina@dadlnet.dk)
P68 Demographic and clinical characteristics of patients with trigeminal neuralgia assisted by neurologists in an Emergency Department
Javier Camiña Muñiz, Germán Ferrer Juan, María Magdalena Rosselló Vadell, Antonio José Moreno Rojas, Francisco José Molina Martínez
Department of Neurology. Hospital Universitari Son Espases, Carretera de Valldemossa, 79. 07120, Palma, Illes Balears, Spain
Correspondence: Javier Camiña Muñiz (javier.camina.muniz@gmail.com)
P69 Systematic review of the safety and efficacy of Occipital Nerve Stimulation for intractable chronic cluster headache
Iris Smet1, Jean-Pierre Van Buyten1, Michel Lanteri-Minet2, Denys Fontaine3, Jennifer Tinsley4, Brooke Kelley5
1 Multidisciplinary Pain Centre AZ Nikolaas, Sint -Niklaas, 9100, BE; 2 Pain Department CHU Nice, FHU INOVPAIN, Côte Azur University, 06001, Nice, FR; 3 Department of Neurosurgery, CHU de Nice, FHU INOVPAIN, University Cote d’Azur, 06001, Nice, FR; 4 Medtronic International Trading Sàrl, Clinical Research, Tolochenaz, 1131 CH; 5 Medtronic Plc, Clinical Research, Minneapolis, Minnesota, 55432, US
Correspondence: Jennifer Tinsley (jennifer.tinsley@medtronic.com)
-
61.8% of patients reduced attack frequency by ≥30% (5 studies; 110 patients) and 54.9% reduced by ≥50% (5 studies; 164 patients)
-
39.3% of patients had reduced CH intensity score of ≥30% (5 studies; 56 patients)
-
mean 41.8% reduction in attack duration (2 studies; 78 patients)
-
43.1% of patients reduced medications to some extent (7 studies; 188 patients)
P70 Safety data from phase 3 clinical studies comparing galcanezumab and placebo in patients with episodic and chronic migraine
Virginia L. Stauffer, Shufang Wang, Mark E. Bangs, Tina M. Oakes, Jeffrey N. Carter, Sheena K. Aurora
Lilly Research Laboratories, Indianapolis, IN, USA
Correspodence: Jeffrey N. Carter (carter_jeffrey_n@lilly.com)
Galcanezumab | ||||
---|---|---|---|---|
Event | Placebo N=1451 n (%) | 120-mg N=705 n (%) | 240-mg N=730 n (%) | Combined N=1435 n (%) |
Injection site pain | 138 (9.5) | 71 (10.1) | 85 (11.6) | 156 (10.9) |
Nasopharyngitis | 94 (6.5) | 52 (7.4) | 31 (4.3)† | 83 (5.8) |
Upper respiratory tract infection | 60 (4.1) | 31 (4.4) | 36 (4.9) | 67 (4.7) |
Injection site reaction | 14 (1.0) | 22 (3.1)‡ | 45 (6.2)‡ | 67 (4.7)‡ |
Dizziness | 41 (2.8) | 20 (2.8) | 20 (2.7) | 40 (2.8) |
Injection site erythema | 20 (1.4) | 20 (2.8)† | 29 (4.0)‡ | 49 (3.4)‡ |
Sinusitis | 31 (2.1) | 20 (2.8) | 19 (2.6) | 39 (2.7) |
Urinary tract infection | 33 (2.3) | 19 (2.7) | 18 (2.5) | 37 (2.6) |
Fatigue | 34 (2.4) | 17 (2.4) | 16 (2.2) | 33 (2.3) |
Injection site pruritus | 2 (0.1) | 15 (2.1)‡ | 24 (3.3)‡ | 39 (2.7)‡ |
Neck pain | 21 (1.5) | 15 (2.1) | 6 (0.8) | 21 (1.5) |
Abdominal pain | 24 (1.7) | 13 (1.8) | 6 (0.8) | 19 (1.3) |
Cough | 19 (1.3) | 12 (1.7) | 13 (1.8) | 25 (1.7) |
Oropharyngeal pain | 13 (0.9) | 10 (1.4) | 12 (1.6) | 22 (1.5) |
Bronchitis | 17 (1.2) | 9 (1.3) | 11 (1.5) | 20 (1.4) |
Influenza | 34 (2.3) | 8 (1.1) | 20 (2.7) | 28 (2.0) |
Constipation | 8 (0.6) | 7 (1.0) | 11 (1.5)† | 18 (1.3)† |
Migraine | 14 (1.0) | 7 (1.0) | 12 (1.6) | 19 (1.3) |
Galcanezumab | ||||
---|---|---|---|---|
Event | Placebo N=1451 n (%) | 120-mg N=705 n (%) | 240-mg N=730 n (%) | Combined N=1435 n (%) |
Deaths | 0 | 0 | 0 | 0 |
SAE | 14 (1.0) | 12 (1.7) | 11 (1.5) | 23 (1.6) |
DCAE | 24 (1.7) | 13 (1.8) | 22 (3.0)† | 35 (2.4) |
TEAE | 827 (57.0) | 441 (62.6)† | 472 (64.7)‡ | 913 (63.6)‡ |
P71 OnabotulinumtoxinA: How and when do our patients improve?
A.Alpuente1,2, VJ. Gallardo2, M.Torres-Ferrús1,2, J.Álvarez-Sabín1, P.Pozo-Rosich1
1Headache Unit, Neurology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain; 2Headache Research Group, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain
Correspondence: P.Pozo-Rosich (ppozorosich@yahoo.com)
P72 The role of foods with a high glycemic index in migraine patients: a real life preliminary study
Gianluca Cecchi, Maria Bravo, Paola Di Caprio, Giorgia Botti, Nicoletta Brunelli, Matteo Paolucci, Manon Khazrai, Fabrizio Vernieri, Claudia Altamura
Headache and Neurosonology Unit, Neurology Unit, Università Campus Bio-Medico di Roma, Rome, Italy.
Correspondence: Gianluca Cecchi (gianlucacecchi250489@gmail.com)
P73 Do evidence-based practice guidelines exist to support physiotherapists in the approach of patients with episodic headache?
Sarah Mingels1,2, Marita Granitzer1
1REVAL Rehabilitation Research Centre, Biomedical Research Institute, Faculty of Medicine and Life Sciences, Hasselt University, Belgium; 2Musculoskeletal Research Unit, Department of Rehabilitation Sciences, Faculty of Kinesiology and Rehabilitation Sciences, Leuven University, Belgium
Correspondence: Sarah Mingels (sarah.mingels@uhasselt.be)
P74 Efficacy and safety of a sequential surgical algorithm in 44 patients with refractory chronic cluster headache
Robert Belvís, Marina Guasch, Paula Marrero, Maria Jesus Alvarez, Rodrigo Rodriguez, Joan Molet, Carles Roig
Department of Neurology and Department of Neurosurgery. Hospital de la Santa Creu i Sant Pau. Barcelona. Spain
Correspondence: Robert Belvís (rbelvis@santpau.cat)
P75 Spectral domain optical coherence tomography findings in RVCL-S, a monogenic vascular migraine model
Irene de Boer1, Sylvie R. Steenmeijer2, Nadine Pelzer1, Greet Dijkman2, Irene C. Notting2 , Gisela M. Terwindt1
1 Department of Neurology, Leiden University Medical Center, Leiden, 2300 WB, The Netherlands; 2 Department of Ophthalmology, Leiden University Medical Center, Leiden, 2300 WB, The Netherlands
TREX1 MC mean ±SD (n=33a) | Controls mean ±SD (n=18) | Estimate | CI | P-value | |
---|---|---|---|---|---|
Nasal sup. (μm) | 84.4 ±34.0 | 107.7 ±26.2 | -23.3 | -42.0;-4.7 | 0.014* |
Nasal (μm) | 61.2 ±21.4 | 87.7 ±25.4 | -26.5 | -42.8;-10.1 | 0.002* |
Nasal inf. (μm) | 84.7 ±34.6 | 118.7 ±30.6 | -34.4 | -56.6;-12.2 | 0.002* |
Temporal inf. (μm) | 102.1 ±37.9 | 133.8 ±20.0 | -32.6 | -52.7;-12.5 | 0.001* |
Temporal (μm) | 61.7 ±26.0 | 63.1 ±10.0 | -1.5 | -12.5;-9.5 | 0.79 |
Temporal sup. (μm) | 109.7 ±37.4 | 131.1 ±16.6 | -21.6 | -39.1;-4.1 | 0.016* |
TREX1 MC mean ±SD (n=34) | Controls mean ±SD (n=18) | Estimate | CI | P-value | |
---|---|---|---|---|---|
TMT (μm) | 292.0 ±32.1 | 313.8 ±15.1 | -21.8 | -38.1;-5.6 | 0.009* |
mRNFL (μm) | 23.0 ±6.3 | 25.7 ±2.2 | -2.7 | -5.6;-0.2 | 0.07 |
GCL (μm) | 29.6 ±9.5 | 38.3 ±3.2 | -8.7 | -13.2;-4.2 | <0.001* |
IPL (μm) | 27.9 ±6.2 | 33.1 ±2.1 | -5.1 | -8.1;-2.2 | 0.001* |
INL (μm) | 33.9 ±5.3 | 35.7 ±3.5 | -1.8 | -4.8;-1.3 | 0.25 |
OPL (μm) | 28.6 ±2.8 | 28.9 ±2.2 | -0.3 | -1.8;-1.2 | 0.70 |
ONL (μm) | 69.8 ±9.5 | 70.0 ±8.2 | -0.2 | -6.3;-6.0 | 0.96 |
RPE (μm) | 13.8 ±1.5 | 14.0 ±1.3 | -0.2 | -1.2;-0.8 | 0.68 |
P76 Life traumatic experiences and stressful events as predictors of detoxification-therapy outcome at 6 months in chronic migraine with medication overuse
Bottiroli Sara1, Sances Grazia1, De Icco Roberto1,2, Vito Bitetto1, 2, Guaschino Elena1, Marta Allena1, Pazzi Stefania1, Giuseppe Nappi1, Tassorelli Cristina1,2
1Headache Science Center, Mondino Foundation, Pavia, Italy; 2Department of Brain and Behavioral Sciences, University of Pavia, Italy
Correspondence: Bottiroli Sara (sara.bottiroli@mondino.it)
P77 Role of transient receptor potential (TRP) channels in a rat model of trigeminal neuropathic pain: focus on TRPA1 channels
Chiara Demartini1, Rosaria Greco1, Anna Maria Zanaboni1,2, Oscar Francesconi3, Cristina Nativi3, Cristina Tassorelli1,2, Kristof Deseure4
1Laboratory of Neurophysiology of Integrative Autonomic Systems, Headache Science Center, IRCCS Mondino Foundation, Pavia, Italy; 2Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italia; 3Department of Chemistry ‘Ugo Schiff’, University of Florence, Florence, Italy; 4Department of Medicine, Laboratory for Pain Research, University of Antwerp, Wilrijk, Belgium
Correspondence: Chiara Demartini (chiara.demartini@mondino.it)
P78 Meningeal contribution to migraine pain: a 3T magnetic resonance angiography study
Sabrina Khan1, Faisal Mohammad Amin1, Casper Emil Christensen1, Hashmat Ghanizada1, Samaira Younis1, Anne Christine Rye Andersen1, Patrick J H de Koning2, Henrik B W Larsson3, Messoud Ashina1
1 Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark; 2 Division of Image Processing, Department of Radiology, Leiden University Medical Center, Leiden, Netherlands; 3 Functional Imaging Unit, Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark
Correspondence: Sabrina Khan (sksabrinakhan@gmail.com)
P79 Sex differences in vascular responses to CGRP
Alejandro Labastida-Ramírez1, Eloísa Rubio-Beltrán1, A. van den Bogaerdt2, J. Schouten3, A.H. Jan Danser1, Carlos M. Villalón4, Antoinette MaassenVanDenBrink1
1Division of Vascular Medicine and Pharmacology, Dept. of Internal Medicine, 2Heart Valve Bank Rotterdam, 3Deparment of Neurosurgery, Erasmus University Medical Center, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands; 4Deparment of Pharmacobiology, Cinvestav-Coapa, Mexico City, Mexico
Correspondence: Alejandro Labastida-Ramírez (a.labastidaramirez@erasmusmc.nl)
P80 Effect of onabotulinumtoxinA prevention on comorbidities of depression and anxiety in chronic migraine: Analysis in headache day frequency responders vs headache day frequency non-responders
Andrew M. Blumenfeld1 Stewart J. Tepper2 Lawrence D. Robbins3 Amelia Orejudos4 Aubrey Manack Adams4 Dawn C. Buse5 Stephen D. Silberstein6
1Headache Center of Southern California, The Neurology Center, Carlsbad, CA, 92024, USA; 2 Neurology Department, Headache Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH, 03748, USA; 3Robbins Headache Clinic, Riverwoods, IL, 60015, USA; 4Allergan plc, Irvine, CA, 92612, USA; 5Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, 10461, USA; 6Department of Neurology, Jefferson Headache Center, Philadelphia, PA, 19107, USA
Correspondence: Andrew M. Blumenfeld (blumenfeld@neurocenter.com)
P81 Life with migraine, effect on relationships, career and finances, and overall health and well-being: Results of the Chronic Migraine Epidemiology and Outcomes (CaMEO) study
Dawn C. Buse1, Sharron Murray2, Paula K. Dumas3, Aubrey Manack Adams4, Michael L. Reed5, Kristina M. Fanning5, Richard B. Lipton1
1Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, 10461, USA; 2Wenatchee, WA, 98801, USA; 3Migraine Again LLC, Alpharetta, GA, 30022, USA; 4Allergan plc, Irvine, CA, 92612, USA; 5Vedanta Research, Chapel Hill, NC, 27517, USA
Correspodence: Dawn C. Buse (dbuse@montefiore.org)
P82 A multicenter, prospective, randomized, open-label study to compare onabotulinumtoxinA and topiramate for headache prevention in adults with chronic migraine: patient reported functional outcomes from the FORWARD study
Andrew M. Blumenfeld1, Atul T. Patel2, Aubrey Manack Adams3, John F. Rothrock4
1Headache Center of Southern California, The Neurology Center, Carlsbad, CA, 92024, USA; 2Department of Rehabilitation Medicine, Kansas City Bone and Joint Clinic, Overland Park, KS, 66211, USA; 3Allergan plc, Irvine, CA, 92612, USA; 4George Washington School of Medicine, Washington, DC, 20037, USA
Correspondence: Andrew M. Blumenfeld (blumenfeld@neurocenter.com)
P83 Headache attributed to psychiatric disorder
Ana Lj Podgorac1, Goran Gajić 1, Bojana Pejušković 1,2, Ljubica Zamurović-Dunđerović 1, Vanja B Mandić-Maravić 1, Aleksandar Misojčić 1, Dušica M Lečić-Toševski 1,2,3
1 Institute of Mental Health, 37 Palmoticeva St, Belgrade, Serbia; 2 School of Medicine University of Belgrade, Belgrade, Serbia; 3 Serbian Academy of Sciences and Arts Belgrade, Serbia
Correspondence: Ana Lj Podgorac (anasundic@gmail.com)
P84 Healthcare expenditure: does society give migraine the focus and recognition patients deserve?
Leonhard Schaetz1, Parth Joshi2, Aoife Callan3, Vivek Khurana2, Jasper Huels1
1Global Patient Access, Novartis Pharma AG, Basel, CH-4002, Switzerland; 2Product Life Cycle Services, NBS, Novartis Healthcare Private Limited, Hyderabad, 500081, India; 3Novartis Global Services Centre, Patient Access Services, Dublin, D04 A9N6, Ireland
Correspondence: Leonhard Schaetz (Leonhard.schaetz@novartis.com)
P85 Gender differences in clinical and pharmacological response to triptans
Daphne S. van Casteren1,2, Tobias Kurth3, Michel D. Ferrari2, Gisela M. Terwindt2,#, Antoinette Maassen van den Brink1,#
1Deparment Of Internal Medicine, Div. of Pharmacology, Erasmus Medical Center, P.O. Box 2040, 3000 CA Rotterdam, the Netherlands; 2Deparment Of Neurology, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, the Netherlands; 3Institute of Public Health, Charité – Universitätsmedizin Berlin, Berlin, Germany.
Correspondence: Daphne S. van Casteren (D.S.van_Casteren@lumc.nl)
P86 Migraine induction with calcitonin gene-related peptide in patients from erenumab trials
Casper Emil Christensen&; Samaira Younis&; Marie Deen; Sabrina Khan; Hashmat Ghanizada; Messoud Ashina
Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Correspondence: Messoud Ashina (ashina@dadlnet.dk)
P87 Mitochondrial DNA and migraine
Sigrid Børte1,2, Bendik S. Winswold2,3, Lars G. Fritsche4,5, Ida Surakka6, Jonas B. Nielsen6, Wei Zhou7, Cristen J. Willer6,7,8, John-Anker Zwart1,2,3
1Research and Communication Unit for Musculoskeletal Health, Division of Clinical Neuroscience, Oslo University Hospital, Ullevål, Oslo, Norway; 2Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; 3Department of Neurology, Oslo University Hospital, Oslo, Norway; 4HUNT Research Centre, Department of Public Health and General Practice, Norwegian University of Science and Technology, 7600 Levanger, Norway; 5Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI 48109, USA; 6Department of Internal Medicine, Division of Cardiology, University of Michigan; Medical School, Ann Arbor, Michigan, 48109, USA; 7Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan, 48109, USA; 8Department of Human Genetics, University of Michigan Medical School, Ann Arbor, Michigan, 48109, USA
Correspondence: Sigrid Børte (sigrid.borte@gmail.com)
P88 Headache in Call Center Employees: an Occupational Disease
Ilir Alimehmeti1, Xhovana Kane1, Jera Kruja2,3
1Department of Family and Occupational Health, Faculty of Medicine, University of Medicine, Tirana, Albania; 2Department of Neurosciences, Faculty of Medicine, University of Medicine, Tirana, Albania; 3Neurology Service, University Hospital Center “Mother Teresa”, Tirana, Albania
Correspondence: Jera Kruja (jkruja@gmail.com)
P89 Depression is not the only cause of cognitive impairment in chronic migraine
Nina Latysheva1,2*, Diana Osipova1, Elena Filatova1,2
1Department of Neurology, Institute for Professional Education, I.M. Sechenov First Moscow State Medical University, Moscow, Russia; 2Alexander Vein Headache Clinic, Moscow, Russia
Correspondence: Nina Latysheva (ninalat@gmail.com)
P90 Psychosocial risk factors for headache
M Zaletel, L Zaletel-Kragelj, B Žvan
University Clinical Center of Ljubljana, Department for vascular Neurology, Ljubljana, Slovenia
Correspondence: M Zaletel (mzaletel34@gmail.com)
P91 The prevalence and some risk factors chronic headache in Mongolia
Selenge Enkhtuya1, Otgonbayar Luvsannorov1, Byambasuren Tsenddorj2, Timothy J Steiner3
1Mongolian National University of Medical Sciences, Department of Neurology; 2Mungunguur hospital; 3Imperial College London, London, UK
Correspondence: Selenge Enkhtuya (selenge317@gmail.com)
P92 Symptoms of dependence in medication overuse headache: daily consumption versus days without consumption
J Azimova1, K Skorobogatykh1, A Amelin2
1University Headache Clinic, Moscow; 2Pavlov First Saint Petersburg State Medical University
Correspondence: J Azimova (azimova.j@mail.ru)
P93 Effectiveness and safety of OnabotulinumtoxinA in the treatment of chronic migraine in patients older than 65
M. Castañón, E. Ameijide, J.M. Sánchez
Servicio de Neurología del Hospital Universitario Central de Asturias, Ausurias, Spain
Corresponence: M. Castañón (elenaviles90@hotmail.com)
P94 Headache education and management in a multi centric study Cameroon
García-Azorín D1, Kurtis Urra M2, Molina M3, Delgado-Suarez C4, Iglesias García P4, García-Morales I5, Gonzalez-Monje M6
1Hospital Clinico Universitario Valladolid, Headache Unit, Valladolid, Spain; 2Hospital Ruber Internacional, Movement Disorders Program, Department of Neurology, Madrid, Spain; 3 Hospital de Móstoles, Neurology department, Mostoles, Spain; 4Hospital Clinico San Carlos, Neurology, Madrid, Spain; 5Hospital Clínico San Carlos, Epilepsy Department, Madrid, Spain; 6Universidad Autónoma de Madrid, Neuroscience Department, Madrid, Spain
Correspondence: García-Azorín D (davilink@hotmail.com)
P95 Non-compliance with follow-up: analysis of two years attendance to a second level headache centre in Italy
Teresa Catarci, Isabella Falomi and Roberto Batistoni
Azienda sanitaria locale Roma1, presidio Luzzatti headache centre, Rome, Italy.
Correspondence: Teresa Catarci (teresa.catarci@aslroma1.it)
P96 A real-world analysis of global patient‑reported outcomes in patients with migraine
Janet H. Ford1, Sarah Cotton2, James Jackson2, Jeffrey S. Andrews1, Shonda A Foster1, Wenyu Ye, Russell M. Nichols1, Antje Tockhorn-Heidenreich3
1Eli Lilly and Company, Indianapolis, USA; 2Adelphi Real World, Bollington, UK; 3Eli Lilly and Company, Erl Wood Manor, UK
Correspondence: Janet H. Ford (ford_janet@lilly.com)
US Population | 5-EU Population | |||
---|---|---|---|---|
≥4 MHDs/ month | < 4 MHDs/ month | ≥4 MHDs/ month | < 4 MHDs/ month | |
(n=584) | (n=789) | (n=1942) | (n=2147) | |
Disability Category by MIDAS Value, n (%) | ||||
Little/No | 102 (41.5) | 291 (69.5) | 247 (35.2) | 477 (56.4) |
Mild | 57 (23.2) | 62 (14.8) | 127 (18.1) | 150 (17.8) |
Moderate | 40 (16.3) | 44 (10.5) | 182 (26.0) | 127 (15.0) |
Severe | 30 (12.2) | 18 ( 4.3) | 101 (14.4) | 77 ( 9.1) |
Very severe | 17 ( 6.9) | 4 ( 1.0) | 44 ( 6.3) | 14 ( 1.7) |
MSQ Domain, Mean (SD) | ||||
Total | 67.6 (21.2) | 78.8 (19.1) | 67.7 (18.6) | 76.1 (17.4) |
Role Function: Restrictive | 63 (21.3) | 75.6 (19.4) | 64.2 (19.6) | 72.4 (18.6) |
Role Function: Preventive | 73.5 (21.9) | 82.1 (20) | 72.3 (19.8) | 79.9 (17.9) |
Emotional | 70.2 (24.9) | 82 (22) | 69.9 (21.8) | 79.7 (19.8) |
WPAI, Mean (SD) | ||||
% work time missed due to problem | 10.4 (22.8) | 5.2 (18.1) | 10 (21.4) | 4 (13.7) |
% impairment while working due to problem | 36.5 (28.3) | 21.7 (24.1) | 34.5 (22.5) | 21.9 (22) |
% overall work impairment due to problem | 40.3 (29.6) | 22.7 (24.7) | 39.7 (24.2) | 23.4 (23.2) |
% activity impairment due to problem | 38.6 (27.4) | 25.3 (24.8) | 39 (23.4) | 27.7 (24) |
EQ-5D-5L, Mean (SD) | ||||
EQ5D Utility Score | 0.9 (0.1) | 0.9 (0.1) | 0.8 (0.2) | 0.9 (0.2) |
EQ5D Visual Analogue Scale | 79.8 (14.7) | 84.3 (13) | 74.8 (15.8) | 80.2 (15.4) |
P97 ONAMIG: Does onabotulinumtoxinA modulate cortical excitability in chronic migraine?
A.Alpuente1,2, N.Raguer3, M.Torres-Ferrús1,2; VJ.Gallardo2, J.Álvarez-Sabín1, P.Pozo- Rosich1
1Headache Unit, Neurology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain; 2Headache Research Group, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain; 3Electromyography Unit, Neurophysiology Department, Vall d'Hebron University Hospital, Barcelona, Spain
Correspondence: P.Pozo- Rosich (ppozorosich@yahoo.com)
P98 Effectiveness of OnabotulinumtoxinA in chronic migraine. If early introduction: faster, cheaper and more satisfactory
Robert Belvís, Noemí Morollón, Marina Guasch, Paula Marrero, Azahara Aceituno, Carles Roig
Headache Unit. Dexeus University Hospital and Headache Unit. Santa Creu i Sant Pau Hospital, Barcelona, Spain
Correspondence: Robert Belvís (rbelvis@santpau.cat)
P99 Sickness absence and disability pension in cluster headache patients and in matched references: a population-based study
Anna Steinberg1, Pontus Josefsson2, Kristina Alexandersson2, Christina Sjöstrand1
1 Division of Neurology, Department of Clinical Neuroscience, Karolinska Institutet, SE 171 77 Stockholm, Sweden; 2 Division of Insurance Medicine, Department of Clinical Neuroscience, Karolinska Institutet, SE 171 77 Stockholm, Sweden
Correspondence: Anna Steinberg (anna.steinberg@sll.se)
P100 Clinical features of pediatric medication overuse headache and applicability of new ICHD-3 criteria
Romina Moavero, Maddalena Stornelli, Laura Papetti, Barbara Battan, Samuela Tarantino, Federico Vigevano, Massimiliano Valeriani
Headache Center, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy
Correspondence: Romina Moavero (rominamoavero@hotmail.com)
P101 C-tactile touch perception and habituation in migraineurs
Hanna Sophie Lapp1, Ilona Croy2, Gudrun Gossrau1
1 Comprehensive Pain Center, Technische Universität Dresden, Dresden, Sachsen, 01307, Germany; 2 Department of Psychotherapy and Psychosomatic Medicine, Technische Universität Dresden, Dresden, Sachsen, 01307, Germany
Correspodence: Hanna Sophie Lapp (Hanna-Sophie.Lapp@uniklinikum-dresden.de)
P102 Endeavor to identify associations between vaping and primary headaches
Marge Vaikjärv1, Kati Toom2,3, Mark Braschinsky2,3
1Faculty of Medicine, University of Tartu; 2Headache Clinic, Tartu University Hospital 3Estonian Headache Society
Correspondence: Marge Vaikjärv (marge.vaikjarv@gmail.com)
P103 NDPH sub-categories and treatment in pediatrics patients
Priyanka Shekhawat, Alex S Silver, Jessica Oppenheimer, Robert Fryer
Department of Child Neurology, Columbia University Medical Center - New York, USA
Correspondence: Priyanka Shekhawat (ps2761@cumc.columbia.edu)
P104 Frequency, referral and demographic characteristics of patients with vestibular migraine from a tertiary centre
Isabel Luzeiro1, Isabel Pavão2
1Centro Hospitalar da Universidade de Coimbra; 2University of Lisbon and Santa Maria Hospital, Lisbon
Correspondence: Isabel Luzeiro (isabeluzeiro@gmail.com)
P105 Migraine comorbidity and cognitive performance in patients with focal epilepsy
Olivia AJ Begasse de Dhaem1, Chris Morrison2, Kimford J Meador3, Dale E Hesdorffer1, Sabrina Cristofaro2, Jacqueline French2, Mia T Minen2, on behalf of the HEP Investigators
1Department of Neurology, Columbia University – New York Presbyterian Hospital, New York, New York, 10023, USA; 2Department of Neurology, New York University, New York, New York, 10016, USA; 3Department of Neurology, Stanford University, Palo Alto, California, 94304, USA
Correspondence: Olivia AJ Begasse de Dhaem (oab2109@cumc.columbia.edu)
P106 Nosographic analysis of osmophobia and field testing of diagnostic criteria including osmophobia
Mona Ameri Chalmer, Thomas Folkmann Hansen, Jes Olesen, Professor
Department of Neurology, Danish Headache Center, Copenhagen University Hospital, Glostrup, Denmark
Correspondence: Mona Ameri Chalmer (mona.ameri.chalmer@regionh.dk)
P107 Living with migraine: a report from the My Migraine Voice survey
Audrey Craven1, Rebeca Quintana2, Veruska Carboni3, Paolo Martelletti4,5, Michel Lanteri Minet6, Todd J. Schwedt7, Hans-Christoph Diener8, Annik K-Laflamme9, Annette Vangaa Rasmussen10, Elena Ruiz de la Torre11, Donna Walsh12, Simon Evans13, Paula Dumas14, Rachel Fink9, Angela Fiorin9, Stephanie Ribbe9, Pamela Vo9
1Migraine Association Ireland, Dublin, Ireland; 2GFK, Madrid, Spain; 3GfK Health, Basel, Switzerland; 4Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy; 5EHF; 6Département d’Evaluation et Traitement de la Douleur, Centre Hospitalo-Universitaire de Nice, France; 7Neurology Arizona, Mayo Clinic, Phoenix, USA; 8Department of Neurology and Headache Center, University Duisburg-Essen, Germany; 9Novartis Pharma AG, Basel, Switzerland; 10Rigshospitalet Glostrup, Copenhagen, Denmark; 11European Headache Alliance; 12European Federation of Neurological Associations, Brussels, Belgium; 13Migraine Action, Leicester, United Kingdom; 14Migraine Again, USA
Correspondence: Audrey Craven (audreycraven@migraine.ie)
P108 A model concept for assessing the cost-effectiveness of prophylactic migraine treatments
Ronan Mahon1*, Pamela Vo2, Philip Cooney1, Andrii Danyliv1, Aikaterini Bilitou1, Nagasuman Toram3, Sreelatha Vadapalle3, Jasper Huels2, Farooq Maniyar4, Peter J Goadsby5 Mark Sculpher6
1Novartis Global Services Centre, Patient Access Services, Dublin, Ireland; 2Novartis Pharma AG, Basel, Switzerland; 3Novartis Global Services Centre, Patient Access Services, Novartis Healthcare Pvt. Ltd., Hyderabad, India; 4Basildon and Thurrock University Hospitals and Queen Mary University, London, England; 5NIHR-Wellcome Trust, King’s Clinical Research Facility, King’s College London, UK; 6Centre for Health Economics, University of York, Heslington, Alcuin 'A' Block, York, YO10 5DD UK
Correspondence: Ronan Mahon (ronan.mahon@novartis.com)
P109 Relative efficacy of outpatient infusion therapy on pediatric patients with post-concussive headaches
Sara J Gould1, Erin Mackenzie Katz2, Carly Ann Cignetti2
1University of Alabama at Birmingham; 2University of Alabama at Birmingham School of Medicine
Correspondence: Sara J Gould (sgould@uabmc.edu)
P110 Movement disorders as positive motor aura symptoms during hemiplegic migraine attacks
Elisa de la Cruz1, Geneviève Demarquay2, Caroline Roos3, Isabelle Sabatier4, Florence Riant5, Victoria Gonzàlez1, Anne Ducros1
1Service de Neurologie, CHU Gui de Chauliac, 34090 Montpellier, France; 2Service de Neurologie clinique et fonctionnelle, Hôpital Pierre Wertheimer, 69667 Bron, France; 3Centre d’Urgences Céphalées, Hôpital Lariboisière, 75010 Paris, France; 4Service de Neuropédiatrie, Hôpital Femme Mère Enfant, 69677 Bron, France; 5Laboratoire de Génétique moléculaire, Hôpital Lariboisière, 75010 Paris, France
Correspondence: Elisa de la Cruz (elisa@sdlc.ca)
P111 Long-term response to onabotulinumtoxin A in chronic migraine: analysis of efficacy and tolerability in a series of 40 patients
D García-Azorín, A Sierra, J Trigo, E Martínez-Pías, AL Guerrero
Headache Unit, Neurology Department. Hospital Clínico Universitario, Valladolid, Spain
Correspondence: García-Azorín D (davilink@hotmail.com)
P112 Acute and preventive treatment patterns and associated work productivity and activity impairment among patients with migraine in Germany
J. Scott Andrews1*, Janet Ford1, Grazia Dell’Agnello2, Sarah Cotton3, Antje Tockhorn-Heidenreich4, Louise Lombard1, Zoe Phillips3, James Jackson3
1Eli Lilly and Company, Indianapolis, IN, 46285, USA; 2Eli Lilly and Company, Florence, Italy; 3Adelphi Real World, Bollington, UK; 4 Eli Lilly and Company Limited, Windlesham, UK
Correspondence: Grazia Dell’Agnello (andrews_jeffrey_scott@lilly.com)
P113 Baseline demographics and disease characteristics of patients with episodic cluster headache: results from a phase 3 clinical trial
James M. Martinez, Jennifer N. Bardos, Tina M. Myers Oakes, Chunmei Zhou
Eli Lilly and Company, Indianapolis, IN, 46285, USA
Correspondence: Jennifer N. Bardos (bardos_jennifer_n@lilly.com)
P114 PrevenBox: Evaluation of concomitant use of preventive medications with OnabotulinumtoxinA in migraine
Marta Torres-Ferrus1,2; Sonia Santos Lasaosa3; Angel Guerrero Peral4; Jose M Laínez5; Javier Viguera Romero6; Ana B Gago Veiga7; Pablo Irimia8; Margarita Sanchez del Río9; Laila Asskour2; Victor J Gallardo2; Patricia Pozo-Rosich1,2
1Headache Unit, Neurology Department, Vall d’Hebron University Hospital, Barcelona, 08035, Spain; 2Headache Research Group, Vall d’Hebron Research Institute, Barcelona, 08035, Spain; 3 Neurology Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, 5009, Spain; 4 Headache Unit, Hospital Clínico Universitario de Valladolid, Valladolid, 47007, Spain; 5 Department of Neurology, Hospital Clinico Universitario de Valencia, Universidad Católica de Valencia, Valencia, 46010, Spain; 6 Department of Neurology, Hospital Virgen Macarena, Sevilla, 41009, Spain; 7 Department of Neurology, La Princesa Health Research Institute, La Princesa University Hospital, Madrid, 28006, Spain; 8 Department of Neurology, Clínica Universidad de Navarra, Pamplona, 31008, Spain; 9 Department of Neurology, Clínica Universidad de Navarra, Madrid, 28027, Spain
Correspondence: Patricia Pozo-Rosich (ppozo@vhebron.net)
P115 Onset of effect of onabotulinumtoxinA for chronic migraine treatment: analysis of PREEMPT data
David W. Dodick1* Stephen D. Silberstein2 Richard B. Lipton3 Ronald E. DeGryse4 Aubrey Manack Adams4 Hans-Christoph Diener5
1Department of Neurology, Mayo Clinic, Phoenix, AZ, 85054, USA; 2Department of Neurology, Jefferson Headache Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA; 3Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, 10461, USA; 4Allergan plc, Irvine, CA, 92612, USA; 5Department of Neurology, University of Duisbury-Essen, Essen, 45122, Germany
P116 New daily persistent headache: A systematic review on an enigmatic disorder
Nooshin Yamani1, 2, Jes Olesen1
1Danish Headache Centre and Department of Neurology, University of Copenhagen, Rigshospitalet Glostrup, Copenhagen, Denmark; 2 Headache Department, Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
Correspondence: Nooshin Yamani (Jes.olesen@regionh.dk)
Reference | Location | Definition criteria | Population surveyed | NDPH prevalence | Female | Male | F:M ratio | Age of onset | Race |
---|---|---|---|---|---|---|---|---|---|
Castillo-1995 | Spain | S-L | 1883 general population 22-73 yr | 0.1%GP | |||||
Li & Rozen-2002 | USA | S-L | 56 NDPH cases | 40(71%) | 16(29%) | 2.5 | 12-78 | Caucasian:87% Black:11% Hispanic:2% | |
Bigal-2004 | USA | S-L | 170 adolescent 13-17 yr with CDH 638 adult with CDH | 21% CDH 10.8% CDH | |||||
Takase- 2004 | Japan | ICHD 2 | 30 NDPH cases of 1760 CDH | 1.7% CDH | 13(43%) | 17(57%) | 0.8 | 13-73 | |
Meineri-2004 | Italy | ICHD2,S-L | 18 NDPH cases of 265 CDH | 6.7% CDH | 11(61%) | 7(39%) | 1.6 | 13-76 | |
Mack-2004 | USA | M-ICHD2 | 175 children <18 yr with CDH | 23% CDH | 27(67.5%) | 13(32.5%) | 2.1 | ||
Kung 2006 | USA | M-ICHD 2 | 306 children and adolescents 6-18 yr in a tertiary headache center | 28% CDH | 34(64.2%) | 19(35.8%) | 1.7 | ||
Grande 2009 | Norway | ICHD 2 | 30000 general population 30-44 yr | 0.03% GP | |||||
Robbins 2010 | USA | M-ICHD2 | 71 NDPH | 51(72%) | 20(28%) | 2.5 | 8-76 | Cacausian:80.3% Black:5.6% Hispanic:9.9% | |
Prakash 2012 | India | M-ICHD2 | 63 NDPH | 36(57%) | 27(43%) | 1.3 | 18-68 | ||
Rozen 2016 | USA | ICHD-3β | 97 NDPH | 65(67%) | 32(33%) | 2 | Mean: F:32.4 M:35.8 | Cacausian:98% Black:1% Hispanic:1% | |
Uniyal 2017 | India | ICHD-3β | 55 NDPH | 45.5% | 54.5% | 0.8 | Mean:28.4 |
A. Persistent headache fulfilling criteria B and C B. Distinct and clearly-remembered onset, with pain becoming continuous and unremitting within 24 hours C. Present for >3 months D. Not better accounted for by another ICHD-3 diagnosis |
Study | Vanst 1986 | Rozen 2002 | Takase 2004 | Meineri 2004 | Kung 2008 | Robins 2010 | Peng 2011 | Prakash 2012 | Uniyal 2017 |
---|---|---|---|---|---|---|---|---|---|
Definition criteria | S-L | ICHD-2 | ICHD-2 | M-ICHD2 | M-ICHD2 | M-ICHD2 | M-ICHD2 | ICHD3β | |
Number of NDPH cases | 45 | 56 | 30 | 18 | 53 | 71 | 92 | 63 | 55 |
Mean age | F:3rd decade M:5th decade | 35 | F:3rd decade M:4th decade | 14.2 (study of pediatrics) | 5th decade | 36.8 | 28.24 | ||
Female:male | 1.4:1 | 2.5:1 | 0.8:1 | 1.6:1 | 1.7:1 | 1.3:1 | 1.3:1 | 0.8:1 | |
Recalling time of onset | - | - | |||||||
Exact date: | 80% | 100% | - | 42% | - | 33% | 20% | ||
Month: | 83 % | 80% | |||||||
Past history of prior headache | none | 38% | 7% | 33% | - | 25.4% | 32% | 54% | 38.2% |
Past history of episodic tension-type headache | none | 19% | - | - | - | 18.3% | 20% | 29% | 29.1% |
Past history of episodic migraine headache | none | 2% | - | - | - | 7% | 12% | 25% | 9.1% |
Location of headache | - | - | |||||||
Bilateral: | 64% | 86% | 100% | 88.7% | 46.7% | 83% | 81.5% | ||
Pain characteristics | - | ||||||||
Throbbing | 28% | 55% | 27% | 61% | 45.1% | 41% | 51% | 41.8% | |
Pressing/tightening | 72% | 54% | 90% | 100% | 100% | 56.4% | |||
Pain severity | |||||||||
Mild: | 18% | - | 28% | 16.9% | - | Mean Headache Score:7.5 | |||
Mod: | 61% | 72% | 57.7% | 87% | |||||
Severe: | 21% | 0 | 10.8 d/m | 23.9% | |||||
Aggregation by physical activity | - | - | - | - | - | 46.5% | 57% | 27% | 16.4% |
Associated features: | |||||||||
Nausea: | 55% | 68% | 33% | 50% | 39% | 47.9% | 35% | 49% | 56.4% |
Vomiting: | 12% | 23% | - | - | - | 12.7% | 7% | 5% | 20% |
Photophobia: | 34% | 66% | 3% | 27% | 69% | 45.1% | 48% | 33% | 45.5% |
Phonophobia: | 37% | 61% | - | 17% | 63% | 40.8% | 58% | 19% | - |
Autonomic features: | - | 23% | - | - | - | 21% | - | 14% | - |
Psychiatric comorbidity: | - | - | - | - | - | (self-reported) | (Self-reported) | ||
Depression: | 35.2% | 19% | 89.1% | ||||||
Anxiety: | 33.8% | 60.8% | 16% | 92.7% | |||||
Family history of headache | - | 29% | - | 33% | 49% | 47.5% | - |
Reference | Number of NDPH patients | No Triggering factor | Infection or flu-like illness | Stressful life event | Trauma /surgery | other |
---|---|---|---|---|---|---|
Mack 2004, USA | 40 (pediatric NDPH) | 5(12%) | 17(43%) | 13(33%) | 5(12%) idiopathic intracranial hypertension, high altitude climbing | |
Takase 2004, Japan | 30 | 24(80%) | - | 6(20%) | - | |
Robins2010, USA | 71 | 38(53.5%) | 10(14.1%) | 7(9.9%) | 6(8%) menarche, SSRI withdrawal, HPV vaccination | |
Peng2011, Taiwan | 92 | 65(71%) | 3(3%) | 24(26%) | ||
Parkash2012 , India | 63 | 29(46%) | 18(29%) | 5(8%) | 10(16%) | 9(14%) postpartum, medication overuse |
Rozen2016, USA | 97 Female:65 Male:34 | 51(53%) Female: 52% Male: 53% Mean age:30.4 | 21(22%) Female: 22% Male: 22% Mean age:31.8 | 9(9%) Female: 11% Male: 6% Mean age:28.1 | 9(9%) Female:9% Male:9% Mean age:63.3 | 7(7%) syncope, hormone, toxin and medication, cervical massage |
Uniyal 2017, India | 55 | 35(63.5%) | 10(18%) | 5(9.1%) | 5(9.1%) |
• Low or raised CSF pressure(Spontaneous CSF leak, Idiopathic intracranial hypertension, Intracranial mass lesion ) • Cerebral venous thrombosis • Cranial artery dissection • Cranial arthritis • Posttraumatic headache (subarachnoid hemorrhage, subdural hematoma,…) • Meningitis • Sphenoid sinusitis • Contact-point headache(caused by contact of intranasal structures) |
P117 Clinical description of 135 patients with typical aura without headache and scale proposal for diagnosis in a first episode
Robert Belvís, Marina Guasch, Paula Marrero, Noemí Morollón, Azahara Aceituno, Carles Roig
Neurology department Hospital de la Santa Creu i Sant Pau, Neurology department Hospital Universitario Dexeus. Barcelona, Spain
Correspondence: Robert Belvís (rbelvis@santpau.cat)
P118 Onabotulinumtoxin A for Chronic Migraine with Medication Overuse: Preliminary Clinical Results and Changes in Catastrophising
Licia Grazzi1 Eleonora Grignani2, Emanuela Sansone1, Alberto Raggi2, Matilde Leonardi2, Domenico D’Amico1, Frank Andrasik3
1Headache and Neuroalgology Unit, Neurological Institute "C. Besta" IRCCS Foundation, Via Celoria 11, 20133, Milan, Italy. 2Neurology, Public Health and Disability Unit, Neurological Institute "C. Besta" IRCCS Foundation, Milan, Italy. 3Department of Psychology, University of Memphis, TN
Correspondence: Licia Grazzi (licia.grazzi@istituto-besta.it)
P119 Mindfulness meditation for migraine in pediatric population: a pilot study
Licia Grazzi1Emanuela Sansone1, Raggi Alberto2, Eleonora Grignani2, Matilde Leonardi2, Chiara Scaratti2, Frank Andrasik3
1Headache and Neuroalgology Unit, Neurological Institute "C. Besta" IRCCS Foundation, Via Celoria 11, 20133, Milan, Italy; 2Neurology, Public Health and Disability Unit, Neurological Institute "C. Besta" IRCCS Foundation, Milan, Italy; 3Department of Psychology, University of Memphis, TN
Correspondence: Licia Grazzi (licia.grazzi@istituto-besta.it)
P120 Prophylactic effect of ultramicronized N-Palmitoyl Ethanol Amide (PEA) on pediatric migraine: a preliminary study
Giorgia Sforza1,2*, Laura Papetti1, Samuela Tarantino1, Barbara Battan1, Michela Ada Noris Ferilli 1,3, Romina Moavero1,2, Federico Vigevano1, Massimiliano Valeriani1
1 Headache Center, Child Neurology Unit, Bambino Gesu’ Children’s Hospital, Rome, Italy; 2 Child Neurology and Psychiatry Unit, Tor Vergata University of Rome, Italy; 3Institute of Neurology, Catholic University of Sacred Heart, Rome, Italy
Correspondence: Giorgia Sforza (sforzagiorgia@gmail.com)
P121 Cerebral Hemodynamics, Patent foramen ovale and White Matter Hyperintensities in patients Migraine with aura, young stroke patients and controls
C Altamura1, CA Mallio2, G Lo Vullo2, N Brunelli1, M Paolucci1, A Cascio Rizzo1, G Cecchi1, CC Quattrocchi2, F Vernieri1
1Headache and Neurosonology Unit, Neurology Unit, Università Campus Bio-Medico di Roma, Rome, Italy; 2Radiology Unit, Università Campus Bio-Medico di Roma, Rome, Italy
Correspondence: C Altamura (c.altamura@unicampus.it)
P122 Prediction of the pterygopalatine ganglion localization in CT images
Joan Crespi1,2,3, Daniel Bratbak2,4, David Dodick2,5, Kent Are Jamtøy2,6, Irina Aschehoug2, Manjit Matharu7, Erling Tronvik1,2,3
1Department of Neurology, St Olav’s University Hospital, Trondheim, Norway; 2NTNU (University of Science and Technology), Department of Neuromedicine and Movement Science, Trondheim, Norway; 3Norwegian Advisory Unit on Headaches, Trondheim, Norway; 4Department of Neurosurgery, St Olav’s University Hospital, Trondheim, Norway; 5Mayo Clinic, Arizona, USA; 6Department of maxillofacial surgery, St Olav’s University Hospital, Trondheim, Norway; 7National Hospital of Neurology and Neurosurgery, London, UK
Correspondence: Joan Crespi (joan.crespi@ntnu.no)
P123 Anxiety, depression and alexithymia in young migraine patients: which relationship with body weight?
Samuela Tarantino1, Alessandra di Stefano2, Laura Papetti1, Barbara Battan1, Giorgia Sfronza3, Federico Vigevano1, Simonetta Gentile2 and Massimiliano Valeriani1,4
1Headache Center, Division of Neurology, 2Unit of Clinical Psychology, Ospedale Pediatrico Bambino Gesù, IRCCS, Piazza Sant’Onofrio 4, Rome, Italy; 3Child Neurology and Psychiatry Unit, Tor Vergata University of Rome; 4Center for Sensory-Motor Interaction, alborg University, Aalborg, Denmark
Correspondence: Samuela Tarantino (samuela.tarantino@opbg.net)
P124 Health care resource use, sick-leaves and comorbidities among migraine patients in occupational healthcare
Minna A. Korolainen1, Samu Kurki2, Iiro Toppila3, Mariann Lassenius3, Timo Purmonen1 and Markku Nissilä2
1Novartis Finland Oy, Espoo, Finland; 2Terveystalo Biobank Finland, Turku, Finland; 3Medaffcon Oy, Espoo, Finland
Correspondence: Minna A. Korolainen (Minna.Korolainen@novartis.com)
-
References:
-
1. Steiner et al. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018;19:17.
P125 The Number of Active Trigger Points is Associated with Pain Features, Depression and Anxiety in Frequent Episodic, but not Chronic, Tension Type Headache
Stella Fuensalida-Novo1, María Palacios-Ceña1,2, Matteo Castaldo1, Kelun Wang1, Lars Arendt-Nielsen1, César Fernández-de-las-Peñas1,2
1SMI, School of Medicine, Aalborg University, Aalborg, DENMARK; 2Departamento de Fisioterapia, Terapia Ocupacional, Rehabilitación y Medicina Física. Universidad Rey Juan Carlos, Alcorcón, Madrid, SPAIN
Correspondence: César Fernández-de-las-Peñas ( cesar.fernandez@urjc.es)
P126 New daily persistent headache in a pediatric cohort
Laura Papetti, Barbara Battan, Romina Moavero, Giorgia Sforza, Samuela Tarantino, Massimiliano Valeriani
Headache Center Bambino Gesù Children Hospital, Rome Italy
Correspondence: Laura Papetti (laura.papetti@opbg.net)
P127 Cerebral vascular reactivity in patients with chronic neck pain
Nevzat Uzuner1, Aycan Guner Ekici2, Gulnur Tekgol Uzuner1, Sacit Gulec2
1Department of Algology and Neurology, Eskisehir Osmangazi University, Eskisehir, TUR; 2Department of Algology and Anaesthesiology, Eskisehir Osmangazi University, Eskisehir, TUR
Correspondence: Nevzat Uzuner (nevzatuzuner@gmail.com)
P128 Chronic migraine is much more related to cardiovascular risk factors: a clinic-based study
Gulnur Tekgol Uzuner1, Osman Ozgur Yalın2, Derya Uluduz3, Aynur Ozge4, Nevzat Uzuner1
1Department of Neurology and Algology, Eskisehir Osmangazi University, Eskisehir, TUR; 2Neurology Clinic, Istanbul Education and Research Hospital, Istanbul, TUR; 3Department of Neurology and Algology, Istanbul University, Istanbul, TUR; 4Department of Neurology and Algology, Mersin University, Mersin, TUR
Correspondence: Gulnur Tekgol Uzuner (uzunergulnur@gmail.com)
P129 The “pure” Trochlear Migraine : two cases and nosographic considerations
Luca Maria Messina1 4, Francesca Cardella2, Rosaria Roppolo2, Francesca Vanadia, Filippo Brighina3, Vincenzo Raieli4
1 Child Neuropsichiatry Department - University of Palermo; 2 Pediatric Diabetology Unit, ISMEP - ARNAS Civico Palermo; 3 Department of Experimental Biomedicine and Clinical Neurosciences - University of Palermo; 4 Child Neuropsychiatry Unit, ISMEP - ARNAS Civico Palermo
Correspondence: Vincenzo Raieli (vinzi.raielk@inwind.it)
Clinical features | ||
---|---|---|
Sex | M | M |
Age at diagnosis trochlear pain | 12 | 11 |
Age at onset of migraine, y | 10 | 10 |
Migraine subtype | Ep MwA | Ep MwA |
Location of migraine pain | Troch. | Troch/fronto-temp |
Age at onset trochlear pain | 10 | Not specified |
Side trochlear pain | Alternanting | Alternanting |
Quality troclear pain | Puls./pre | Puls |
Temporal pattern of active pain period | Recurrent episodes | Recurrent episodes |
Intensity of trochlear pain (not included excerbations) | 7-9 | 7-8 |
Photo/phonophobia associated to trochlear pain | + | + |
Nausea associated to trochlear pain | + | + |
Vomiting associated to trochlear pain | + | - |
Diplopia | - | - |
Trigger trochlear for migraine attacks | Not applicable | Not applicable |
Response to local steroid injection | Not applicable | Not applicable |
P130 Efficient therapy for treatment of migraine without aura: ergotamine based drugs or sumatriptan
Sinisa Miljkovic1, Dz. Smajlovic2, S. Crncevic1, T. Jurisic3, M. Tiric Campara4, L. Duranovic Vinkovic5, Z. Dostovic2, Z. Pasic2
1University Clinical Center Banja Luka, Department of Neurology, Bosnia and Herzegovina; 2University Clinical Center Tuzla, Department of Neurology, Bosnia and Herzegovina; 3University Clinical Hospital Mostar, Department of Neurology, Bosnia and Herzegovina; 4University Clinical Center Sarajevo, Department of Neurology, Bosnia and Herzegovina; 5Cantonal Hospital “Dr. Safet Mujić“ Mostar (Regional Medical Center), Department of Neurology, Bosnia and Herzegovina
Correspondence: Sinisa Miljkovic (sinisa.miljkovic@kc-bl.com)
P131 Analysis of Initial Non Responders to Galcanezumab in Patients with Episodic or Chronic Migraine: Results from the EVOLVE-1, EVOLVE-2, and REGAIN Randomized, Double-Blind, Placebo-Controlled Trials
Russell M. Nichols, Dustin Ruff, Eric Pearlman, Sheena K. Aurora
1Eli Lilly and Company, Indianapolis, IN, USA
Correspondence: Russell M. Nichols
P132 Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Post-hoc Analyses of Two Phase 3 Studies
Sheena K. Aurora, Holland C. Detke, Brian A. Millen, Hans-Peter Hundemer
Eli Lilly and Company, Indianapolis, IN, USA
Odds ratio | 95% CI | p-value | |
---|---|---|---|
Study 1 (EVOLVE-1) | |||
Week 1 | 2.71 | 2.00, 3.66 | <0.001 |
Week 2 | 3.08 | 2.27, 4.17 | <0.001 |
Week 3 | 2.11 | 1.55, 2.86 | <0.001 |
Week 4 | 1.56 | 1.15, 2.11 | 0.004 |
Study 2 (EVOLVE-2) | |||
Week 1 | 2.88 | 2.16, 3.86 | <0.001 |
Week 2 | 2.76 | 2.07, 3.68 | <0.001 |
Week 3 | 2.41 | 1.80, 3.22 | <0.001 |
Week 4 | 2.67 | 1.99, 3.58 | <0.001 |
P133 Migraine and cluster headache – the common link
Anne Luise Vollesen1, & (luisevollesen@gmail.com), Silvia Benemei2, & (Italy. silvia.benemei@unifi.it), Francesca Cortese3, & (francesca.cortese@hotmail.com), Alejandro Labastida-Ramírez4, & (a.labastidaramirez@erasmusmc.nl), Francesca Marchese5, & (marchesefrancescaa@gmail.com), Lanfranco Pellesi6, & (lanfranco.pellesi@gmail.com), Michele Romoli7, & (romoli.mic@gmail.com), Messoud Ashina1 (ashina@dadlnet.dk), Christian Lampl8, and on behalf of the School of Advanced Studies of the European Headache Federation (EHF-SAS)
1Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; 2Health Sciences Department, University of Florence, and Headache Centre, Careggi University Hospital, Florence; 3Department of Medico-Surgical Sciences and Biotechnologies, Sapienza. University of Rome, Polo Pontino, Latina, Italy; 4Dep Internal Medicine, Division of Vascular Pharmacology, Erasmus Medical Center, Rotterdam, The Netherlands; 5Child Neuropsichiatry Unit, University of Palermo, Palermo, Italy; 6Medical Toxicology, Headache and Drug Abuse Center, University of Modena and Reggio Emilia, Modena, Italy; 7Neurology Clinic, University of Perugia - S.M. Misericordiae Hospital, Perugia, Italy; 8Department of Neurogeriatric Medicine, Headache Medical Center Linz, Linz, Austria.
Correspondence: Christian Lampl (christian.lampl@ordensklinikum.at)
P134 Providing care: Cost-effective and affordable
Michela Tinelli (m.tinelli@lse.ac.uk)
Personal Social Services Research Unit, London School of Economics (LSE), Houghton Street, London WC2A 2AE, UK
P135 The Activity Impairment in Migraine – Diary (AIM-D): A novel migraine-specific patient-reported outcome measure to assess functioning based on activity impairment in episodic and chronic migraine patients
ML Cala1, CA Graham1, RB Lipton2, N Lyn1, DW Dodick3, C Burk4, JS Yu5, CJ Evans1, HN Viswanathan5
1Endpoint Outcomes, Boston, MA, USA; 2Albert Einstein College of Medicine, Bronx, NY, USA; 3Mayo Clinic, Phoenix, AZ, USA; 4Independent consultant, Orange County, CA, USA; 5Allergan plc, Irvine, CA, USA
Correspondence: RB Lipton
P136 Epidemiology of chronic and episodic migraine in Europe
Hicham Benhaddi1, Timothy Fitzgerald2, Sophie McCabe3, Ruth Zeidman3
1Teva Pharmaceuticals, Wilrijk, Belgium; 2Teva Pharmaceuticals, Frazer, Pennsylvania, USA; 3Covance Market Access, London, UK
Correspondence: Hicham Benhaddi (kgora@hcg-int.com)
P137 The impact of offering monthly and quarterly dosing options for a new class of migraine preventive therapy on likelihood of acceptance and adherence in adults with migraine
Robert Cowan1, Joshua Cohen2, Erik Rosenman3, Tim Fitzgerald2, Ravi Iyer2
1Neurology, Stanford University School of Medicine, Stanford, California, 94305, USA; 2Teva Pharmaceutical Industries, Frazer, Pennsylvania, 19355, USA; 3IQVIA, Inc., Cambridge, Massachusetts, 02139, USA
Correspondence: Ravi Iyer (pjsisi1999@gmail.com)
P138 Prognosis of trigeminal neuralgia is very favourable when managed by specialists - a two-year prospective real-life study
Tone Bruvik Heinskou1, Stine Maarbjerg1, Frauke Wolfram2, Per Rochat3, Jannick Brennum3, Jes Olesen1 and Lars Bendtsen1
1Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, 2600 Glostrup, Denmark; 2Department of Diagnostics, Herlev Hospital, 2730 Herlev, Denmark; 3Department of Neurosurgery, Rigshospitalet Blegdamsvej, University of Copenhagen, 2100 Copenhagen, Denmark
Correspondence: Tone Bruvik Heinskou (tone.bruvik.heinskou@regionh.dk)
P139 Serum changes of apolipoproteins in Medication Overuse Headache (MOH)
Lanfranco Pellesi1, Elisa Bellei2, Carlo Baraldi1, Flavia 1, Simona Guerzoni1, Emanuela Monari2, Luigi Alberto Pini1,3
1Medical Toxicology, Headache and Drug Abuse Centre, University of Modena and Reggio Emilia, Modena, Italy; 2Department of Diagnostic Medicine, Clinic and Public Health, Proteomic Lab, University of Modena and Reggio Emilia, Modena, Italy; 3Center for Neuroscience and Neurotechnology, University of Modena and Reggio Emilia, Modena, Italy
Correspondence: Lanfranco Pellesi (lanfranco.pellesi@gmail.com)
P140 Robust association between Obstructive sleep apnea (OSA) and Idiopathic intracranial hypertension (IIH) in Chronic daily headache (CDH).
G. Demonte1, L. Rapisarda1, F. Tosto1, F. Roccia2, M. Sturniolo3, A. Gambardella3, F. Bono2
1Headache center, Institute of Neurology, Department of Medical and Surgical Sciences - Magna Graecia University – Catanzaro; 2Rehabilitative Cardiology - AOU Mater Domini - Catanzaro; 3Institute of Neurology, Department of Medical and Surgical Sciences - Magna Graecia University – Catanzaro
Correspondence: G. Demonte (g.dem.1990@gmail.com)
P141 Loss of periventricular white matter microstructure integrity in idiopathic intracranial hypertension
Laura Rapisarda1, Giulio Demonte1, Federico Tosto1, Maria Curcio1, Alessia Sarica2, Antonio Cerasa2, Antonio Gambardella1,2, Francesco Bono1,2
1Headache Center, Institute of Neurology, Department of Medical and Surgical Sciences, Magna Graecia University- Catanzaro, Italy; 2Neuroscience Research Center, Department of Medical and Surgical Sciences, Magna Graecia University of Catanzaro, Italy
Correspondence: Laura Rapisarda (laura_rapisarda90@yahoo.it)
P142 Quality of life in the active phase of cluster headache
Ertsey C1, Dióssy M1, Magyar M1,2, Gyüre T2, Csépány É1,2, Bozsik Gy1
1Dept. of Neurology, Semmelweis University, Budapest, Hungary; 2Szentágothai János Doctoral School of Neurosciences, Semmelweis University, Budapest, Hungary
Correspondence: Ertsey C (konfreg1@bcdtravel.hu)
P143 Self-detoxification from medication overuse reduces disability among patients with MOH
Espen Saxhaug Kristoffersen1,2,3, Ragnhild Berling Grande1,4, Kjersti Aaseth1,3, Michael Bjørn Russell1,5 and Christofer Lundqvist1,3,5,6
1Head and Neck Research Group, Research Centre, Akershus University Hospital, Lørenskog; 2Department of General Practice, Institute of Health and Society, University of Oslo, Oslo; 3Department of Neurology, Akershus University Hospital, Lørenskog; 4The National Center for Epilepsy, Division for Surgery and Clinical Neuroscience, Oslo University Hospital, Oslo; 5Institute of Clinical Medicine, Campus Akershus University Hospital, University of Oslo, Nordbyhagen; 6Health Services Research Centre, Akershus University Hospital, Lørenskog, Norway
P144 Effects of non-invasive vagus nerve stimulation (nVNS) on resting-state EEG and laser-evoked potentials in migraine: findings from a subgroup of patients enrolled in the randomised, sham-controlled, double-blind PRESTO study
Eleonora Vecchio1, Iege Bassez2, Katia Ricci1, Cristina Tassorelli3,4, Eric Liebler5, Marina de Tommaso1
1Applied Neurophysiology and Pain Unit, SMBNOS Department, Polyclinic General Hospital, University of Bari Aldo Moro, Bari, Italy; 2Department of Data Analysis, Ghent University, Ghent, Belgium; 3Headache Science Centre, National Neurological Institute C. Mondino Foundation, Pavia, Italy; 4Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy; 5electroCore, LLC, Basking Ridge, New Jersey, USA
Correspondence: Eleonora Vecchio (eleonora.vecchio@gmail.com)
P145 Migraine, thrombophilic alterations, and vascular disease: results from a case-control study
Cinzia Cavestro1, Diana Degan2, GianmatteoMicca3,4, Raffaele Aloi5, Silvia Mandrino1, Carlo Di Pietrantonj6, Maria Cristina Frigeri7, Francesca Pistoia2, Filippo Molinari3, Simona Sacco2
1Headache Center, Department of Neurology, ‘San Lazzaro’ Hospital, ASL CN2 Alba, Italy; 2Institute of Neurology, Department of Applied Clinical Sciences and Biotechnology, University of L’Aquila, L’Aquila, Italy; 3Main Laboratory and Hematology and Coagulation Disorders Laboratory, ASL CN2 Alba, Italy; 4Main Laboratory and Hematology and Coagulation Disorders Laboratory, ‘Santa Croce’ Hospital, Cuneo, Italy; 5Occupational Medicine Service, ASL CN2, Alba, Italy; 6Regional Service of Epidemiology, Alessandria, Italy; 7Administrative Medical Office, ‘San Lazzaro’ Hospital, ASL CN2, Alba, Italy
Correspondence: Cinzia Cavestro (cicaves@alice.it); Simona Sacco (simona.sacco@univaq.it)
IS or TIA | Coronary heart disease | Peripheral venous thrombosis | |||||||
---|---|---|---|---|---|---|---|---|---|
OR | 95% CI | p | OR | 95% CI | p | OR | 95% CI | p | |
Age | 1.0 | 0.9-1.0 | 0.187 | - | - | - | 1.0 | 0.9-1.0 | 0.516 |
Arterialhypertension | 3.1 | 0.7-13.4 | 0.127 | 3.7 | 0.2-81.4 | 0.407 | 3.9 | 1.0-14.4 | 0.047 |
Diabetesmellitus | 1.2 | 0.1-13.6 | 0.903 | 1.9 | 0.1-318.8 | 0.801 | - | - | - |
Hypercholesterolemia | 1.4 | 0.3-6.9 | 0.705 | 8.0 | 0.4.174.2 | 0.187 | - | - | - |
BMI | 0.9 | 0.8-1.0 | 0.041 | 0.8 | 0.5-1.1 | 0.141 | 0.9 | 0.8-1.0 | 0.080 |
aPLspositivity | 5.6 | 1.5-20.4 | 0.009 | 27.6 | 1.4-531.3 | 0.028 | 3.4 | 0.9-12.3 | 0.063 |
Free protein S deficiency | 14.3 | 2.8-74.4 | 0.002 | 6.2 | 0.1-1298.5 | 0.502 | - | - | - |
P146 Healthcare Resource Utilisation in Patients Treated with OnabotulinumtoxinA for Chronic Migraine: The REPOSE study
Katja Kollewe1, Angela Antonakakis2, Katherine Sommer3, Justin S. Yu4
1Hannover Medical School, Hannover, Germany; 2Schmerzzentrum Rhein-Main, Frankfurt, Germany; 3Allergn plc, Marlow, Buckinghamshire, UK; 4Allergan plc, Irvine, CA, USA
P147 Proposed new diagnostic criteria for chronic migraine
Mona Ameri Chalmer1, Thomas Folkmann Hansen1, Elena Lebedeva2, David Dodick3, Jes Olesen1
1Department of Neurology, Danish Headache Center, Copenhagen University Hospital, Glostrup, Denmark; 2Department of Neurology and Neurosurgery, Urals State Medical University, Russia; 3Mayo Clinic, Scottsdale, AZ, USA
Correspondence: Mona Ameri Chalmer (mona.ameri.chalmer@regionh.dk)
Danish Headache Center | The Mayo Clinic | Russian students | |
---|---|---|---|
CM | 174 | T.b.c. | 17 |
pCM | 350 | T.b.c. | 46 |
pCM-CM | 176 | T.b.c. | 29 |
CM | pCM-CM | |
---|---|---|
Early retirement pension | 17 (12.6%) | 15 (10.6%) |
Sickness benefit | 113 (83.7%) | 113 (80.1%) |
P148 Safety and efficacy of cervical 10 kHz cervical spinal cord stimulation (SCS) for the management of refractory chronic migraine: a prospective, proof-of-concept open label study
Lambru Giorgio1, Al-Kaisy Adnan1,2, Palmisani Stefano1,2, Carganillo Roy2, Wesley Samuel2, Pang David2
1The Headache Centre, Guy’s and St Thomas’ NHS Foundation Trust, London, UK; 2Pain and Neuromodulation Academic Research Centre, Guy’s and St Thomas’ NHS Foundation Trust, London, UK
Correspondence: Lambru Giorgio (giorgiolambru@gmail.com)
P149 Is pituitary screening necessary in cluster headache?
Lou Grangeon1,2, Emer O’Connor1, Daisuke Danno1, Thanh Mai Pham Ngoc3, Indran Davagnanam4, Manjit Matharu1
1Headache Group, UCL Institute of Neurology and The National Hospital for Neurology and Neurosurgery, Queen Square, London; 2Department of Neurology, Rouen University Hospital, 76031, Rouen, France; 3Mathematics Institute of Orsay, Paris Sud University, CNRS, 91405 Orsay, France; 4Department of Brain Repair and Rehabilitation, UCL Institute of Neurology, Queen Square, London
Correspondence: Manjit Matharu (m.matharu@uclmail.net)
P150 The impact on physician prescribing of monthly and quarterly dosing options for a new class of migraine preventive therapy
Robert Cowan1, Erik Rosenman3, Tim Fitzgerald2, Joshua Cohen2, Ravi Iyer2
1Teva Pharmaceutical Industries, Frazer, Pennsylvania, 19355, USA; 2Neurology, Stanford University School of Medicine, Stanford, California, 94305, USA; 3IQVIA, Inc., Cambridge, Massachusetts, 02139, USA
Correspondence: Robert Cowan
P151 A multicentre, double-blind, randomised, sham-controlled study of non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: the PREMIUM trial
Hans-Christoph Diener1, Peter J. Goadsby2, Messoud Ashina3, Mohammad Al-Mahdi Al-Karagholi3, Alexandra Sinclair4, Dimos Mitsikostas5, Delphine Magis6, Patricia Pozo-Rosich7,8, Pablo Irimia Sieira9, Miguel J.A. Làinez10, Charly Gaul11, Nicholas Silver12, Jan Hoffmann13, Eric Liebler14, Michel D. Ferrari15
1Klinik für Neurologie, Universitätsklinikum Essen, Essen, Germany; 2NIHR-Wellcome Trust King's Clinical Research Facility, King's College London, UK; 3Danish Headache Center, Rigshospitalet Glostrup, University of Copenhagen, Denmark; 4Metabolic Neurology, Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK; 51st Neurology Department, Aeginition Hospital, National and Kapodistrian University of Athens, Athens, Greece; 6CHR de la Citadelle, University of Liège, Liège, Belgium; 7Headache Clinic, Neurology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain; 8Headache Research Group, Vall d’Hebron Research Institute, Universitat Autonoma de Barcelona, Barcelona, Spain; 9Clinica Universidad de Navarra, Pamplona, Spain; 10Catholic University of Valencia, University Clinic Hospital, Valencia, Spain; 11Migraine and Headache Clinic, Königstein, Germany; 12The Walton Centre, Liverpool, UK; 13Department of Systems Neuroscience, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 14electroCore, LLC, Basking Ridge, New Jersey, USA; 15Leiden University Center, Leiden, The Netherlands
Correspondence: Hans-Christoph Diener (h.diener@uni-essen.de)
P152 Post hoc analysis of the effects of more frequent non-invasive vagus nerve stimulation (nVNS) for patients with chronic cluster headache from the PREVA trial
Charly Gaul1, Eric Liebler2, Candace McClure3, Annelie Andersson2, Andreas Straube4
1Migraine and Headache Clinic, Königstein, Germany; 2electroCore, LLC, Basking Ridge, NJ, USA; 3North American Science Associates Inc., Minneapolis, MN, USA; 4Ludwig Maximilian University of Munich, Munich, Germany
Correspondence: Charly Gaul (c.gaul@migraene-klinik.de)
P153 IMPACT OF MEDICAL CARE ON SYMPTOMATIC DRUG CONSUMPTION AND QUALITY OF LIFE IN HEADACHE: a one-year population study
Antonaci F1, Cotta Ramusino M1, Perini G1, Vanacore N2, Costa A1
1Department of Brain and Behavioral Sciences, C. Mondino National Institute of Neurology Foundation, IRCCS, University of Pavia, Pavia, Italy; 2National Centre for Epidemiology, Surveillance, and Health Promotion, National Institute of Health, Rome, Italy
Correspondence: Antonaci F (fabio.antonaci@unipv.it)
P154 Habituation determined by algometry as a marker of response in Chronic Migraine
García-Azorín D, Ruiz-Piñero M, Sierra A, Martinez B, Guerrero Peral AL
Headache Unit, Clinico University Hospital. 47005. Valladolid, Spain
Correspondence: García-Azorín D (davilink@hotmail.com)
P155 Study on the phenotypic characterization of delayed alcohol induced headache: series of 1184 sufferers
García-Azorín D, Aparicio Cordero L, Sierra Mencía A, Guerrero Peral AL.
Headache Unit, Hospital Clínico Universitario, 47005. Valladolid, Spain.
Correspondence: García-Azorín D (davilink@hotmail.com)
P156 Ibuprofen and not paracetamol as first line analgesic for acute migraine due to its interaction with TRPA1 in the cinnamaldehyde target engagement biomarker model
Dorien Bamps, Laura Macours, Linde Buntinx, Jan de Hoon
Center for Clinical Pharmacology, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Belgium
Correspondence: Dorien Bamps (dorien.bamps@kuleuven.be)
P157 Efficacy and safety of external trigeminal neurostimulation with the Cefaly® device in chronic migraine: an open trial
Jean Schoenen1, Marius Birlea2
1Headache Research Unit. CHR Citadelle. University of Liège. Belgium; 2University of Colorado Anschutz Medical Campus, Department of Neurology, Aurora, USA
Correspondence: Jean Schoenen (jschoenen@uliege.be)
P158 Abortive home treatment of migraine with external trigeminal neurostimulation using the Cefaly® device: a pilot trial
Jean Schoenen1, Joseph Mann2
1Headache Research Unit. CHR Citadelle. University of Liège, Belgium; 2Rochester Clinical Research Center , NY, USA
Correspondence: Jean Schoenen (jschoenen@uliege.be)
Primary outcomes | |
Pain Freedom at 2 hours | 35.56% (16) |
MBS Freedom at 2 hours | 57.78% (26) |
Secondary outcomes | |
Pain Relief at 2 hours | 68.89% (31) |
Absence of symptoms at 2 hours | 44.44% (20) |
Use of rescue medication | 51.11% (23) |
Sustained pain freedom at 24 hours | 26.67% (12) |
P159 Paroxismal body pain without migraine; corpalgia
Levent Ertuğrul İnan1, F. Figen Ayhan2, F. Ayşen Eren3
1Neurology and Algology Department, Ankara Training and Research Hospital of Ministery of Health, Ankara, Turkey; 2Physical Medicine Rehabilitation Department, Ankara Training and Research Hospital of Ministery of Health, Ankara, Turkey; 3Algology Department, Ankara Training and Research Hospital of Ministery of Health, Ankara, Turkey.
Correspondence: Levent Ertuğrul İnan; F. Ayşen Eren (aysendilbaz@gmail.com)
P160 PREVALENCE AND CLINICAL PROFILE OF MIGRAINE WITH AURA IN A COHORT OF YOUNG PATIENTS WITH MINOR STROKE: A RETROSPECTIVE ANALYSIS.
Claudia Altamura, Angelo Cascio Rizzo, Matteo Paolucci, Nicoletta Brunelli, Gianluca Cecchi, and Fabrizio Vernieri
Headache and Neurosonology Unit, Clinical Neurology, Università Campus Bio-Medico di Roma, Rome, Italy
Correspondence: Claudia Altamura (c.altamura@unicampus.it)
P161 The increase of subcutaneous abdominal and body fat is a characteristic associated to allodynia in migraineurs
Mínguez-Olaondo A.1, Romero S.2,3, Frühbeck G.2,3, Martínez-Vila E.1, Irimia P.1
1Neurology, Clínica Universidad de Navarra, Pamplona; 2Endocrinology, Clínica Universidad de Navarra; 3CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), ISCIII
Correspondence: Irimia P (pirimia@unav.es)
P162 CLINICAL PROFILE OF MIGRAINE WITH AURA AND PATENT FORAMEN OVALE: A RETROSPECTIVE ANALYSIS.
Claudia Altamura, Matteo Paolucci, Nicoletta Brunelli, Gianluca Cecchi, Angelo Cascio Rizzo, and Fabrizio Vernieri
Headache and Neurosonology Unit, Clinical Neurology, Università Campus Biomedico di Roma
Correspondence: Claudia Altamura (c.altamura@unicampus.it)
P163 The Association Between Low Carbohydrate Diet Score and Migraine
Soodeh Razeghi Jahromi1,2, Zeinab Ghorbani3,2, Mansoureh Togha2, Azita Hekmatdoost1, Faezeh Khorsha2,3, Boshra Torkan2, Nasim Rezaeimanesh1,2
1Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 2Headache Department, Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran; 3School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.
Correspondence: Mansoureh Togha (toghae@tums.ac.ir)
P164 The expanding burden of Idiopathic Intracranial Hypertension
Susan P Mollan1,2, Magda Aguiar3, Felicity Evison4, Emma Frew5, Alexandra J Sinclair 1,2,6
1Birmingham Neuro-Ophthalmology Unit, University Hospitals Birmingham NHS Foundation Trust, B15 2TH, United Kingdom (UK); 2Metabolic Neurology, Institute of Metabolism and Systems Research, University of Birmingham, Edgbaston, B15 2TT, UK; 3Health Economics Unit, Institute of Applied Health Research, University of Birmingham, Birmingham, B12 2TT, UK; 4Department of Informatics, University Hospitals Birmingham NHS Trust, Queen Elizabeth Hospital Birmingham, Mindelsohn Way, Edgbaston, Birmingham, B15 2WB, UK; 5Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, B15 2TH, UK; 6Department of Neurology, University Hospitals Birmingham NHS Foundation Trust, B15 2TH, UK.
Correspondence: Susan P Mollan (susan.mollan@uhb.nhs.uk)
P165 The Number of Active and Latent Trigger Points is Associated with Restricted Cervical Range of motion in Tension Type Headache
María Palacios-Ceña1,2, Stella Fuensalida-Novo1, Matteo Castaldo1, Kelun Wang1, Lars Arendt-Nielsen1, César Fernández-de-las-Peñas1,2
1SMI, School of Medicine, Aalborg University, Aalborg, DENMARK; 2Departamento de Fisioterapia, Terapia Ocupacional, Rehabilitación y Medicina Física. Universidad Rey Juan Carlos, Alcorcón, Madrid, SPAIN
Correspondence: María Palacios-Ceña; César Fernández-de-las-Peñas (cesar.fernandez@urjc.es)
P166 Evaluation of the 6-Item Identify Chronic Migraine (ID-CM) Screener in a Large Medical Group
Jelena M. Pavlovic1, Justin S. Yu2, Stephen D. Silberstein3, Michael L. Reed4, Steve H. Kawahara5, Robert P. Cowan6, Firas Dabbous7, Karen L. Campbell2, Riya Pulicharam5, Hema N. Viswanathan2, Richard B. Lipton8
1Montefiore Medical Center, Bronx, NY, USA; 2Allergan plc, Irvine, CA, USA; 3Jefferson Headache Center, Philadelphia, PA, USA; 4Vedanta Research, Chapel Hill, NC, USA; 5DaVita Medical Group, El Segundo, CA, USA; 6Stanford University School of Medicine, Stanford, CA, USA; 7Independent Consultant, La Jolla, CA, USA; 8Albert Einstein College of Medicine, Bronx, NY, USA
P167 HEADACHE IN PHARMACY : OBSERVATIONAL STUDY OF PHARMACOLOGICAL HABIT OF CEPHALALGIC PATIENT
Giorgio Dalla Volta1, Giorgio Zanchin2, Maria Pia Prudenzano3, Lidia Savi4
1Headache Center of Neurological Unit of Istituto Clinico Citta’ di Brescia, Brescia; 2Headache Centre, Department of Neurosciences, Padua University, Padua; 3Headache Centre. Department of Basic Medical Sciences, Neuroscience and Sense Organs. University of Bari; 4Headache Center of Lugano
Correspondence: Giorgio Dalla Volta (dalla@numerica.it)
P168 The Italian chROnic migraiNe (IRON) Registry: first report from 28 headache centers
Piero Barbanti1, Luisa Fofi, Gabriella Egeo, Cinzia Aurilia, Sabina Cevoli2, Giulia Pierangeli2, Paola Torelli3, Giancamillo Manzoni3, Cecilia Camarda4, Licia Grazzi5, Domenico D’Amico5, Fabrizio Vernieri6, Patrizia Balsamo7, Fabio Frediani8, Giacomo D'Arrigo8, Paola Di Fiore8, Cinzia Finocchi9, Francesco Perini10, Florindo d'Onofrio11, Francesco Bono12, Antonio Russo13, Roberto De Simone14, Guido Ferra14, Vincenzo Busillo15, Antonio Carnevale16, Francesco Pierelli17, Cherubino Di Lorenzo17, Fabio Valguarnera18, Renata Rao19, Salvatore Caratozzolo19, Stefano Messina20, Bruno Colombo21, Alfonso Coppola22, Gabriella Turano23, Giovanni Battista Allais24, Chiara Lia25, Ottavio Di Marco26, Marcella Curone27, Gennaro Bussone27, Vincenzo Tullo27, Maria Gabriella Saracco28, Nicola Vanacore29
1IRCCS S.Raffaele, Unità per la cura e la ricerca su cefalee e dolore, Roma; 2IRCCS Istituto delle Scienze Neurologiche Bologna; 3Dipartimento di Neuroscienze, Centro Cefalee, Parma; 4UO di Neuologia e Patologie Cognitive. AOU Policlinico "P. Giaccone", Palermo; 5Fondazione IRCCS Ist. Nazionale Neurologico "Carlo Besta", Milano; 6Università Campus Bio-Medico, Roma; 7Poliambulatorio ASL5 Ghilarza; 8ASST Santi Paolo Carlo, UOC Neurologia e Stroke Unit Centro Cefalee, Milano; 9Dip. Scienze Neurologiche Oftalmologia e genetica, Cl. Neurologica II, Genova; 10S. Bortolo Vicenza – Neurologia; 11A.O.Rilievo Nazionale "S.G.Moscati", Avellino; 12Policlinico Mater Domini, Clinica Neurologica, Catanzaro; 13SUN - II Divisione di Neurologia, Napoli; 14Università Federico II, Dip. Scienze Neuologiche, Napoli; 15Ospedale Maria SS Addolorata - Div. Neurologica, Salerno; 16UOC Neurologia, Ospedale San Filippo Neri -ASL Roma 1; 17Centro per la cura dell’emicrania e delle cefalee, ICOT, Latina; 18Dip. Neurologia, C.Cefalee ASL 3 genovese, Ospedale Sestri Ponente "Padre Antero Micone", Genova; 19Ospedali Civili, U.O. I Neurologia, Brescia; 20IRCCS Ist. Auxologico Italiano - Università degli Studi di Milano, UO Neurologia, Milano; 21IRCCS Ospedale San Raffaele, Milano; 22A.O. "G.Salvini" - U.O. Neurologia, Garbagnate Milanese; 23S.C. Neurologia, Ospedale Regina Montis Regalis, Cuneo; 24Centro Cefalee della Donna - Dip. di discipline Ginecologiche e Ostetriche, Ospedale Sant’Anna, Torino; 25Ospedale Regionale della Valle d'Aosta, S.C. di Neurologia, Centro Cefalee Regionale; 26Ospedale SS Trinità, Frosinone; 27Casa di Cura Igea, Milano; 28Azienda Sanitaria Locale di Asti, Ospedale Cardinal Massaia, Soc. Neurologia; 29Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della Salute, Istituto Superiore di Sanità, Roma
Correspondence: Piero Barbanti (piero.barbanti@sanraffaele.it)
P169 Spontaneous intracranial hypotension in a patient with meningeal diverticula: a case report
Torrente A., Davì M., Pilati L., Portera E., Scardina S., Di Marco S., Gangitano M., Cosentino G., Fierro B., Brighina F.
Department of Experimental Biomedicine and Clinical Neurosciences (BioNeC), University of Palermo, Palermo, Italy
P170 Estimation of the Economic Burden and Labor Impact of Migraine in Spain: Results from the Spanish Atlas of Migraine Survey 2018
Pablo Irimia1, Marco Garrido-Cumbrera2,3, Sonia Santos-Lasaosa4, Isabel Colomina5, Francisco Javier León6, Carles Blanch7, Patricia Pozo-Rosich8,9
1Clínica Universidad de Navarra, Pamplona; 2Health & Territory Research, Sevilla; 3Universidad de Sevilla, Sevilla; 4Hospital Clínico de Zaragoza; 5AEPAC, Madrid; 6UGC Zaidín-Sur, Granada; 7Novartis, Barcelona; 8Headache Unit, Neurology Department, Hospital Vall d’Hebron, Barcelona; 9Headache Research Group. Vall d’Hebron Institut de Recerca (VHIR), Universitat Autonoma of Barcelona
Correspondence: Pablo Irimia (pirimia@unav.es)
P171 Chromig10: evolution of migraine after 10 years
E. Caronna1, E. Fonseca Hernández1, VJ. Gallardo2, JB. Gomez2, A. Alpuente1,2, M. Torres-Ferrús1,2, P. Pozo- Rosich1,2
1Headache Unit, Neurology Department, Vall d’Hebron Hospital, Barcelona, 08035, Spain; 2Headache Research Group, Vall d’Hebron Research Institute, Barcelona, 08035, Spain
Correspondence: P. Pozo- Rosich (ppozo@vhebron.net)
P172 WHOLE GRAIN CEREAL CONSUMPTION REDUCES MIGRAINE RELATED DISABILITY
Claudia Altamura, Gianluca Cecchi, Giorgia Botti, Maria Bravo, Paola Di Caprio, Nicoletta Brunelli, Matteo Paolucci, Manon Khazrai and Fabrizio Vernieri
Headache and Neurosonology Unit, Neurology Unit, Università Campus Bio-Medico di Roma, Rome, Italy
Correspondence: Claudia Altamura (c.altamura@unicampus.it)
P173 The Association Between Dietary Tryptophan Intake and Migraine
Soodeh Razeghi Jahromi1,2, Mansoureh Togha2, Zeinab Ghorbani2,3, Hossein Ansari4, Azita Hekmatdoost1, Faezeh Khorsha2,3, Pedram Shirani1, Morvarid Nourmohammadi2
1Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 2Headache Department, Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran; 3School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran; 4Department of Neurology, University of California San Diego (UCSD), USA
Correspondence: Hossein Ansari (headache@hansari.com)
P174 Serum Vitamin B12 and Methyl-malonic Acid Status in a group of Migraine Patients Compared to Healthy Controls: A Case-Control Study
Mansoureh Togha1, Soodeh Razeghi Jahromi2,1, Zeinab Ghorbani1,3, Fahimeh Martami1,2, Maryam Seifishahpar1,2.
1Headache Department, Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran; 2Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 3School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran
Correspondence: Mansoureh Togha (toghae@tums.ac.ir)
P175 PRELIMINARY EFFICACY STUDY IN PROPHYLAXES OF EPISODIC TENSION CEPHALA AND HEMICRANIA WITHOUT AURA USING A COMBINATION OF MAGNESIUM, L-TRIPTOFANO, BOSWELLIA SERRATA CASPEROME®, NIACINA, RIBOFLAVINA AND VITAMIN D COMPARED WITH AMITRIPTILINE
L. Balzano1, B. Ciccone2
1Neurologist – Clinic for the diagnosis and treatment of headaches – Torre del Greco (NA) ASL NA3 SUD; 2Neurophysiopathologist - Clinic for the diagnosis and treatment of headaches ATHENA Saviano (NA)
Correspondence: L. Balzano (neurogino@yahoo.it)
SISC Poster Presentation
P176 Efficacy in high frequency migraine with aura prevention of a combination of Tanacethum Parthenium, 5 - hydroxy tryptophan and magnesium (Aurastop©)
Giorgio Dalla Volta, Paola Zavarise, Gaelle Ngonga, Danilo Fontana
Headache Center of Neurological Unit of Istituto Clinico Citta' di Brescia, Brescia
Correspondence: Giorgio Dalla Volta (dalla@numerica.it)
P177 Quantitative analysis of perfusion Computed Tomography images increases the evidence of hypoperfusion during migrainous aura
Laura D’Acunto1, Antonio Granato1, Miloš Ajčević1, Giovanni Furlanis1, Maja Ukmar2, Irene Zorzenon2, Mariana Ridolfi1, Paolo Manganotti1
1Department of Medical, Technological and Translational Sciences, Headache Centre, University of Trieste, Italy; 2Department of Radiology, Cattinara Hospital, University of Trieste, Italy
Correspondence: Laura D’Acunto (laura.d.acun@gmail.com)
Patients | Age | Gender | History of migraine | Symptoms | Headache at the onset of symptoms | NIHSS | Time to PTC after symptoms onset | Symptoms duration | ΔMTT (%) |
---|---|---|---|---|---|---|---|---|---|
1 | 52 | F | Yes, without aura | Right hemiparaestesia and dysphasia | Yes | 2 | 60 min | 2 hours | 1,8 |
2 | 83 | F | Yes, with aura | Aphasia | Yes | 4 | 60 min | 2 hours | 13 |
3 | 49 | F | Yes, without aura | left hemiparesis left sensitive-motor | No | 3 | 90 min | 2 hours | 8,4 |
4 | 28 | M | Yes, with aura | hemisyndrome and left homonymous hemianopsia | No | 7 | 90 min | 24 hours | 30,2 |
5 | 21 | M | Yes, without aura | Aphasia | Yes | 1 | 60 min | 2 hours | 60,2 |
6 | 26 | F | Yes, without aura | left hemiparesis | No | 3 | 60 min | 10 hours | 6,1 |
P178 Cerebello-thalamo-cortical inhibitory activity impairment in patients with chronic migraine
Gianluca Coppola1, Clarissa Elizabeth Centurioni1, Chiara Abagnale1, Vincenzo Maria Parisi2, Mariano Serrao1, Cherubino Di Lorenzo3, Francesco Pierelli1,4
1Sapienza University of Rome Polo Pontino, Department of Medico-Surgical Sciences and Biotechnologies, Latina, Italy; 2G.B. Bietti Foundation IRCCS, Research Unit of Neurophysiology of Vision and Neurophthalmology, Rome, Italy; 3Don Carlo Gnocchi Onlus Foundation, Milan, Italy; 4IRCCS-Neuromed, Pozzilli (IS), Italy
Correspondence: Gianluca Coppola (gianluca.coppola@gmail.com)
P179 Transcranial direct current stimulation as add-on therapy in the detoxification of patients with chronic migraine and medication overuse headache: clinical and EEG findings
Roberto De Icco1,2, Cristina Tassorelli1,2, Irene De Paoli1, Raffaele Manni3, Michele Terzaghi3, Riccardo Cremascoli2,3, Giorgio Sandrini1,2, Grazia Sances1
1Headache Science Center, IRCCS Mondino Foundation; 2Department of Brain and Behavioral Sciences, University of Pavia; 3Unit of Sleep Medicine and Epilepsy, IRCCS Mondino Foundation
Correspondence: Roberto De Icco (rob.deicco@gmail.com)
P180 Ultrasound biomicroscopy detects secondary hemicrania continua attributed to hidden narrow angle glaucoma
A. Granato, A. Dinoto, C. Bertolotti, D. Stokelj, L. Antonutti, P. Manganotti
Department of Medical, Technological and Translational Sciences, Headache Centre, University of Trieste, Italy
Correspondence: A. Granato (antonio_granato@hotmail.com)
P181 Analysis of Injection Site Reactions across Four Placebo Controlled Trials of Erenumab for Migraine Prevention
Julio Pascual1, David Doležil2, Brendan Davies3, Hernan Picard4, Frank Hong5, Feng Zhang4, Fei Xue4, Dan Mikol4, Jan Klatt5
1Service of Neurology, University Hospital Marqués de Valdecilla and IDIVAL, Santander, Spain; 2DADO MEDICAL sro, Prague Headache Center, Prague, Czech Republic; 3Department of Neurology, Royal Stoke University Hospital, Stoke-on-Trent, UK; 4Amgen Inc., Thousand Oaks, CA, USA; 5Novartis Pharma AG, Basel, Switzerland
P182 "Fusion Imaging” to identify Periaqueductal Gray Matter (PAG) in a Medication Overuse Headache (MOH) patient
Elena Guaschino1,2, Natascia Ghiotto1,2, Cristina Tassorelli2,3, Ana Bacila4, Daniele Bosone1, Grazia Sances2
IRCCS Mondino Foundation, Pavia; 1Neurovascular Ambulatory, Clinical Neurophysiology Unit; 2Headache Science Centre; 3Department of Brain and Behavioral Sciences, University of Pavia, Italy; 4Neuroradiology Department
Correspondence: Elena Guaschino; Natascia Ghiotto (natascia.ghiotto@mondino.it)
P183 Early BoNT-A treatment after controlled withdrawal in Medication Overuse Headache: selection criteria for an optimal cost-benefit ratio
V. Rebecchi, L. Princiotta Cariddi, A.M Clerici, M. Mauri
Headache Center - Neurology and Stroke Unit, Osp. Di Circolo - University of Insubria, Varese, Italy
Correspondence: L. Princiotta Cariddi (luciapc86@hotmail.it)
P184 Efficacy of Erenumab for the Treatment of Patients With Chronic Migraine With and Without Aura
Messoud Ashina1, David Dodick2, Peter J Goadsby3, David Kudrow4, Uwe Reuter5, Stewart J Tepper6, Sunfa Cheng7, Dean K Leonardi7, Robert A Lenz7, Daniel D Mikol7
1Danish Headache Center, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; 2Mayo Clinic, Scottsdale, AZ, USA; 3NIHR-Wellcome Trust King’s Clinical Research Facility, Kings College London, London, UK; 4California Medical Clinic for Headache, Santa Monica, CA, USA; 5Charité Universitätsmedizin Berlin, Berlin, Germany; 6Geisel School of Medicine at Dartmouth, Hanover, NH, USA; 7Amgen Inc., Thousand Oaks, CA, USA
P185 Efficacy and safety of erenumab in episodic migraine patients with 2–4 prior preventive treatment failures: Results from the Phase 3b LIBERTY study
Uwe Reuter1, Peter J. Goadsby2, Michel Lanteri-Minet3, Michel Ferrari4, Shihua Wen5, Jan Klatt6
1Deprtment of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany; 2NIHR-Wellcome Trust Kings Clinical Research Facility, King’s College London, London, UK; 3Department of Pain-CHU Nice, FHU Inov-Côte Azur University, Nice, France; 4Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands; 5Novartis Pharmaceutical Corporation, East Hanover, NJ, USA; 6Novartis Pharma AG, Basel, Switzerland
P186 Case Report: Chronic Migraine successfully treated with Cannabinoids
E. Dini, M. Cafalli, C. De Luca, F. Baldacci, S. Gori, U. Bonuccelli
Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
Correspondence: E. Dini (dini.elisa87@gmail.com)
P187 Abnormal intracortical facilitation pattern in episodic migraine without aura: results of a paired-pulse TMS study
S. Ferlisi, G. Cosentino, W. Capitano, S. Di Marco, L. Pilati, S. Scardina, A. Torrente, G. La Bianca, B. Fierro, F. Brighina
Department of Experimental Biomedicine and Clinical Neurosciences (BioNeC), University of Palermo
Correspondence: S. Ferlisi (fransalvo1@gmail.com)
P188 Migraine with aura: a great mimicker or a misleading herald?
Alberto Terrin1, Anna Maria Basile2, Federico Mainardi3, Giorgio Zanchin1, Ferdinando Maggioni1
1Headache Centre of the Veneto Region, Department of Neuroscience, University of Padova, Padova, Italy; 2Stroke Unit, St. Anthony Hospital, Padua, Italy; 3Headache Centre. Hospital SS. Giovanni and Paolo, Venice, Italy
Correspondence: Alberto Terrin (alberto.terrin89@gmail.com)
P189 Central and peripheral FAAH inhibition and migraine pain: potential mechanisms and targets in an animal model
Rosaria Greco1, Chiara Demartini1, Anna Maria Zanaboni1,2, Elena Tumelero1, Alessandra Misto3, Angelo Reggiani3, Daniele Piomelli4, Cristina Tassorelli1,2
1Laboratory of Neurophysiology of Integrative Autonomic Systems, Headache Science Centre, IRCCS Mondino Foundation, Pavia, Italy; 2Department of Brain and Behavioral Sciences, University of Pavia, Italy; 3Dept. of Drug Discovery and Development, Istituto Italiano di Tecnologia, Genova, Italy; 4Department of Anatomy and Neurobiology, University of California, Irvine, CA, USA
Correspondence: Rosaria Greco (rosaria.greco@mondino.it)
P190 Possible effects, side-effects and adverse events of a selective cannabinoid (6% THC/7.5% CBD) in refractory chronic migraine. 2013-2018 pilot data
Maria Nicolodi1, Maria Stella Pinnarò1,2, Vanessa Sandoval1, Anna Torrini1
1Foundation Prevention and Therapy Primary Pain and Headache, Florence 50125, IT; 2Department Neuroscience, University of Florence, Florence 50139 Florence, IT
Correspondence: Maria Nicolodi (info@fondazionesicuterinicolodi.it); Maria Stella Pinnarò
P191 Physical Therapy and Onabotulinumtoxin A in chronic migraine: a three-arm randomized perspective study
A. Granato1, M. Deodato2, UG. Sisto1, C. Borgino2, L. D’Acunto1, P. Manganotti1
1Department of Medical, Technological and Translational Sciences, Headache Centre, University of Trieste, Italy; 2Department of Experimental and Clinical Medicine and Experimental and Clinical Neurosciences, Physiotherapy, University of Trieste, Italy
Correspondence: A. Granato (antonio_granato@hotmail.com)
P192 Visual cortical hyperactivity to sound induced flash illusions in pediatric migraine
Salvatore Di Marco1, Alice Pavone1,Giuseppe Cosentino1, Laura Pilati1, Angelo Torrente1, Simona Maccora1, Giuseppe Santangelo2, Vincenzo Raieli2, Serena Scardina1, Brigida Fierro1, Filippo Brighina1
1Department of Experimental Biomedicine and Clinical Neuroscience (BioNeC), University of Palermo; 2Child Neuropsychiatry Unit, Di Cristina Hospital, ARNAS CIVICO Palermo
Correspondence: Salvatore Di Marco (dimarcosal@gmail.com)
P193 Clinical features of pediatric medication overuse headache and applicability of new ICHD-3 criteria
Romina Moavero, Maddalena Stornelli, Laura Papetti, Barbara Battan, Samuela Tarantino, Federico Vigevano, Massimiliano Valeriani
Headache Center, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy
Correspondence: Romina Moavero (rominamoavero@hotmail.com)
P194 C677T Methylenetetrahydrofolate reductase homozygous mutation: vitamin supplement in migraineur children
Elisabetta Tozzi, Giulia Iapadre, Luca Zagaroli, Agnese Onofri
Neuropsychiatric Clinic- Headache Center- San Salvatore Hospital -University L'Aquila Italy
Correspondence: Elisabetta Tozzi (elisabetta.tozzi@univaq.it)
P195 The use of nutraceuticals in childhood and adolescence headaches
Agnese Onofri, Martina Mazzilli, Cristina Gammella, Giulia Iapadre, Elisabetta Tozzi
Neuropsychiatric Clinic- Headache Center- San Salvatore Hospital -University L'Aquila Italy
Correspondence: Agnese Onofri; Elisabetta Tozzi (elisabetta.tozzi@univaq.it)
P196 Changes on cervical range of motion in migraine patients after a strain counterstrain treatment
Valerio Giustino1,2, Valentina Contrò3, Jessica Brusa1,2, Patrizia Proia3, Giuseppe Messina1,2,3, Filippo Brighina4
1Posturology and Biomechanics Laboratory Research Unit, University of Palermo, Palermo, Italy; 2Posturalab Italia Research Institute, Palermo, Italy; 3Department of Psychological, Pedagogical and Educational Sciences, University of Palermo, Palermo, Italy; 4Department of Experimental Biomedicine and Clinical Neurosciences (BioNeC), University of Palermo, Palermo, Italy
Correspondence: Valerio Giustino (valeriogiustino@msn.com)
P197 The role of metacognitive executive dysfunctions in medication-overuse headache
Milena Zucca, Elisa Rubino, Alessandro Vacca, Flora Govone, Annalisa Gai, Paola De Martino, Silvia Boschi, Maria T. Giordana, Innocenzo Rainero
Neurology I, Department of Neuroscience “Rita Levi Montalcini”, University of Turin, Italy
Correspondence: Milena Zucca, Elisa Rubino (milena.zucca@unito.it)
P198 Aortic pulse wave velocity in children with migraine: a case- control study
Laura Pilati1, S. Di Marco1, A. Pavone1, S. Scardina1, G. Cosentino1, G. Mule'2, V.Raieli3, M.Gangitano1, B. Fierro1, F. Brighina1
1Department of Experimental Biomedicine and Clinical Neurosciences (BioNeC) - University of Palermo – Palermo; 2Biomedical Department of Internal Medicine, and Specialist (DIBIMIS) - University of Palermo – Palermo; 3Child Neuropsichiatry unit, Di Cristina Hospital, ARNAS CIVICO Palermo
Correspondence: Laura Pilati (laura.pilati.91@gmail.com)
P199 Efficacy of KUZIK® in the prophylaxis of migraine without aura: a case report
E. Pucci1,2, R. Galante3
1Headache Science Center – IRCCS Mondino Foundation, Pavia, Italy; 2Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy; 3Gam Farma Srl. Milan
Correspondence: E. Pucci (ennio.pucci@mondino.it)
P200 Anxiety, depression and alexithymia in young migraine patients: which relationship with body weight?
Samuela Tarantino1, Alessandra di Stefano2, Laura Papetti1, Barbara Battan1, Giorgia Sforza, Federico Vigevano1, Simonetta Gentile2 and Massimiliano Valeriani1,4
1Headache Center, Division of Neurology, Ospedale Pediatrico Bambino Gesù, IRCCS, Piazza Sant’Onofrio 4, Rome, Italy; 2Unit of Clinical Psychology, Ospedale Pediatrico Bambino Gesù, IRCCS, Piazza Sant’Onofrio 4, Rome, Italy; 3Child Neurology and Psychiatry Unit, Tor Vergata University of Rome, Rome, Italy; 4Center for Sensory-Motor Interaction, Aalborg University, Aalborg, Denmark
Correspondence: Samuela Tarantino (samuela.tarantino@opbg.net)
P201 Does a dedicated social network help specialists’ training in the management of headaches? Comparison with other networks - a four-year experience
Laura Silvestri1, Carmela Loiacono1, Luca Messina1, Marco Micale1, Edvige Correnti1, Francesca Marchese1,2, Francesca Vanadia2, Filippo Brighina3, Vincenzo Raieli2
1Child Neuropsychiatry School – University of Palermo; 2UO NPI- P.O. Cristina - ARNAS Civico Palermo; 3Department of Experimental Biomedicine and Clinical Neurosciences - University of Palermo
Correspondence: Vincenzo Raieli (vinzi.raielk@inwind.it)
Total 48 groups | Downloads | Discussions | members | active members |
---|---|---|---|---|
JBOARD CLUB AlgologyGroups: 8 | 84 | 180 | 84 | 37 |
JBOARD CLUB Dermatology Groups: 3 | 13 | 8 | 33 | 16 |
JBOARD CLUB Hematology Groups: 4 | 19 | 1 | 82 | 19 |
JBOARD CLUB Digestive Endoscopy Groups: 1 | 0 | 3 | 17 | 8 |
JBOARD CLUB Gastroenterology Groups: 13 | 260 | 11 | 183 | 70 |
JBOARD CLUB Immunology Groups: 1 | 0 | 0 | 5 | 2 |
JBOARD CLUB Infettivology Groups : 2 | 0 | 0 | 3 | 2 |
JBOARD CLUB Nefrology Groups : 1 | 0 | 1 | 19 | 2 |
JBOARD CLUB Neurology Groups: 3 | 1437 | 54 | 121 | 98 |
JBOARD CLUB Oncology Groups: 8 | 163 | 9 | 86 | 42 |
JBOARD CLUB Psichiatry Groups : 2 | 32 | 1 | 201 | 45 |
Total | 2008 | 268 | 834 | 341 |
P202 VITAMIN D SERUM LEVEL IN HEADACHE PATIENTS: PRELIMINARY ANALYSIS
Vincenzo Pizza1, Silvana Montella1, Domenico Cassano2, Maria Cristina Lerza3, Vincenzo Busillo3
1Neurology Unit, S. Luca Hospital, Vallo della Lucania (SA); 260 District, Nocera Inferiore; 3Neurology Unit, Maria SS Addolorata Hospital, Eboli, ASL SALERNO, Italy
Correspondence: Vincenzo Pizza (vpizza@libero.it)
P203 Prescholar headaches and red flags in the Emergency Department
Flavia Drago1, Edvige Correnti1, Francesca Marchese1, Luca Maria Messina1, Marco Micale1, Lucia Rocchitelli1, Francesca Vanadia2, Vincenzo Raieli2
1Child Neuropsichiatry Dept.- University of Palermo; 2Child Neuropsichiatr Unit, ISMEP- ARNAS Civico Palermo
Ptosis of cerebellar tonsil | Sinusitis | Arachnoid cysts | Expansion of liquor spaces | Cerebrovascular anomalies | Pineal calcifications | Intracranial tumors | Haemorrhage | Negative TC |
---|---|---|---|---|---|---|---|---|
42 | 10 | 3 | 18 | 13 | 11 | 2 | 1 | 10 |
P204 Tecnostress and chronic headaches for the use of drugs: wash-out combined with enzymatic add-on therapy
Ennio Pucci1, Silvano Cristina1, Marcello Imbriani3, Giuseppe Taino4
1Headache Science Center – IRCCS Mondino Foundation, Pavia, Italy; 2Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy; 3Department of Public Health, Experimental and Forensic Medicine - University of Pavia, Pavia, Italy; 4U.O. Hospital Occupational Medicine - IRCCS "S. Maugeri" Foundation, Pavia, Italy
Correspondence: Ennio Pucci (ennio.pucci@mondino.it)
P205 Atypical facial pain after a nasal trauma
M. Puma1, B. Petolicchio1,2, A. Viganò1, V. Di Piero1,2
1Department of Human Neuroscience, Sapienza University of Rome, 00185 - Rome, Italy; 2“Enzo Borzomati” Pain Medicine Unit – University Hospital Policlinico Umberto I, 00161-Rome, Italy
Correspondence: M. Puma (martapuma@hotmail.it)
P206 Prophylactic effect of ultramicronized N-Palmitoyl Ethanol Amide (PEA) on pediatric migraine: a preliminary study
Giorgia Sforza1,2, Laura Papetti1, Samuela Tarantino1, Barbara Battan1, Michela Ada Noris Ferilli1,3, Romina Moavero1,2, Federico Vigevano1, Massimiliano Valeriani1
1Headache Center, Child Neurology Unit, Bambino Gesu’ Children’s Hospital, Rome, Italy; 2Child Neurology and Psychiatry Unit, Tor Vergata University of Rome, Italy; 3Institute of Neurology, Catholic University of Sacred Heart, Rome, Italy
Correspondence: Giorgia Sforza (sforzagiorgia@gmail.com)
P207 The attention to social and health problems of headaches by central and peripheral structures of social and health services
Gregorio Iannone1, Carlo Piccolini2
1Deputy coordinator S.I.S.C. Umbria - Marche – Abruzzo Already responsible for the center - headaches company hospital "Santa Maria" Terni; 2A.O”S.Maria” Neuroscience and neurorehabilitation Department Terni Italy
Correspondence: Gregorio Iannone (iannonegregorio45@gmail.com)
P208 The Neurologist of Territory and headache: critical issues and perspectives
Domenico Cassano (info@domenicocassano.it)
Headache Centre, ASL SA, Campania, Distretto 60, Via S. Giordano, 7, 84014 Nocera Inf. (SA)
P209 Headaches, TTH and Migraine
G.Andrisani1, G. Andrisani2
1Studio Dentistico Andrisani, Matera, Italy; 2Tandzorg Delft Centrum, Tandarts Praktijk, Delft, Netherland
P210 Hopelessness in Migraine: a new psychological marker for disease evolution and response to treatment?
R. Lo Baido1, M. S. Epifanio2, N. Bellavia2, M. Piombo2, A. Torrente3, B. Fierro3, S. La Grutta2, F. Brighina3
1Dipartimento di Biopatologia e Biotecnologie Mediche (DiBiMed); 2Dipartimento di Scienze Psicologiche, Pedagogiche e della Formazione (SPPF); 3Dipartimento di Biomedicina sperimentale e neuroscienze cliniche (BioNeC)
P211 Selected cannabinoids and cutaneous allodynia in chronic refractory migraine
Maria Nicolodi1, Maria Stella Pinnarò1 2, Vanessa Sandoval1
1Foundation Prevention and Therapy Primary Pain and Headache, Florence 50125, Italy; 2Department Neuroscience, University of Florence,Florence 50139 Florence, Italy
Correspondence: Maria Nicolodi (info@fondazionesicuterinicolodi.it)
P212 Follow-up study of 17-25 years on subtypes of headache in a population children below 6 years old
Lucia Rocchitelli1, Francesca Marchese1, Marco Micale1, Carmela Loiacono1, Francesca Vanadia2, Filippo Brighina3, Salvatore Mangano1, Vincenzo Raieli2
1Child Neuropsichiatry Department - University of Palermo; 2Child Neuropsychiatr Unit, ISMEP - ARNAS Civico Palermo; 3Department of Experimental Biomedicine and Clinical Neurosciences - University of Palermo
Correspondence: Lucia Rocchitelli (luciana.91@hotmail.it)
P213 Optimization of Outpatient Appointment Scheduling in Cephalalgic Day Service
Rosario Iannacchero1, Domenico Conforti2, Giuseppe Ielpa3, Maria Carmela Groccia2, Rosita Guido2
1Regional Headache Centre, Neurology Division, "Pugliese-Ciaccio" Hospital, Catanzaro, Italy; 2Department of Mechanical Energy Management Engineering, University of Calabria, Rende, Italy;3Department of Mathematics and Computer Science, University of Calabria, Rende, Italy
Correspondence: Rosario Iannacchero (centrocefaleeaopc@gmail.com)
-
References